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ABSTRACT
The aberrant glycosylation of α-dystroglycan is associated with a subset of clinically
heterogeneous muscular dystrophies collectively referred to as dystroglycanopathies.
Mutations in seven genes are currently known to result in these autosomal recessive
disorders. To define the mutation frequency and clinical phenotypes associated with
mutations in five of these genes, I analysed a large cohort of patients. This study
redefined the clinical spectrum associated with mutations in POMT1, POMT2,
POMGNT1, FKTN and LARGE. Mutations in these genes were detected in
approximately a third of all cases indicating that, after the exclusion of FKRP
involvement, the majority of patients with a dystroglycanopathy harbour mutations in
novel genes. In order to identify novel genes in these disorders I applied a candidate
gene approach to the whole genome. Genes known to be causative in
dystroglycanopathy animal models and those predicted to function within the pathway
of dystroglycan glycosylation were investigated. Mutation screening indicated that
defects in GYLTL1B, β3GNT1, WWP1, GYG1, GYG2, MGAT5B and DAG1 are not
frequent causes of human dystroglycanopathy. In order to evaluate the function of a
subset of candidate genes, I optimised a cell culture model of dystroglycanopathy.
Using a ribonucleotide interference based strategy, the expression of candidate genes
were modulated in a mouse myogenic cell line. The down regulation of β3gnt1 induced
a marked reduction in the glyco-epitope present on α-dystroglycan. This finding
confirms β3gnt1 as a key enzyme functioning in the pathway of α-dystroglycan
glycosylation. In addition, I combined the use of high density single nucleotide
polymorphism genotyping platforms, expression microarrays and sequencing data to
investigate the cause of disease in a small consanguineous pedigree. In summary, this
data set has refined genotype-phenotype correlations of known causative genes as well
as investigated the involvement of novel loci in muscular dystrophies with defective
glycosylation of dystroglycan.[4]
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AIMS OF THIS THESIS
Prior to the commencement of work for this thesis, muscular dystrophies caused by
defective glycosylation of dystroglycan were ill defined. Individual studies assessing the
mutation frequency and clinical spectrum associated with each causative gene were only
carried out on a small number of families and individuals. The underlying genetic defect
in a large number of patients had yet to be established.
The aims of this thesis were therefore to:
1) Refine genotype-phenotype correlations within the dystroglycanopathies.
2) Apply the candidate gene approach to dystroglycanopathy cases with no molecular
diagnosis.
3) Further analyse a consanguineous pedigree previously reported to be linked to 1q42.
The following chapters reflect the approximate chronological sequence of work
performed for this thesis. The refinement of genotype-phenotype correlations described
in results chapter 3 formed the basis of the candidate gene approach in results chapter 4.
Results chapter 5 describes further analysis of a family previously studied in the
Dubowitz Neuromuscular Centre. An overall introduction, description of methods and
discussion comprise chapters 1, 2 and 6 respectively.[19]
CHAPTER 1. INTRODUCTION[20]
1 INTRODUCTION
1.1 MUSCULAR DYSTROPHY
The term muscular dystrophy encompasses a large group of hereditary diseases
characterised by progressive weakness and degeneration of skeletal muscle. Distinct
muscular dystrophies demonstrate varied patterns of muscular involvement which can
include differential weakness of the limbs, respiratory impairment, cardiac involvement,
as well as including damage to the nerves controlling the muscle itself. Diseases vary
widely in their clinical severity ranging from neonatal presentation associated with early
death to late onset adult forms of relatively mild muscular dystrophy. In all cases
progressive muscle weakness follows the progression of muscle damage which can lead
to loss of ambulation and premature death if respiratory and/or cardiac muscles are
significantly compromised. A variety of different inheritance patterns exist within this
group of clinically and genetically heterogeneous diseases (Guglieri et al., 2008;
Mercuri et al., 2002).
Originally, defects in structural proteins were identified in muscular dystrophies. More
recently it has been recognised that underlying pathological mechanisms not only
involve defective structural proteins but include the disruption of proteins functioning in
a variety of cellular systems. These proteins reside in a number of discrete subcellular
components of skeletal myofibres and include the nucleus, Golgi apparatus,
endoplasmic reticulum (ER), sarcomere, extracellular matrix and sarcolemma (Figure 1)
(Davies and Nowak, 2006).[21]
Figure 1. The structure of a single muscle fibre.
An individual skeletal muscle consists of hundreds of thousands of muscle fibres. Fibres
are long multinucleated cylindrical cells formed by the fusion of developmental
myoblasts. The muscle’s contractile units lying within each fibre are known as
myofibrils. Each myofibre is composed of regularly aligning myofilaments organised
into units known as sarcomeres. They are enveloped by a plasma membrane known as
the sarcolemma and an overlying basal lamina. The sarcolemma acts as a physical
barrier separating the fibre from the surrounding extracellular environment as well as
mediating interactions between the synactia and extracellular matrix. Figure modified
from Davies et al. (Davies and Nowak, 2006). Permission to reproduce this figure has
been granted by Nature Publishing Group.[22]
Historically, forms of muscular dystrophy have been recognised according to their
distinct clinical manifestations, for example: Duchenne muscular dystrophy, Becker
muscular dystrophy, muscle eye brain disease (MEB) and Walker-Warburg syndrome
(WWS). As the molecular basis of these conditions is uncovered, common pathogenic
mechanisms have been identified. This has lead to the grouping of different forms of
muscular dystrophy; Duchenne muscular dystrophy and Becker muscular dystrophy,
both caused by defects in dystrophin, are now collectively referred to as
‘dystrophinopathies’ This nomenclature has been further complicated by allele
heterogeneity which underlies extreme clinical diversity.
This may be best exemplified by the laminopathies where defects in lamin A and C
(encoded by LMNA) cause a variety of human diseases (Gruenbaum et al., 2005).
Autosomal dominant (AD) LMNA mutations were initially associated with Emery-
Dreifuss muscular dystrophy yet are also associated with familial partial lipodystrophy,
dilated cardiomyopathy and Hutch-Gilford progeria syndrome. Autosomal recessive
(AR) LMNA mutations are associated with Charcot Marie Tooth and Mandibuloacral
muscular dystrophy as well as rare cases of Emery-Dreifuss muscular dystrophy.
Autosomal dominant and AR mutations in emerin, another component of the nuclear
envelope, also cause Emery-Dreifuss muscular dystrophy (Brown et al., 2008). Lamin A
and C participate in the LINC complex that, along with nesprin, link the nucleoskeleton
with the cytoskeleton (Crisp et al., 2006). Mutations in the genes encoding the nuclear
envelope proteins nesprin-1 and -2 (encoded by SYNE1 and SYNE2 respectively) have
recently been described in patients with features of Emery-Dreifuss muscular dystrophy
(Zhang et al., 2007). Recessive mutations in SYNE1 have also been linked to
Arthrogryposis multiplex congenita and adult onset cerebellar ataxia (Attali et al., 2009;
Gros-Louis et al., 2007). This example clearly illustrates how delineating the underlying
aetiology of muscular dystrophy is a complex task.
To date, over 30 different genes are implicated in muscular dystrophy whose encoded
proteins now include enzymes, signalling molecules, RNA binding proteins and protein
kinases (Davies and Nowak, 2006). There is currently no reliable data on the prevalence
or incidence of the majority of muscular dystrophies, or indeed these diseases as a
whole. The most common type of muscular dystrophy in the United Kingdom is the
severe Duchenne Muscular Dystrophy (DMD) which affects 1 in 3500 newborn boys.[23]
DMD is caused by an absence of the protein dystrophin and is characterised by
progressive muscular dystrophy, cardiomyopathy and respiratory failure. The majority
of patients are diagnosed before 6 years of age, become wheelchair bound in their early
teens and rarely live beyond 30 years of age (Manzur et al., 2008). The DMD gene is the
longest human gene spanning 2.4 megabases of the X chromosome and encoding a
3684 amino acid dystrophin protein (Davies et al., 1983; Koenig et al., 1988). DMD was
the first gene to be associated with muscular dystrophy. Its discovery in turn led to the
identification of a number of structural muscle proteins in rapid succession (Ervasti et
al., 1990; Koenig et al., 1988).
A skeletal muscle biopsy often plays an integral role in the diagnosis of muscular
dystrophy. In the Dubowitz Neuromuscular Centre, open, or commonly, needle biopsies
are typically taken from the quadriceps (Dubowitz and Sewry, 2006). Key dystrophic
features are observed by histological staining of transverse sections of skeletal muscle.
The overall morphology of the muscle fibres in relation to non contractile elements such
as nuclei, connective tissue and blood vessels can be observed using the histological
stain haematoxylin and eosin (Figure 2) (Dubowitz and Sewry, 2006).[24]
Figure 2. Dystrophic skeletal muscle.
Muscle histology is often used to confirm that the muscle has dystrophic changes.
Dystrophic changes are detected on transverse sections of skeletal muscle biopsies.
Haematoxylin and eosin staining of normal muscle (A) and dystrophic muscle (B).
Normal myofibres are approximately equal in diameter with nuclei located around the
periphery (A). Dystrophic muscle is characterised by an accumulation of fat and
connective tissue between fibres, increased variability in fibre size, a rounded
morphology of cells, the presence of central nuclei (
†), necrotic fibres (
††) and the
presence of regenerating fibres (basophilic fibre
‡) (Dubowitz and Sewry, 2006). Images
from Dr Lucy Feng, Dubowitz Neuromuscular Centre, Institute of Child Health, UCL.
A
B[25]
1.1.1 Dystrophin Glycoprotein Complex
The dystrophin glycoprotein complex (DGC) is an oligomeric assemblage of proteins.
This macromolecular structure can be purified from plasma membranes solubilised with
detergent (Ervasti et al., 1990; Yoshida and Ozawa, 1990). Initially components of this
complex were designated as either dystrophin-associated proteins (DAP) or dystrophin-
associated glycoproteins (DAG) (Ervasti et al., 1990). Proteins were referred to as
156DAG, 59DAP, 50DAG, 43DAG, 35DAG and 25DAP reflecting their approximate
molecular weights. A subsequent report describing this complex referred to proteins as
A0, A1, A2, A3a/A3b, A4 and A5 and divided them into two sub-complexes; the
dystrophin and sarcoglycan complexes (Yoshida and Ozawa, 1990). The DGC is
present along the sarcolemma of skeletal muscle fibres and contains an array of
cytoplasmic, transmembrane and extracellular matrix proteins. Components of the DGC
include: the cytoplasmic proteins dystrophin and syntrophins (α and β), the
transmembrane protein sarcospan, the glycoproteins dystroglycan (α and β) and
sarcoglycans (α, β, γ, and δ) (Figure 3) (Ervasti and Campbell, 1991).[26]
Figure 3. Integral components of the dystrophin glycoprotein complex.
The dystrophin glycoprotein complex forms a crucial connection between the
intracellular cytoskeleton and the extracellular matrix. Alpha-dystroglycan has a
dumbbell like appearance. Attached O-linked glycans are depicted in red and occur in
the central mucin like region of α-dystroglycan. These glycans facilitate the attachment
of extracellular matrix ligands. Figure based on that from Davies et al. (Davies and
Nowak, 2006).[27]
Although the exact function of this complex has yet to be fully elucidated, it is thought
these proteins confer structural stability to the sarcolemma during cyclic contraction and
relaxation (Petrof et al., 1993). Defects in protein members of the DGC are thought to
render muscle fibres more venerable to damage. Various forms of muscular dystrophy
have now been linked to mutations in genes encoding components of the DGC (Table
1).[28]
* Protein (encoding gene)
** Gene ID
† Function Associated muscular dystrophy
‡
Dystroglycan; α- and β-
(DAG1)
1605
Connects the extracellular
matrix with the intracellular
cytoskeleton.
A range of muscular dystrophies are associated with hypoglycosylation of α-
dystroglycan. Walker-Warburg syndrome [OMIM_236670], Muscle eye brain
disease [OMIM_253280], Fukuyama congenital muscular dystrophy
[OMIM_253800], MDC1C [OMIM_606612], MDC1D [OMIM_608840],
LGMD2I [OMIM_607155], LGMD2K [OMIM_609308], CDG1O
[OMIM_612937].
Sarcospan (SSPN) 8082
Uncharacterised structural
role
No mutations detected in muscular dystrophy patients to date.
T
r
a
n
s
m
e
m
b
r
a
n
e
Sarcoglycans; α- (SGCA), β-
(SGCB), γ- (SGCG), and δ-
(SGCD)
6442, 6443, 6445,
6444
Structural and signalling
role.
LGMD2D [OMIM_608099], LGMD2E [OMIM_604286], LGMD2F
[OMIM_601287] and LGMD2C [OMIM_253700] respectively.
Dystrophin (DMD) 1756
Anchoring the cytoskeleton
to the sarcolemma
Duchenne [OMIM_310200] and Becker muscular Dystrophy [OMIM_300376].
C
y
t
o
p
l
a
s
m
i
c
Syntrophins; α- (SNTA1) and
β- (SNTB1)
6640, 6641
Connects dystrophin to
nNOS
No mutations detected in muscular dystrophy patients to date.
Table 1. Muscular dystrophies caused by defective components of the DGC.[29]
New nomenclature for genetic loci is based on the age of onset and mode of inheritance (LGMD1 for autosomal forms and LGMD2 for
dominant forms of late onset muscular dystrophy, CMD for congenital forms of muscular dystrophy, all of which are recessive). Within each
category a numerical suffix indicates the chronological order of their discovery (Bushby and Beckmann, 1995).
* Skeletal myofiber subcellular
localisation. ** Gene symbols and names as per HUGO nomenclature (www.genomes.org).
† Entrez Gene Identifier in the NCBI database
(http://www.ncbi.nlm.nih.gov/).
‡ Muscular dystrophy caused by mutations in the respective gene (reviewed in (Davies and Nowak, 2006))
followed by the Online Mendelian Inheritance in Man reference (http://www.ncbi.nlm.nih.gov/OMIM). ECM; extra-cellular matrix.[30]
Dystroglycan is an integral membrane protein linking the intracellular cytoskeleton to
proteins within the extracellular matrix. Dystroglycan was originally isolated from
skeletal muscle through its interaction with dystrophin. Research has primarily focussed
on its role in skeletal muscle and its function within the DGC has been extensively
studied. Dystroglycan is also expressed in numerous developing and adult tissues and is
typically found in cells facing basement membranes. Novel roles have continued to
emerge and dystroglycan has been found to function in a diverse range of cellular
processes including development, signalling and adhesion (Barresi and Campbell, 2006;
Smalheiser and Schwartz, 1987).
1.2 DYSTROGLYCAN
The gene encoding dystroglycan, DAG1, was initially cloned in 1992 and subsequently
mapped to 3p21 in 1993 (Ibraghimov-Beskrovnaya et al., 1992; Ibraghimov-
Beskrovnaya et al., 1993). The primary structure of dystroglycan is highly conserved
across mammalian species and displays a high degree of homology throughout lower
invertebrates. Mammalian DAG1 consists of two coding exons and encodes a single
mRNA species which is translated into a pro-peptide of 895 amino acids (Holt et al.,
2000). An N-terminal signal peptide directs insertion of dystroglycan into the ER
membrane. The pro-peptide is post-translationally cleaved at Ser654 yielding two non-
covalently associated subunits known as α and β (Figure 4) (Ibraghimov-Beskrovnaya
et al., 1992). Alpha-dystroglycan is a peripheral membrane glycoprotein and binds to
components of the extracellular matrix. Beta-dystroglycan is a transmembrane protein
that binds via its cytoplasmic domain to components of the cell cytoskeleton (Yoshida
and Ozawa, 1990).[31]
Figure 4. The structure of dystroglycan encoded by DAG1.
Black branches indicate N-linked sugar chains. Red branches indicate O-linked sugar
chains. SP; signal peptide, TM; transmembrane domain, PPXY; dystrophin-binding site,
C; C-terminus, N; N-terminus ends. Numbers indicate amino acids within each domain.
Figure based on that from Michele et al. (Michele et al., 2002).[32]
The molecular mechanism underlying the dystroglycan pro-peptide cleavage into its α
and β subunits remains largely undefined. Cleavage occurs within a full sea urchin,
enterokinase, agrin module suggesting an autoproteolysis mechanism (Akhavan et al.,
2008). The pro-peptide is cleaved in an early processing event within the ER and
proceeds glycosylation (Smalheiser and Kim, 1995). The functional significance is not
yet fully understood particularly because the peptide is not cleaved into subunits in
Drosophila melanogaster (Patnaik and Stanley, 2005). Despite this, studies have
indicated that this event is crucial for normal muscle development in mammals.
Jayasinha et al. demonstrated that the overexpression of an uncleaved dystroglycan
precursor in transgenic mice induced muscular dystrophy along with disorders in the
proliferation and differentiation of neurons (Jayasinha et al., 2003).
In the context of the DGC, transmembrane β-dystroglycan binds intracellularly to
members of the dystrophin family, which in turn bind to the actin associated
cytoskeleton. In tissues other than skeletal muscle, dystroglycan binds to various
alternative splice forms of dystrophin or one of its autosomal orthologs, utrophin
(Chung and Campanelli, 1999). The carboxy terminal 15 amino acids of β-dystroglycan
contains a PPXY motif facilitating binding to the C-terminal cysteine-rich regions of
dystrophin (or utrophin) which in turn comprise of a WW-like domain, an EF hand
domain and a ZZ domain. WW domains are named after two highly conserved
tryptophan residues, in this case 21 amino acids apart and are widely conserved among
structural, regulatory and signalling proteins (Sudol et al., 1995). The EF hand region
stabilises the WW domain, which is in turn stabilised and strengthened by the ZZ
domain. A more distantly related paralog of dystrophin lacking a WW domain, yet
containing an EF hand domain; α-dystrobrevin, also binds to β-dystroglycan (Chung
and Campanelli, 1999). A WW-like domain in Caveolin-3 also recognises the PPXY
domain of β-dystroglycan. It has been demonstrated that Caveolin-3 can effectively
block the interaction of dystrophin with β-dystroglycan in vitro and may therefore
competitively regulate the recruitment of dystrophin to the sarcolemma in vivo (Sotgia
et al., 2000).
Beta-dystroglycan also interacts with rapsyn, a postsynaptic protein involved in
clustering of acetylcholine receptors and the signalling adapter molecule Grb2 (Cartaud
et al., 1998; Yang et al., 1995). The biological significance of these interactions has[33]
remained elusive. The cytoplasmic tail of β-dystroglycan also binds to components of
the ERK-MAP kinase cascade including MEK and ERK (Spence et al., 2004). These
interactions implicate β-dystroglycan in signal transduction pathways and in the
formation of neuromuscular junctions (Henry and Campbell, 1999).
Alpha-dystroglycan is heavily glycosylated. Electron microscopy of α-dystroglycan by
Brancaccio et al. showed a dumbbell like appearance with a globular N-domain, a long
stalk like region in the mucin domain and a globular C-domain (Brancaccio et al.,
1995). This subunit is retained at the cell surface and binds to extracellular matrix
ligands (Brancaccio et al., 1995; Brancaccio et al., 1997). Primary sequence analysis of
α-dystroglycan predicts its molecular mass to be approximately 70 kDa although it
migrates in a heterogeneous pattern on sodium dodecyl sulphate gels (Ibraghimov-
Beskrovnaya et al., 1992). Its molecular mass is increased to 156 kDa in mammalian
skeletal and cardiac muscle due to its extensive glycosylation. Alpha-dystroglycan
migrates at 140 kDa and 120 kDa in brain and peripheral nerve respectively, reflecting
tissue specific modifications (Ibraghimov-Beskrovnaya et al., 1993; Leschziner et al.,
2000; Yamada et al., 1994). In addition, the varied molecular weight of human and
chick skeletal muscle α-dystroglycan during different developmental stages reflects
developmentally regulated modifications (Brown et al., 2004; Leschziner et al., 2000).
The structural characterisation of the mucin rich portion of α-dystroglycan has so far
remained unsuccessful due to its extensive glycosylation (Chiba et al., 1997).
Alpha-dystroglycan establishes a network of interactions with components of the
extracellular matrix such as laminin 1 and 2, agrin, perlecan, neurexin and biglycan
(Henry and Campbell, 1999). The binding of biglycan, an extracellular proteoglycan,
binds to the C-terminal domain of α-dystroglycan. This interaction is dependent on the
chondroitin sulphate side chains present on biglycan (Bowe et al., 2000). In contrast to
biglycan, the binding of laminins, agrin, perlecan and neurexin is strictly dependent on
the glycosylation status of α-dystroglycan (Michele et al., 2002; Michele and Campbell,
2003). Each of these ligands contain a laminin G domain mediating their high affinity
Ca2+ -dependent binding to α-dystroglycan (Hohenester et al., 1999; Talts et al., 1999;
Tisi et al., 2000). Laminins are composed of three distinct chains termed α, β, and γ. To 
date five α, four β, and three γ chains have been identified that can combine to form 15 
different isoforms. Dystroglycan binds with high affinity to the laminin G domains of[34]
laminin 1 (α1β1γ1) and laminin 2 (α2β1γ1) α chains (Talts et al., 1999). Laminin α2
forms a crucial link between α-dystroglycan and the basal lamina (Henry and Campbell,
1999).
The sarcoglycans form an integral subcomplex within the DGC. These four single span
transmembrane subunits (α, β, γ and δ) are tightly associated with sarcospan. Evidence 
has indicated that these proteins serve to stabilise dystroglycan. Although a mechanism
for this is unknown, evidence suggests that δ-sarcoglycan is in close molecular
proximity to dystroglycan (Chan et al., 1998). Recently a novel function of the
sarcoglycan complex has been demonstrated in whole body glucose homeostasis and
skeletal muscle metabolism (Groh et al., 2009). The transmembrane integrin subunits
are associated with members of the laminin family and have been found to co-localise
with dystroglycan in certain cell types. Despite this there is no evidence of direct
binding between the two proteins.
1.2.1 Glycosylation
The glycosylation of proteins enables immense functional diversity and the importance
of the glycome in a vast range of biological processes is only just beginning to emerge.
Between 1-2% of the human genome encodes enzymes involved in glycan formation.
Glycans serve a variety of structural and functional roles and are synthesised by several
biochemical pathways (Varki, 2008). Inherited pathological mutations occur in all
major glycan families. Defects in the human glycome have been associated with over 30
different genetic diseases. These rare human diseases are biochemically and clinically
heterogeneous and usually affect multiple organ systems (Freeze, 2006).
Major glycan groups are classified according to their glycan-peptide linkage regions. N-
linked glycans describe the attachment of an oligosaccharide to the amide group of an
asparagine residue via an aspartylglycosylamine link. The largest number of known
glycosylation disorders affect N-glycosylation and are referred to as congenital
disorders of glycosylation (referred to as CDGs).
Congenital disorders of glycosylation are classified according to their defects and are
subdivided into two types; I and II. Type I CDGs are caused by defects in the assembly[35]
of lipid linked oligosaccharides in the ER resulting in the production of incomplete
glycan structures. A complete loss of N-glycosylation is lethal therefore viable
mutations create hypomorphic alleles where insufficient or incomplete glycan
precursors are produced that are inefficiently transferred to proteins. Type II CDGs are
caused by defects in altered processing of protein bound sugar chains and describe a
more diverse aetiology with mutations occurring in glycosyltransferases, nucleotide
sugar transporters and cytoplasmic proteins that traffic into and within the Golgi
apparatus.
Accurate diagnosis is often problematic due to the variability of clinical features as well
as their overlap with other multisystemic metabolic disorders (Freeze, 2006). To
overcome this, a diagnostic assay has been developed on the basis that the majority of
patients demonstrate an under sialylation of serum glycoproteins detected by the
analysis of serum transferrin. Transferrin has two N-glycosylation sites with a typical
desialylated biantennary glycan on each side. Isoelectric focusing using ion-exchange
chromatography is used to identify the glycoforms present on transferrin.
Both α-dystroglycan and β-dystroglycan also contain N-linked glycans, yet enzymatic
removal of these glycans only alters α-dystroglycan’s molecular weight by
approximately 4 kDa (Ervasti and Campbell, 1991). However full chemical
deglycosylation results in the complete loss of ligand binding activity (Ervasti and
Campbell, 1993). The remainder of α-dystroglycan glycosylation is thought to reside in
the serine/threonine rich ‘mucin’ domain. The mucin domain contains fifty-five
potential sites for glycosylation of serine or threonine residues in the middle third of the
molecule.
O-linked glycans describe the attachment of a reducing terminal N-acetylgalactosamine
(GalNAc) to the hydroxyl group of serine/threonine residues. Several unique types of
O-glycosylation have also been identified such as O-linked fucose, glucose, N-
acetylglucosamine (GlcNAc) and mannose. O-mannosylation describes the attachment
of an oligosaccharide to the hydroxyl group of a serine or threonine residue via
mannose. O-mannosylation is well characterised in yeast and is essential for viability
affecting cell wall integrity and rigidity. Subsequently mammalian O-mannosylation
was found to reside on dystroglycan (Endo, 1999). Alpha-dystroglycan glycan[36]
sequencing studies have been performed on three different tissues from three different
species: bovine peripheral nerve; rabbit skeletal muscle and sheep brain (Matsumura et
al., 1997; Smalheiser and Schwartz, 1987; Toda et al., 2003). In all these studies the
following glycan was identified NeuAcα2,3Galβ1,4GlcNAcβ1,2Manα-O-Ser/Thr.
Alpha-dystroglycan is the only identified carrier of this glycan. Phosphorimaging of a
recombinant dystroglycan containing only the mucin-like domain has suggested that
phosphorylation occurs on the O-linked mannose residue (Yoshida-Moriguchi et al.,
2010). A significant amount of Galβ1,3GalNAcα-O was also identified, suggesting that
multiple O-linked structures exist. In addition to the structures found in peripheral nerve
and skeletal muscle the O-mannosyl-linked LewisX antigen
Galβ1,4(Fucα1,3)GlcNAcβ1,2Manα-O was detected in the brain. Analysis of whole rat
brain revealed O-mannose based glycans account for one third of all O-linked glycans
in the brain. As well as those structures previously reported by α-dystroglycan glycan
sequencing studies, 1,6 substituted Manα-O structures have also been found in O-linked
brain glycans including;
NeuAcα2,3Galβ1,4GlcNAcβ1,2[NeuAcα2,3Galβ1,4GlcNAcβ1,6]Manα-O (Chai et al.,
1999). It has not yet been shown if this structure resides on dystroglycan or other O-
linked glycans in the brain (Figure 5).[37]
Figure 5. Glycan structures and dystroglycan.
The three glycan structures identified on α-dystroglycan by glycan sequencing studies
are shown in the blue shaded boxes. Glycan sequences shown in the orange boxes
represent those posited to be present on α-dystroglycan based on lectin and antibody
binding analyses. The O-linked branched mannose structure shown in the green shaded
box has been included due to its presence in brain tissue although it has not yet been
established if this exists on α-dystroglycan (Martin, 2003). Symbolic representation of
monosaccharides follows the nomenclature proposed by the Consortium for Functional
Glycomics (www.functionalglycomics.org).[38]
It is worth noting that all studies to date have all been performed using dystroglycan
purified by carbohydrate binding lectins (e.g. wheat germ agglutinin). Due to the use of
this enriched form of dystroglycan, these structures may only represent a subset of
glycans present on this glycoprotein (Martin, 2003). Further studies are needed to
clarify the heterogeneity and distribution of O-mannosyl glycans in various tissues both
during development and under pathological conditions.
1.2.2 Aberrant Post-Translational Modifications in Disease
More recently it has emerged that perturbation of extensive post-translational processing
of dystroglycan plays a role in human disease. Defects in a number of proteins that
glycosylate dystroglycan, or are thought to do so, have been shown to cause muscular
dystrophy (Michele et al., 2002; Muntoni et al., 2008). The processing of dystroglycan
also affects its function as a cellular receptor for human pathogens and has implications
in the progression of cancer (Cao et al., 1998; Rambukkana et al., 1998; Singh et al.,
2004).
Abnormalities in the structure and function of basement membranes are hallmarks of
metastatic disease. Disruption of the interaction between cancer cells and the
extracellular matrix is believed to provide a mechanism by which tumours can invade
surrounding tissues and metastasise. The expression of dystroglycan at the interface
between the basal lamina and the plasma membrane, as well as its function in cell
adhesion suggests a possible role in this process. Multiple post-translational
modifications of dystroglycan have been identified in carcinoma cells, which are
thought to modulate the composition and function of dystroglycan. The glycosylation of
dystroglycan is altered in invasive carcinoma cells causing a complete loss of its
laminin binding properties (Singh 2004). Low or absent dystroglycan has been
correlated with a higher tumour stage, high proliferation index, and lower overall
survival in these cells. Beta-dystroglycan expression is preserved in cancer cell lines
although a truncated β-dystroglycan is observed and expressed as a 31 kDa protein.
Singh et al also described the loss of α-dystroglycan caused by protease-dependent
shedding from the cell surface (Singh et al., 2004). These studies indicate that
abnormalities in dystroglycan processing can be a common feature in carcinogenesis[39]
and may contribute to the progression of metastatic disease (Henry et al., 2001;
Muschler et al., 2002).
Glycosylation of α-dystroglycan has also been implicated in the binding of human
pathogens. The first cellular receptor for Old World arenaviruses was identified as
dystroglycan. Arenaviruses represent a genus of virus and are subdivided into two major
groups; the Old World arenaviruses found in Europe and Africa and the New World
arenaviruses, endemic in the Americas. Each arenavirus species has a natural reservoir
in one or a limited number of closely related rodent species. The virus is maintained in
the asymptomatic natural rodent host as a persistent infection. Viral transmission to
humans via contact with infected rodents can cause severe disease. The attachment of
the virus to its cellular receptor represents an important determinant for cellular tropism,
host range and disease potential. Alpha-dystroglycan is the primary receptor for the Old
World lymphocytic choriomeningitis virus (LCMV), the Lassa virus, the related African
arenaviruses Mopeia and Mobala, as well as the Clade C New World arenaviruses
Latino and Oliveros.
The COOH-terminal region of α-dystroglycan’s first globular domain and the NH2-
terminal end of the mucin-like domain form the binding site for LCMV. LCMV and
laminin-1 use, in part, an overlapping binding site on α-dystroglycan and the ability of
an LCMV isolate to compete with laminin-1 for receptor binding is determined by its
binding affinity to α-dystroglycan (Kunz et al., 2001). The construction of deletion
constructs has indicated that β-dystroglycan does not act as a cofactor with α-
dystroglycan for arenavirus binding and entry (Kunz et al., 2003). Post-translational
modifications of α-dystroglycan are crucial for its function as a cellular receptor for the
Lassa virus, the LCMV, African arenaviruses Mopeia and Clade C New World
arenaviruses (Imperiali et al., 2005; Kunz et al., 2005).
1.3 DYSTROGLYCANOPATHIES
Post-translational modifications of dystroglycan are associated with a number of
autosomal recessive muscular dystrophies. The aberrant glycosylation of α-
dystroglycan, yet not β-dystroglycan, is the primary pathological mechanism in a range[40]
of disorders characterised by muscular dystrophy with variable brain and ocular
abnormalities (Michele et al., 2002).
Phenotypic severity in patients is extremely variable. At the most severe end of the
clinical spectrum are WWS, MEB and Fukuyama congenital muscular dystrophy
(FCMD) (Beltran-Valero de Bernabe et al., 2002; Kobayashi et al., 1998; Yoshida et al.,
2001). These conditions are characterised by congenital muscular dystrophy (CMD)
with severe structural brain and eye abnormalities, which in WWS results in early
infantile death (van Reeuwijk et al., 2005a). Conversely, individuals at the mildest end
of the clinical spectrum may present in adult life with limb girdle muscular dystrophy
(LGMD) with no associated brain or eye involvement (Brockington et al., 2001b). A
number of intermediate phenotypes between these extremes have also been described
including: congenital muscular dystrophy type 1D, with subtle brain involvement and
mental retardation (Longman et al., 2003); congenital muscular dystrophy type 1C
(MDC1C), a CMD variant in which the brain can be entirely normal and LGMD2K, a
variant with microcephaly and mental retardation but a relatively mild LGMD–like
phenotype (Balci et al., 2005; Brockington et al., 2001a). Recently the term
‘dystroglycanopathy’ has been adopted to encompass this clinically and genetically
heterogeneous collection of disorders (Godfrey et al., 2007).
Common to all these disorders is the pathological feature of reduced glycosylation
(hypoglycosylation) of α-dystroglycan (Michele et al., 2002). The finding that α-
dystroglycan glycosylation is perturbed is based on loss of immunoreactivity to one or
both monoclonal antibodies IIH6 and VIA4-1 which are specific for glycoepitopes
present on α-dystroglycan. The glycan structures recognised by the antibodies IIH6 and
VIA4-1 are as yet uncharacterised.
Immunofluorescence is evaluated in parallel with β-dystroglycan labelling and routinely
performed on transverse sections of skeletal muscle. A reduction or complete absence of
binding using the carbohydrate dependent antibodies IIH6 and/or VIA4-1, in
conjunction with the retention of β-dystroglycan labelling is now used as a routine
diagnostic tool (Figure 6) (Jimenez-Mallebrera et al., 2003). The extent of
hypoglycosylation is variable between patients and ranges from a virtual absence of
epitope in muscle to a minimal reduction in some fibres (Jimenez-Mallebrera et al.,[41]
2008). The evalutation of immunoreactivity to IIH6 and β-dystroglycan labelling on
western blot is a powerful technique yet is often only performed on a research basis due
to the shortage of material available for analysis. A secondary reduction in laminin α-2
labelling is also observed and reflects the reduced capacity of hypoglycosylated α-
dystroglycan to bind its extracellular matrix ligands.[42]
Figure 6. Hypoglycosylation of α-dystroglycan as detected on skeletal muscle biopsy.
Diagnostic features of dystroglycanopathy skeletal muscle using antibodies against β-
dystroglycan; β-DG, carbohydrate moieties present on α-dystroglycan; IIH6 and VIA4-
1 and core α-dystroglycan; GT20ADG. A) Immunohistochemical analysis of transverse
sections of skeletal muscle from a dystroglycanopathy patient and a control normal
muscle. The hallmark of dystroglycanopathy muscle is a specific reduction of
immunoreactivity to either IIH6 or V1A-4 yet the retention of immunoreactivity to β-
dystroglycan and GT20ADG. B) Immunoblot analysis of WGA-enriched total muscle
from control normal muscle (C) and a dystroglycanopathy patient (P). The molecular[43]
weight of β-dystroglycan is unchanged on western blot analysis yet a dramatic reduction
in molecular weight of α-dystroglycan is seen using the GT20ADG antibody due to
hypoglycosylation. Primary sequence analysis of α-dystroglycan predicts a molecular
mass of 72 kDa however α-dystroglycan in skeletal muscle migrates to 156 kDa. Figure
modified from Michele et al. (Michele et al., 2002). Permission to reproduce this figure
has been granted by Nature Publishing Group.[44]
1.3.1 Molecular Defects
Proteins residing within the Golgi apparatus and the ER mediate post-translational
processing such as the attachment and modification of carbohydrate molecules to form
glycoproteins. Whereas genetic defects in DAG1 itself have not yet been identified in
human disease, defects in four proteins of the Golgi apparatus and three proteins of the
ER have been shown to cause a dystroglycanopathy phenotype (Table 2). The detection
of mutations in genes encoding these putative or demonstrated glycosyltransferases and
accessory glycosyltransferase proteins uncovers a novel pathogenic mechanism causing
muscular dystrophy (Muntoni et al., 2002).
Functional analysis of the glycosyltransferases POMT1, POMT2 and POMGNT1 has
demonstrated their pathway specific function in the production of O-mannose linked
glycans (Figure 7). The function of FKTN, FKRP and LARGE have yet to be fully
characterised (Brockington et al., 2001a; Kobayashi et al., 1998; Longman et al., 2003).
Very recently a somewhat unexpected report described mutations in DPM3 giving rise
to a dystroglycanopathy-like phenotype (Lefeber et al., 2009).[45]
Protein (encoding gene) *
Gene ID
**
location
†
Molecular
function
††
Subcellular
localisation
‡ Initial phenotypic description
‡‡ OMIM reference
±
Fukutin (FKTN) 607440
9q31-
q33
Molecular function
unclassified
Golgi apparatus
Fukuyama congenital muscular
dystrophy (FCMD) (Kobayashi et al.,
1998)
OMIM_253800
Fukutin related protein (FKRP) 606596 19q13.3
Molecular function
unclassified
Golgi apparatus
≠
Congenital muscular dystrophy 1C
(MDC1C) (Brockington et al.,
2001a)
OMIM_606612
Protein-O-linked mannose beta 1,2-N-
acetylglucosaminyltransferase
(POMGNT1)
606822 1p34.1 Glycosyltransferase Golgi apparatus
Muscle eye brain disease
(MEB) (Yoshida et al., 2001)
OMIM_253280
Protein-O-mannosyltransferase 1
(POMT1)
607423 9q34.1 Glycosyltransferase Endoplasmic reticulum
Walker-Warburg syndrome
(WWS) (Beltran-Valero de Bernabe
et al., 2002)
OMIM_236670
Like-glycosyltransferase (LARGE) 603590 22q12.3 Glycosyltransferase Golgi apparatus
Congenital muscular dystrophy 1D
(MDC1D) (Longman et al., 2003)
OMIM_608840
Protein-O-mannosyltransferase 2
(POMT2)
607439 14q24 Glycosyltransferase Endoplasmic reticulum
Walker-Warburg syndrome
(WWS) (van Reeuwijk et al., 2005b)
OMIM_236670
Dolichyl-phosphate
mannosyltransferase polypeptide 3
(DPM3)
605951 1q22
Molecular function
unclassified
Endoplasmic reticulum
Mild muscular dystrophy with
dilated cardiomyopathy (CDG type I)
(Lefeber et al., 2009)
OMIM_612937
±±[46]
Table 2. An overview of causative dystroglycanopathy genes.
* Gene symbols and names as per HUGO nomenclature (www.genenames.org/). ** Entrez Gene Identifier from the NCBI database
(http://www.ncbi.nlm.nih.gov/).
† Denotes chromosomal location.
†† Molecular function as classified by the PANTHER (Protein ANalysis
THrough Evolutionary Relationships) Classification System (http://www.pantherdb.org/).
‡ Subcellular localisation as annotated via the
Universal Protein Resource Knowledge Base (UniProtKB) (www.uniprot.org).
≠ The subcellular localisation of FKRP is controversial with
reports using tagged recombinant proteins differing from those using antibodies to endogenous FKRP protein (Beedle et al., 2007; Esapa et al.,
2002; Keramaris-Vrantsis et al., 2007; Matsumoto et al., 2004; Torelli et al., 2005).
‡‡ Initial phenotype associated with mutations in the
respective gene.
± Online Mendelian Inheritance in Man reference (http://www.ncbi.nlm.nih.gov/OMIM).
±± To date mutations in DPM3 have
only been detected in a single patient.[47]
Fukutin; FKTN
Fukuyama congenital muscular dystrophy (FCMD) [OMIM 253800] was described
within the Japanese population where it is the second most common form of muscular
dystrophy after Duchenne muscular dystrophy (Kobayashi et al., 1998). The high
incidence of FCMD in Japan is related to a founder mutation in the gene Fukutin
(FKTN) occurring over 2000 years ago (Colombo et al., 2000). A 3 kb retrotransposon
is present in the 3’ untranslated region and is present in the homozygous state in
approximately 90% of all Japanese FCMD patients (Kobayashi et al., 1998). With a
carrier frequency of this mutation of 1 in 188, FCMD is the most common autosomal
recessive disease in Japan (Watanabe et al., 2005). The 3 kb insertion is thought to
render the transcript unstable and globally down regulate the FKTN transcript. This
mutation was the first report of a human disease caused by an ancient retrotransposal
integration (Kobayashi et al., 1998). Dystroglycan glycosylation was subsequently
shown to be perturbed in FCMD (Hayashi et al., 2001).
The FKTN gene encodes a 461-amino acid protein showing similarities to a family of
proteins involved in modifying cell surface molecules such as glycoproteins and
glycolipids (Aravind and Koonin, 1999). The protein has a putative glycosyltransferase
domain (DxD) yet despite this, enzymatic activity is yet to be demonstrated and the
function of fukutin remains largely unknown (Breton and Imberty, 1999).
Knockout mice generated for Fktn are embryonically lethal (Kurahashi et al., 2005). To
overcome the embryonic lethality of these mice, chimeric knockout mice were
generated. Mice composed of less than 50% Fktn null cells demonstrate compromised
survival, typical muscular dystrophy and associated brain and ocular abnormalities
(Takeda et al., 2003).
Fukutin related protein; FKRP
Patients with a severe form of congenital muscular dystrophy were reported to harbour
mutations in a homologue of FKTN; Fukutin Related Protein; FKRP (Brockington et
al., 2001a) (referred to as MDC1C [OMIM 606612]. These reports were immediately
followed by the identification of mutations in patients with a mild form of limb girdle[48]
muscular dystrophy; LGMD2I [OMIM 607155) (Brockington et al., 2001a;
Brockington et al., 2001b). The incidence of LGMD2I is particularly high in northern
European Caucasian populations due to the prevalence of a single mutation: c.826C>A;
Leu276Ile. The occurrence of this mutation on a common core haplotype suggests that
Leu276Ile is a founder mutation that is dispersed among populations of European origin
(Frosk et al., 2005).
FKRP encodes a 495 amino acid protein predicted to contain a hydrophobic
transmembrane spanning region followed by a stem region and a putative catalytic
domain. Despite the presence of a DxD domain no transferase activity has been
identified (Brockington et al., 2001a). The downregulation of FKRP in zebrafish
embryos causes alterations in somatic structure and muscle fibre organisation as well as
defects in developing neuronal structures and eye morphology (Thornhill et al., 2008).
An FKRP murine knockdown model exists where the inclusion of a Neo cassette causes
a reduction in mRNA causing mild muscular involvement yet severe neuronal
abnormalities and mice die soon after birth (Ackroyd et al., 2009).
Protein-O-linked mannose beta 1,2-N-acetylglucosaminyltransferase; POMGNT1
Muscle eye brain disease [OMIM 253280] is particularly prevalent in the Finnish
population. Linkage analysis revealed a founder splice site mutation in Protein-O-linked
mannose beta 1,2-N-acetylglucosaminyltransferase (POMGNT1) (Diesen et al., 2004).
This type II membrane protein, similar to other Golgi glycosyltransferases, catalyses the
addition of an N-acetylglucosamine (GlcNAc) residue through Beta1,2 linkage to the
mannose group using uridine 5’-diphosphate (UDP)-GlcNAc as a donor substrate.
POMGNT1 encodes a 660 amino acid protein containing an N-terminal cytoplasmic
tail, a transmembrane domain, a stem domain and a C-terminal catalytic domain
(Yoshida et al., 2001; Zhang et al., 2002). POMGNT1 has been shown to directly
interact with FKTN in the Golgi apparatus. The formation of this complex is thought to
modulate POMGNT1 enzymatic activity (Xiong et al., 2006). The abolition of Pomgnt1
expression in mice causes multiple developmental defects in muscle, eye, and brain,
similar to the phenotypes observed in human MEB (Liu et al., 2006).
Protein-O-mannosyltransferase 1; POMT1[49]
The gene encoding glycosyltransferase Protein-O-mannosyltransferase 1 (POMT1) was
cloned in 1999 and was the first O-mannosyl-transferase detected in humans. It was
suggested as a promising candidate for dystroglycanopathy phenotypes as it was
predicted to function as O-mannosyl glycan GlcNAc transferase and catalyse the first
step in the assembly of the O-mannose-linked glycan moiety of α-dystroglycan (Jurado
et al., 1999). Mutations were subsequently identified in patients with WWS; the most
severe end of the clinical spectrum of dystroglycanopathies [OMIM 236670] (Beltran-
Valero de Bernabe et al., 2002). POMT1 encodes a 747 amino acid protein that is
localised to the Golgi apparatus. RNA interference (RNAi) knockdown experiments in
Drosophila melanogaster caused a rotation of the abdomen by 30-60° demonstrating its
requirement for normal muscle development in the fly (Ichimiya et al., 2004). As with
Fktn null mice, Pomt1 ablation is early embryonically lethal (Willer et al., 2004).
Like-glycosyltransferase; LARGE
The transgenic enervated (enr) mouse and the myodystrophy mouse (Large
myd) present
with pathological features similar to congenital muscular dystrophy patients and were
later shown to have hypoglycosylated α-dystroglycan (Grewal et al., 2001; Holzfeind et
al., 2002; Levedakou et al., 2005). Both mice harbour part gene deletions in the gene
Large, thus named due to its extensive genomic span. Candidate gene analysis of the
human ortholog in a cohort of dystroglycanopathy patients revealed a mutation in a
congenial muscular dystrophy patient with mental retardation; MDC1D [OMIM
608840] (Longman et al., 2003).
LARGE was originally named due to its extensive genomic coverage of approximately
650 kb despite a coding region of only 2268 base pairs (bp). The 756 amino acid protein
contains an N-terminal transmembrane domain, a coiled-coil domain and three
conserved DxD motifs located in two predicted catalytic domains suggesting the
possibility of a bifunctional enzyme (Brockington et al., 2005). The exact activity of
LARGE is unknown and enzymes related to LARGE catalyse modifications unrelated to
O-mannosylation (Patnaik and Stanley, 2005). The protein resides in the Golgi
apparatus and appears to recognise an aminoterminal region of α-dystroglycan defining
an enzyme-substrate recognition motif necessary to initiate functional glycosylation.[50]
Molecular recognition of α-dystroglycan by LARGE is required for the biosynthesis of a
functional dystroglycan and to prevent muscle degeneration (Kanagawa et al., 2004). A
recent report from Yoshida-Moriguchi et al. described the treatment of wheat germ
agglutinin enriched glycoproteins from skeletal muscle with cold aqueous hydrofluoric
acid which specifically cleaves phosphodiester linkages. This led to a reduction in the
molecular weight of α-dystroglycan along with a loss of IIH6 immunoreactivity and
laminin binding function (Yoshida-Moriguchi et al., 2010). Using patient cell lines, the
authors speculate that LARGE participates in post-phosphoryl modification of the O-
mannosyl glycan.
Protein-O-mannosyltransferase 2; POMT2
Protein-O-mannosyltransferase (POMT2) was the second eukaryotic O-
mannosyltransferase gene to be described showing high identity to its paralog POMT1
(Willer et al., 2002). Candidate gene screening in combination with homozygosity
mapping detected mutations in POMT2 in a cohort of WWS patients [OMIM 236670]
(van Reeuwijk et al., 2005b). The coexpression of POMT1 and POMT2 is necessary for
enzymatic activity (Manya et al., 2004). POMT1 and POMT2 reside in the ER and
transfer a mannosyl residue from dolichol-phosphate-mannose (Dol-P-Man) to serine or
threonine residues (Manya et al., 2004).
A clockwise helical rotation of the body is caused by mutation of the Pomt homologs in
Drosophila melanogaster. The rotated abdomen (rt) and twisted (tw) phenotypes are
thought to be due to insufficient torque in muscle architecture needed during segmental
development (Lyalin et al., 2006; Martin-Blanco and Garcia-Bellido, 1996).
Dolichyl-phosphate mannosyltransferase polypeptide 3; DPM3
In July 2009 Lefber et al. reported a patient presenting with mild muscular dystrophy,
dilated cardiomyopathy and stroke like episodes with no associated brain or eye
involvement with an intriguing molecular defect [OMIM 612937]. A reduction in
immunoreactivity to IIH6 was seen on immunohistochemistry from a skeletal muscle
biopsy. Due to the patient’s unusual clinical presentation transferrin isoelectric focusing
of the patient’s blood serum was performed. The assay revealed an abnormal transferrin[51]
profile suggesting a CDG type I pattern consistent with a disorder in N-glycosylation
and a defect in the ER. Further to this, analysis of the patient’s fibroblasts revealed a
reduction in Dol-P-Man synthase activity (Lefeber et al., 2009).
Dol-P-Man is the glycol donor for all mannosylation reactions taking place on the
luminal side of the ER. The donation of mannose is required for four different pathways
of glycosylation; N-glycosylation, C-mannosylation, O-mannosylation and GPI-anchor
formation. In higher eukaryotes the Dol-P-Man synthase complex is composed of three
subunits. The catalytic subunit DPM1 is located in the cytoplasm and transfers mannose
from the nucleotide sugar GDP-Mannose to membrane embedded dolichol-phosphate
resulting in the formation of Dol-P-Man. DPM3 anchors this catalytic subunit to the ER
via its coiled-coil domain. DPM2 is located in the ER membrane and is required for
stabilisation of the complex. Mutation analysis performed on the DPM subunits
identified a homozygous missense mutation in DMP3. This sequence alteration was
confirmed as pathogenic by co-transfection experiments in Chinese hamster ovary cells
showing a reduced binding capacity of DMP3 that tethers catalytic DPM1 to the ER
membrane. Although the mild defect in Dol-P-Man would be expected to affect all four
glycosylation pathways, O-mannosylation was found to be more sensitive to this
reduction and considered to be the cause of clinical features (Lefeber et al., 2009).
Prior to this report CDGs and dystroglycanopathies had been regarded as two separate
groups of glycosylation disorders. Although children with CDGs are profoundly
hypotonic, skeletal muscle is not a primary target. This patient has a clinical
presentation of dystroglycanopathy with hypoglycosylation of α-dystroglycan, yet the
biochemical features of a CDG, therefore bridging the gap between these two
glycosylation disorders.[52]
Figure 7. O-mannose biosynthetic pathway.[53]
A diagrammatic representation of O-mannose linked glycan assembly beginning in the
ER and completed in the Golgi apparatus. The Dol-P-Man synthase complex
(comprising of DMP1, DMP2 and DMP3) transfers mannose from GDP-mannose to
dolichol-phosphate resulting in dolichol-phosphate mannose (A). The heterodimeric
enzyme protein-O-mannosyltransferase (POMT1/POMT2) then adds mannose in α1-O
linkage to Serine (Ser) / Threonine (Thr) residues located in the central portion of α-
dystroglycan’s mucin domain (B). In the Golgi apparatus (C-E) a pathway specific
protein O-mannose β1,2GlcNAc transferase (POMGNT1) uses UDP-GlcNAc to add a
β1,2GlcNAc residue to the mannose creating a disaccharide (C). The O-mannose
structure is completed by the addition of a β1,4-galactose and 2,3-sialic acid residues
added by unspecified transferases (D-E). The functions of LARGE, FKRP and FKTN
remain uncharacterised. Those enzymes depicted in boxes are known to cause a
dystroglycanopathy phenotype when mutated. Diagram based on those from Freeze et
al. (Freeze, 2006; Varki, 2008).[54]
1.3.2 Mechanisms of Pathogenesis
To further understand the role of dystroglycan a variety of knockout and conditional
knockout mouse models have been developed. Global abolition of Dag1 expression
results in embryonic lethality around day 5.5 due to structural and functional
perturbations of the Reichert’s membrane; a thick, early forming basement membrane
that surrounds the rodent embryo separating it from the maternal circulation
(Williamson et al., 1997). However, another basement membrane forming between the
visceral endoderm and ectoderm appears to persist in Dag1 null embryos arguing
against a general role for dystroglycan in basement membrane assembly (Henry et al.,
1998). In contrast, the abolition of dystroglycan expression in lower species such as
zebrafish does not impair embryonic development although adult fish display a severe
form of dystrophy (Parsons et al., 2002).
Work is underway to better understand the underlying mechanisms and functional
consequences underlying dystroglycanopathy phenotypes specifically. A number of
both naturally occurring and targeted animal models defective in genes implicated in the
pathway of glycosylation have also been studied. As with Dag1 null mice, Pomt1
ablation is early embryonically lethal, both strains of mice fail to synthesise the
Reichert’s membrane, a basement membrane that surrounds the blastocyst (Willer et al.,
2004).
Chimeric dystroglycan knockout mice developed a form of muscular dystrophy (Cote et
al., 1999). Conditional knockout mice with the specific ablation of dystroglycan in
skeletal muscle resulted in the loss of the dystrophin glycoprotein complex and
demonstrated that dystroglycan has a central role in maintenance of muscle fibre
integrity (Cohn et al., 2002).
Skeletal muscle dystrophy
The glycosylated moiety of α-dystroglycan is crucial for binding with extracellular
matrix ligands in skeletal muscle which connect the sarcolemma with the extracellular
matrix. Abnormal dystroglycan-ligand interactions underlie a major pathological[55]
hallmark of disease (Figure 8). A secondary reduction in laminin was first described in
FCMD patients (Hayashi et al., 1993). Alpha-dystroglycan glycosylation is required for
the clustering of agrin and laminin 1 (Campanelli et al., 1994; Cohen et al., 1997).
The monoclonal antibody IH6 is known to bind to a carbohydrate moiety that mediates
and functionally blocks the interaction between α-dystroglycan and laminin α-2 (Brown
et al., 1999). Antibody blocking studies using the monoclonal antibody IIH6 in primary
muscle cultures results in myotubes that are decreased in size, show myofibril
disorganisation and a loss of spontaneous contractile activity compared to controls
(Brown et al., 1999).
The perturbation of basement membranes in muscle has been described in both patients
with WWS and FCMD and is thought to represent an important pathogenic event.
Electron microscopy of skeletal muscle fibres in all patients studied with FCMD had a
thin and disrupted appearance of the basement membrane (Ishii et al., 1997). Studies in
a patient with WWS caused by mutations in POMT1 showed alterations in non necrotic
fibres in two distinct subcellular compartments; the basal lamina and nucleus (Sabatelli
et al., 2003).[56]
Figure 8. Hypoglycosylation of dystroglycan within the DGC.
The basement membrane of skeletal muscle fibres consists of layers of extracellular
matrix material. The inner layer, referred to as the basal lamina, is directly linked to the
plasma membrane (sarcolemma). The glycosylated moiety of α-dystroglycan is crucial
for binding with extracellular matrix ligands such as laminin (A). Abnormal ligand-
matrix interactions and altered basal lamina composition and organisation are thought to
underlie the pathological mechanisms in skeletal muscle from dystroglycanopathy
patients (B). Figure based on that from Barresi et al. (Barresi et al., 2004).[57]
Aberrant neuronal migration during cortical development
Brain involvement is a frequent yet not constant feature in patients with a
dystroglycanopathy. Patients vary from normal cognitive development and normal brain
magnetic resonance imaging to severe structural brain abnormalities in patients with
associated learning difficulties. A hierarchical pattern of changes is observed from
isolated cerebellar cysts, to structural involvement affecting brainstems and pons,
polymicrogyria and cobblestone lissencephalic changes, ventricular dilation and white
matter abnormalities (Clement et al., 2008a).
Disruptions in neuronal migration and development of the cerebral wall are observed at
the most severe end of the clinical spectrum of dystroglycanopathy patients.
Lissencephaly describes the smooth appearance of the cortex and is caused by defective
neuronal migration during development of the cerebral cortex. Whereas mutations in
regulators of the microtubule cytoskeleton have been identified in classic lissencephaly,
mutations in the basal lamina of the central nervous system underlie cobblestone
lissencephaly (also referred to as type II lissencephaly) (Olson and Walsh, 2002).
The human cerebral cortex is a highly folded sheet of six neuronal layers each with
characteristic histological and functional properties. These layers are established during
embryonic development by the radial migration of postmitotic neurons from the middle
of the brain to the developing cortical layers near the surface. Neurons are generated in
specialised proliferative zones along ventricular cavities called ventricular zones.
Neurons migrate along specialised elongated cells known as radial glial cells. These
span the entire cortical wall from the ventricular zone and are attached to the basal
lamina via specialised radial end feet. Neurons then migrate along radial glial cells from
the proliferative zone, through the fibre rich intermediate zone and into the developing
cortical plate immediately beneath the marginal zone. The neuronal layers are laid in an
inside out pattern with early generated neurons occupying deep layers and those later
migrating cells located in superficial layers (Figure 9) (Olson and Walsh, 2002).[58]
Figure 9. Neuronal migration during cortical development.
Neurons (solid green cells) migrate on specialised elongated cells; radial glial cells
(solid blue cell) which span the whole cortical wall from the ventricular zone (VZ) to
the basal lamina (BL) of the pial surface, where the specialised glial endfeet terminate.
Neurons migrate from the proliferative ventricular zone through the fibre-rich
intermediate zone (IZ) into the developing cortical plate (CP). Neurons arrest migration
at the top of the cortical plate (CP), immediately beneath the marginal zone (MZ).
Figure based on that from Olson et al. (Olson and Walsh, 2002).[59]
The correct formation of the basement membrane is essential for neuronal migration.
Disordered cortical layering and clusters of neurons and glial beyond the pial basement
membrane have been identified in patients with FCMD, MEB and WWS. The migration
of neurons or neuronal precursors, out of the developing brain through breaches in the
superficial neural basal lamina, produces bumpy neuronal cobblestones (ectopia)
(Figure 10). Glycosylated α-dystroglycan is highly expressed in both the pial
membranes and neurons themselves although its exact role remains unknown (Saito et
al., 2006).[60]
Figure 10. Neuronal migration defects and cobblestone lissencephaly.
A) The normal mammalian neocortex is comprised of six cellular layers overlying a
band of white matter (WM). The cortical plate (green cells, layers 2-6) is sandwiched
between layer 1 (upper red cells) and the subplate (SP; lower red cells). B) Description
of cobblestone lissencephaly showing characteristic features. The basal lamina is
fragmented and neurons migrate through the breach to form ectopic bumps on the
surface of the brain. Figure based on that from Olson et al. (Olson and Walsh, 2002).[61]
Whereas the neocortex has deep grooves (sulci) and wrinkles (gyri) in primates, rodents
have a smooth cortical appearance therefore cannot display lissencephaly as such.
Mutant mice with cortical migration defects do show deficiencies in basal lamina
integrity as well as superficial bumps of neurons analogous to the cobblestone cortex
observed in humans. Both the Fkrp-Neo
Try307Asn knockdown and Pomgnt1 knockout
mice brains display pial basement membrane breaches during rapid cerebral cortical
expansion at embryonic day 13.5 with radial end feet growing out of the neural
boundary. Basement membrane breaches are also found in chimeric mice of Fktn KO
and the Large
myd mice. Brain specific ablation of mouse dystroglycan causes structural
defects with discontinuities in the pial surface basal lamina (glia limitans) (Moore et al.,
2002).
Ocular abnormalities
Ocular abnormalities can be a frequent feature in patients with a dystroglycanopathy.
Eye abnormalities including congenital cataracts and microphthalmia are common
findings in patients with WWS. Congenital glaucoma, progressive myopathy, retinal
atrophy and juvenile cataracts are observed in patients with MEB disease. Little is
known of the pathogenic mechanisms operating in these patients.
Ocular abnormalities are observed in mouse models of dystroglycanopathies. The Fkrp-
Neo
Try307Asn, Fktn chimera, Pomgnt1 null and Large
myd mice all show eye involvement.
The inner limiting membrane is a basement membrane that separates the retina from the
vitreous body. The mechanical strength of the inner limiting membrane is known to be
essential for normal eye development. Fkrp-Neo
Try307Asn newborn mice show a marked
disorganisation of the inner limiting membrane and an invasion of cells into the vitreous
body. Ectopic nuclei were present outside the inner limiting vitreous body (Ackroyd et
al., 2009). A disorganisation of the retinal lamina, retinal detachment and lens
opacification are present in Fktn chimeric mice (Takeda et al., 2003). Thinner inner and
outer neuroblastic layers are also present in Pomgnt1 null mice and Large
myd mice
(Holzfeind et al., 2002; Liu et al., 2006).
1.4 PERSPECTIVES[62]
Recent years have seen an explosion in our understanding of aberrant glycosylation in
muscular dystrophies. Emphasis has moved away from identifying structural proteins of
skeletal muscle towards the discovery of enzymes and proteins involved in modifying
these components. Since its original description in 2002, hypoglycosylation of α-
dystroglycan has been identified in several forms of muscular dystrophy. Defects have
been identified in putative and demonstrated glycosyltransferases and accessory
glycosyltransferase proteins implicated in the formation of characterised and
uncharacterised glycans. The correct glycosylation of α-dystroglycan seems to be
crucial for muscle function and in more severe clinical presentations, brain and eye
formation. The molecular characterisation of many of these patients remains to be
performed and with the recent promise of therapeutic strategies for these disorders,
these fundamental issues are ever more pressing.[63]
CHAPTER 2: PATIENTS AND METHODS[64]
2 PATIENTS AND METHODS
2.1 PATIENTS
2.1.1 Patient cohorts
Three different patient cohorts (A, B and C) were studied, the inclusion criteria for each
is detailed below. Research pertaining to patient cohorts A, B and C is detailed in
chapters 3, 4 and 5 respectively. Clinical data was analysed by Professor F Muntoni and
Dr E Clement. Muscle pathology was evaluated by Professor C Sewry, Dr L Feng and
Dr C Jimenez-Mallebrera. This work was performed via the Dubowitz Neuromuscular
Centre which provides a national specialist diagnostic and assessment service for
Congenital Muscular Dystrophies and Congenital Myopathies (National Commissioning
Group service). This study was approved by Hammersmith Hospital Ethics Committee
REC reference number: 2000/5802.
Patient cohort A
Patient cohort A consisted of 92 unrelated individuals (Patients A1-A92). This included
a large group of patients from Australia (27 patients) and Turkey (16 patients). The
majority of the remaining patients were recruited via the Hammersmith Hospital
National Commissioning Group service and included DNA from individuals referred
from across the UK and Europe with a few samples from further afield. Mutations in
FKRP had previously been excluded in all cases (Brockington et al., 2001a).
The inclusion criterion was specified as hypoglycosylation of α-dystroglycan at the
sarcolemma by immunolabeling of skeletal muscle sections (Brown et al., 2004;
Dubowitz and Sewry, 2007). Eighty patients met this criterion whilst in the remaining
12 cases there was no muscle available to perform α-dystroglycan studies. This later
group of patients were included due to their clinical phenotype being highly suggestive
of a dystroglycanopathy and consisted of children with CMD, elevated serum creatine
kinase and brain MRI evocative of a cobblestone lissencephaly. All the patients who
had had a muscle biopsy were studied by standard immunocytochemical and/or Western[65]
blotting analysis in order to rule out dystrophinopathy, LGMDs such as
sarcoglycanopathies, calpainopathy and dysferlinopathy, merosin deficient CMD and
collagen VI deficiency (Dubowitz and Sewry, 2007). Clinical data was collated and
patients were divided into phenotypic categories.
Patient cohort B
Patient cohort B consisted of 40 unrelated individuals (Patients B1-B40). The majority
of the patients were recruited via the Dubowitz Neuromuscular Centre. In addition to
meeting the inclusion criteria stipulated for cohort A, mutations in POMT1, POMT2,
POMGNT1, LARGE, FKTN and FKRP had previously been excluded in each patient by
uni-directional sequencing. In eleven of the forty patients, no muscle was available for
immunocytochemical study.
Patient cohort C
A consanguineous family was studied for linkage analysis and is referred to throughout
this thesis as pedigree 1. The proband (patient C1-1) had previously been included in
cohort A and therefore screened for mutations in POMT1, POMT2, POMGNT1,
LARGE, FKTN and FKRP.
Pedigree 1 has previously been described in Brockington et al. and Muntoni et al. The
parents of the four affected children are first cousins of United Arab origin
(Brockington et al., 2000; Muntoni et al., 1998). Early motor milestones were delayed
in the four affected children; they were able to walk but could not run, and they rose
from the floor with the use of a Gower manoeuvre. Facial weakness, generalized muscle
hypertrophy, and wasting of the sternocleidomastoids and pectoralis muscle were
consistent features. For over nine years, there was no significant progression of the
muscle weakness; however, the two oldest girls died of respiratory complications, one
at 4 years of age and the other at 7 years of age. The two remaining children, aged 8 and
5 years old, were found to be hypoventilating at night. They have been ventilated by use
of nocturnal ventilation via a biphasic positive airway pressure machine with excellent
results. Intellect was normal. Investigations revealed grossly elevated creatine kinase
levels in all the children (range 2,270–7,650 IU/litre; normal values <190 IU/litre).[66]
Ethnically matched control cohort
Control samples were from a cohort of parental bloods of White European ethnicity
following ethical approval by the Hammersmith and Queen Charlotte’s and Chelsea
Trust Research Ethics Committee (2001/6029).
2.2 METHODS
Unless otherwise stated, all water was purified using an Elix system (Millipore)
combining reverse osmosis and electro-deionisation.
2.2.1 Genomic DNA Manipulation
Genomic DNA extraction
Unless otherwise stated genomic DNA was extracted in the referring centre’s laboratory
using standard protocols. DNA was stored at 4°C for short-term storage or -20°C for
long-term storage.
DNA from lymphoblastoid cells (Patients C1-1, Table 4) was extracted using the
DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer’s protocol. The
DNeasy procedure combines the selective binding properties of a silica-based
membrane with centrifugation. DNA adsorbs to the DNeasy membrane in the presence
of high concentrations of chaotropic salt, which removes hydrated molecules in
solution. Cells are first lysed using proteinase K. Lysate is added to the spin column and
DNA is selectively bound to the DNeasy membrane during centrifugation.
Contaminants are removed during a series of wash steps and the DNA is eluted in 200
μl of H20.
Whole genome amplification
The availability of patient samples is frequently a limitation in downstream analysis. In
order to preserve precious genetic material, methods of whole genome amplification[67]
have been developed. This allows the amplification of the entire genome from limited
initial quantities of high molecular weight DNA ensuring those samples are not
exhausted during mutation screening. Recently a technique known as Multiple
Displacement Amplification has been developed and involves the binding of random
hexamers to denatured DNA. The enzyme φ29 DNA polymerase carries out strand
displacement synthesis under isothermic conditions. Subsequent additional priming
events occur on displaced strands leading to a network of hyper branched DNA
structures (Figure 11). The high fidelity φ29 enzyme does not disassociate from the
genomic DNA template facilitating the generation of fragments of up to 100 kb
(average product length being more than 10 kb) (Dean et al., 2002). The enzyme’s 3’ to
5’ exonuclease proofreading ability means that error rates are 100 times lower than Taq
polymerase therefore maintaining high fidelity during replication (Hosono et al., 2003).
The enzyme’s ability to resolve secondary structures reduces amplification bias to less
than 3 fold in contrast to 4-6 orders of magnitude for polymerase chain reaction (PCR)
based whole genome amplification methods (Dean et al., 2002).[68]
Figure 11. Sequential representation of the branched structures created during multiple
displacement amplification.
A) Random hexamers (green) are hybridised to linear DNA (blue) and extension is
carried out by φ29 DNA polymerase (red). B) As the front of the extending
complementary strand of DNA encounters a double-stranded section of DNA, the
advancing new strand displaces the old one from the template. C) and D) hexamers
subsequently hybridise with these displaced strands creating an extensive series of
branched structures.[69]
Multiple displacement amplification reactions were performed on purified genomic
DNA using the Repli-g UltraFast Mini kit (Qiagen) and the Repli-g Midi kit (Qiagen)
following the manufacturer’s recommended protocol. In brief, the sample material is
lysed and the DNA is denatured by adding a denaturation buffer. After denaturation has
been stopped by the addition of a neutralisation buffer, a master mix, containing a
reaction buffer and REPLI-g UltraFast DNA Polymerase is added. The isothermal
reaction proceeds for 1.5 hours at 30°C. Amplified DNA was stored at 4°C for short-
term storage or -20°C for long-term storage. A 1:12.5 dilution was used for downstream
PCR amplification.
Whole genome amplification from the remainder of patient C1-1’s skeletal muscle
biopsy was carried out using the REPLI-g Midi kit according to a user-developed
protocol available from Qiagen. This protocol had been optimised for WGA from flash-
frozen tissue sections as follows; the remainder of the skeletal muscle biopsy from
patient C1-1 was placed in a microcentrifuge containing 10 μl of
Tris(hydroxymethyl)aminomethane (Tris)-acetate buffer and incubated at room
temperature (15-25°C) for 10 minutes with occasional vortexing. 10 μl of buffer D2
(containing 1 M DTT and Reconstituted Buffer DLB) was added, vortexed briefly and
placed on ice for 30 minutes. 10 μl of Stop Solution was then added to the lysed tissue
and mixed briefly by vortexing. The tissue debris and lysed tissue cells were then
separated by pulse centrifugation. 40 μl of master mix containing REPLI-g Midi
Reaction Buffer, REPLI-g Midi DNA Polymerase and Nuclease-free H20 was added to
10 μl of lysed tissue cells and mixed by vortexing and brief centrifugation. The mixture
was incubated at 30°C for 16 hours followed by heat inactivation at 65°C for 3 minutes.
Purification of multiple displacement amplification
The QIAamp DNA Micro Kit was used to clean up multiple displacement amplified
samples prior to submission for whole genome single nucleotide polymorphism (SNP)
analysis following the manufacturer’s recommended protocol. This protocol removes
enzymes, unused primers and nucleotides and results in a pure DNA in aqueous
solution.[70]
A total of 10 µl of amplified product was bound to a silica membrane using the Buffers
AW1 and AW2. Contaminants are removed with a single wash step with Buffer AW2.
DNA is eluted from the column in a volume of 20 μl of Buffer AE.
Genomic DNA quantification and concentration
Genomic DNA concentration was determined using the NanoDrop ND-1000
Spectrophotometer according to manufacturer’s instructions. Genomic DNA samples
were concentrated to >50 ng/μl prior to submission to the UCL Genomics facility using
the RC10.10 vacuum centrifuge (Jouan) at 50°C for approximately 20 minutes.
DNA agarose gel electrophoresis
Agarose gels of 1-2% (w/v) in 1 x Tris-acetate-EDTA (TAE) buffer were routinely used
to analyse PCR products, whole genome amplification products and genomic DNA
quality. Gels were prepared by heating the agarose-TAE suspension in a microwave
until dissolved. After the solution had cooled, ethidium bromide was added to a
concentration of 0.1 mg/ml and the solution was poured into an appropriate gel tray.
Once set, the gel was submerged in 1 x TAE running buffer. One volume of gel loading
buffer was added to 5 volumes of sample and loaded into the wells. Electrophoresis was
carried out at 70 volts (V), until DNA fragments were resolved. DNA was visualised
under ultra-violet light using the ImageMaster VDS (Pharmacia Biotech). The size of
DNA fragments was estimated by comparison to DNA markers run simultaneously with
the samples. One hundred bps and 1 kilo base (kb) ladders (Invitrogen) were routinely
used.
Single nucleotide polymorphism array
Genotypes from patient cohort C were generated with the use of SNP genotyping
platforms (GeneChip Human Mapping 500K Nsp array, Affymetrix) by the UCL
Genomics facility (www.genomics.ucl.ac.uk/).
Genotypes were examined by Professor R Kleta and Dr H Stanescu in the UCL School
of Life and Medical Sciences. Multipoint linkage analysis and haplotype reconstruction[71]
was performed with Simwalk (version 2.91) and Allegro (version 2.0) for an autosomal
recessive model with complete penetrance. The data was formatted with Mega2 (version
4.0) through ALOHOMORA (version 0.30, Win32). Mendelian inconsistencies were
checked with the use of PedCheck (version 1.1) and Graphical Representation of
Relationship Errors. Unlikely genotypes were filtered with the use of Merlin (version
1.1, alpha 3). Haplotype output files were visualised with HaploPainter.
2.2.2 RNA Manipulation
RNA extraction
RNA from tissue and cells was extracted using the RNeasy mini kit (Qiagen) following
the manufacturer’s protocol. The RNeasy procedure combines the selective binding
properties of a silica-based membrane with centrifugation. A specialised high-salt buffer
system allows up to 100 μg of RNA longer than 200 bases to bind to the RNeasy silica
membrane thus providing enrichment for mRNA. Samples are first lysed and
homogenized in the presence of a highly denaturing guanidine-thiocyanate-containing
buffer which immediately inactivates RNases to ensure purification of intact RNA.
Initially solid tissue samples were disrupted by grinding to a fine powder under liquid
nitrogen. The ground sample was then transferred to a liquid nitrogen cooled 1.5 ml
tube and 350 μl lysis buffer added. When extracting RNA from pre-cut 10-12 μm
muscle sections, 350 μl of Lysis buffer was added directly to the sample without the
need for tissue disruption. Extraction of RNA from patient lymphoblastoid cell lines and
C2C12 cells was initiated by the addition of 350 μl of lysis buffer and dislodged from
the surface of the tissue culture plastic by agitation with a cell scraper. Following the
manufacturer’s recommended protocol the disrupted cell and tissue lysates were
subsequently homogenised by passing through a QIAshredder spin column. Ethanol is
subsequently added to the homogenate to provide appropriate binding conditions and
transferred to an RNeasy Mini Spin Column. On column digestion of DNA during RNA
purification was performed using the RNase-Free DNase Set. Contaminants are washed
away and the RNA is eluted in 30 μl of H20.
RNA quantification[72]
Total RNA concentration was determined using the NanoDrop ND-1000
Spectrophotometer according to manufacturer’s instructions.
Synthesis of first-strand complementary DNA
The Superscript III First–Strand Synthesis System for Reverse Transcription PCR (RT-
PCR) was used in the synthesis of first-strand complementary DNA (cDNA). RT
reactions were performed by initially mixing 1-2 μl of RNA (typically between 150 -
300 ng/μl), 0.5 μg (1 μl) random primer and 1 μl 10 mM deoxyribonucleotide
triphosphate (dNTP) mix and nuclease free H20 to a total of 10 μl, denatured at 65°C for
5 minutes and chilled on ice for 1 minute. The following components were then added;
2 μl of 5 x reaction buffer, 4 μl 25 mM MgCl2, 2 μl 0.1 M Dithiothreitol (DTT), 200 U
(1 μl) RNase OUT and 200 U (1 μl) SuperScript III RT enzyme. The reaction was then
annealed at 20°C for 20 minutes and cDNA synthesised at 50°C for 50 minutes. The
reaction was terminated at 85°C for 5 minutes. 200 U (1 μl) of RNase H was
subsequently added and incubated at 37°C for 20 minutes to facilitate the removal of
RNA-DNA hybrids. Products were then stored at -20 for future use. cDNA used in Real
Time PCR reactions was created using random hexamers (please refer to section 2.2.2).
Relative quantification Real Time PCR
Relative Quantification Real Time PCR was performed in triplicate using the Taqman
System (Applied Biosystems). A sample volume of 25 μl in each well was prepared
with 12.5 μl of Real Time PCR master mix (2 x) (Applied Biosystems), 11.25 μl of H20
and cDNA and 1.25 μl of the appropriate probe. cDNA was amplified using the 9600
Emulation mode; reactions were initially heated at 50°C for 2 minutes and 95°C for 10
minutes, followed by 40 cycles of segments of 95°C for 15 seconds and 60°C for 1
minute in a 7500 Applied Biosystems Sequence Detection System. The housekeeping
gene β-actin (Actb) was used for normalisation. Data acquisition and analysis was
performed using the Applied Biosystems 7500 Fast System. Relative Quantification was
calculated by the Comparative Ct method. The following TaqMan Gene Expression
Assays were used: mβ3gnt1, Mm00723578_m1; mActb, Mm00607939_s1; mMgat5b,[73]
Mm00556891_m1; mPomt1, Mm00520170_m1; mGyg, Mm00516516_m1; mGyltl1b,
Mm00554376_m1; mWwp1, Mm01214107_m1.
Expression arrays
RNA was used for expression analysis from patients C1-1 and C1-4 and three
unaffected controls (see Table 4). Samples were submitted to the UCL Genomics
facility for analysis using the GeneChip
(R) Human Gene 1.0 ST Arrays (Affymetrix).
Microarray analysis was performed by the UCL Genomics facility with a two-way
empirical Bayes ANOVA approach.
2.2.3 Mutation Screening
The mutation screening of POMT1, POMT2, POMGNT1, LARGE and FKTN was
carried out by myself at the DNA laboratory, GSTS Pathology at Guy’s Hospital,
London prior to the start of this thesis by a combination of uni-directional sequencing
and heteroduplex analysis as previously described (Godfrey et al., 2007; Godfrey et al.,
2006). Candidate gene mutation screening was performed using a combination of bi-
directional and uni-directional sequencing. High throughput automated sequencing was
performed at the DNA laboratory, GSTS Pathology at Guy’s Hospital, London by
myself. Low throughput mutation screening was performed manually at the Dubowitz
Neuromuscular Centre, Institute of Child Health.
Mutation screening was typically carried out using uni-directional sequencing of
multiple displacement amplified DNA. Bi-directional sequencing was performed on
problematic templates. Sequence alterations detected with multiple displacement
amplified DNA were confirmed with bi-directional sequencing from unamplified
genomic DNA.
Products were detected using an ABI3730xl automated genetic analyser (Applied
Biosystems). Analysis of uni-directional and bidirectional sequence traces was
performed using Mutation Surveyor software version 2.61 (Soft Genetics). Sequence
variants were investigated using the Alamut software (Interactive Biosoftware).[74]
Mutation nomenclature was based on the following GenBank Accession numbers;
β3GNT1; NM_006876.2, DAG1; NM_004393.2, GYG1; NM_004130.2, GYG2;
NM_001079855.1, GYLTL1B; NM_152312.3, FKTN; NM_006731.1, KCNK1;
NM_002245.3, LARGE; NM_133642.2, LBR; NM_002296.2, MGAT5B;
NM_144677.2, NRXN1; NM_004801.4 and NM_138735.2, POMGNT1; NM_017739.1,
POMT1; NM_007171.2, POMT2; NM_013382.3, PSEN2; NM_000447.2, TCAP;
NM_003673.3, TTC13; NM_024525.3, WWP1; NM_007013.3 with nucleotide number
1 corresponding to the first base of the translation initiation codon. Gene names and
sequence variations are in accordance with guidelines stipulated by the Human Genome
Variation Society (HGVS).
Primer design
Genomic sequences were obtained via the ensembl genome browser
(www.ensembl.org). A combination of automated primer design via Primer3
(http://www2.eur.nl/fgg/kgen/primer/), the PCR Suite (http://www-
fgg.eur.nl/kgen/primer/) and manual design was incorporated. Genomic DNA primers
were designed to amplify the entire coding region and were located a minimum of 50
base pairs from each intron/exon boundary.
SNPs were avoided within the primer binding sites to prevent allele specific non
amplification. SNPs within the primer binding sites were avoided using the Diagnostic
SNP Check software available online from the National Genetics Reference Laboratory
(www.ngrl.man.ac.uk/SNPCheck).
To facilitate a stream line sequencing approach a non fluorescent 24 nucleotide
sequence tag was attached to the 5’ end of both the forward and reverse primers. This
system enabled all amplified fragments to be sequenced with a universal primer.
Primer tags (5’ to 3’)
Forward GTCTCAGTTCAGGTGTCCTTCCTG
Reverse AGACGTCTTGTGTCGTGGCTACTG
Universal sequencing primers (5’ to 3’)[75]
Forward CAGTTCAGGTGTCCTTCCT
Reverse GTCTTGTGTCGTGGCTACT
Primers were supplied by Sigma and Operon. Primer stocks were stored at -20 ˚C at a
concentration of 250 pmol/µl. Working primer dilutions were stored at 4 ˚C at a variety
of concentrations.
Polymerase chain reaction
The amplification efficiency of genomic primer pairs was initially assessed in 10 µl
reactions and processed manually. Four different PCR protocols (PCR protocols A, B, C
and D) were tested sequentially until the reaction, analysed by gel electrophoresis,
resulted in a suitable product for downstream analysis. The PCR conditions for each are
detailed below;
PCR protocol A; 5 µl of 2x QIAGEN Multiplex PCR Buffer, 3 µl of primer mix
(containing forward and reverse primers) at 1 pmol/µl and 2 µl of control genomic DNA
(25 pmol/µl). Cycling conditions were 95°C for 15 minutes; 32 cycles of 95°C for 1
minute, 56°C for 1 minute 30 seconds, 72°C for 1 minute 30 seconds, followed by 72°C
for 5 minutes and 60°C for 30 minutes.
PCR protocol B; this protocol was identical to that described above yet with a higher
annealing temperature of 62°C.
PCR protocol C; this protocol contains identical PCR components yet incorporates a
series of reduced extension temperatures to allow the amplification of AT rich regions
modified from Su et al. (Su et al., 1996). Cycling conditions were 95°C for 15 minutes;
32 cycles of 95°C for 30 seconds, 55°C for 1 minute 30 seconds, 50°C for 30 seconds,
60°C for 1 minute 30 seconds, followed by 60°C for 5 minutes.
PCR protocol D; 5 µl of 2x QIAGEN Multiplex PCR Buffer, 1 µl of primer mix
(containing forward and reverse primers) at 2.5 pmol/µl, 2 µl of 7-deaza dGTP (Roche),
1 µl of DMSO (Sigma) and 1 µl of control genomic DNA (25 pmol/µl). Cycling
conditions were 95°C for 15 minutes; 32 cycles of 95°C for 1 minute, 56°C for 1 minute[76]
30 seconds, 72°C for 1 minute 30 seconds, followed by 72°C for 5 minutes and 60°C
for 30 minutes.
Appendices Tables 2-14 detail specific amplicon primer sequences and amplification
conditions. A negative PCR control containing all the reaction components except
template was included for the amplification of each fragment.
Automated mutation screening
To increase sample throughput and facilitate the screening of both a large number of
amplicons and patient DNA samples, each stage of mutation screening was fully
automated in 384 well plates using a combination of three liquid handling platforms;
MultiPROBE II Liquid Handling System (PerkinElmer, Life Sciences), the Biomek
NXP liquid handling robot (Beckman Coulter) and the Nanodrop II Liquid Handler
(Innovadyne). Protocols used routinely in Guy’s DNA laboratory for high throughput
processing were followed and are summarised below.
PCRs were automated on the MultiPROBE II Liquid Handling System (PerkinElmer,
Life Sciences). The MultiPROBE II system is controlled by WinPREP applications
software facilitating the set up of complex protocols created in Excel and transferred as
comma separated variable files. A variable number of patient DNA samples and
amplicons were set up on each plate.
PCR volumes were typically scaled down to 5 μl for automation. A volume of 2 µl of
primer mix (1 pmol/µl forward and reverse primer mix) was initially dispensed into
each well of a 384 well plate and dried down on a heating block at 55 ˚C for 45 minutes.
3 µl of Qiagen MultiMix and 2 µl of DNA (approximately 25 ng/µl) was then pipetted
into each well and the appropriate PCR program performed on a DNA Engine Dyad
thermal cycler (Bio-Rad formerly MJ Research).
The removal of unincorporated dNTPs, primers and salts was fully automated using the
Ampure system (Agencourt) on the Biomek NXP liquid handling robot (Beckman
Coulter). This was performed in accordance to manufacturer’s instructions and DNA
laboratory, GSTS Pathology at Guy’s Hospital standard protocols. Initially AMPure[77]
beads are added to the PCR reaction and the PCR amplicon is bound to magnetic beads.
Upon transfer of the PCR plate to a magnetic plate the bound PCR amplicons are
separated from contaminants by washing with ethanol. The amplicons are then eluted
from the magnetic beads in 30 μl of H20.
The set up of cycle sequencing was fully automated on the Nanodrop II Liquid Handler
(Innovadyne). 2 µl of universal sequencing mix was added to 1 µl of AMPure purified
PCR product. Sequencing mix consisted of 0.15 µl of BigDye version 3.1 (Applied
Biosystems), 0.45 µl of Big Dye Buffer (Applied Biosystems), 0.6 µl of Q solution
(Qiagen), 0.3 µl of universal primer (5 pmol/µl) to a total volume of 2 µl with H20.
Cycle sequencing conditions were 30 cycles of; 96°C for 30 seconds (ramped to 96°C at
1 per second), 50°C for 15 seconds (ramped to 50°C at 1 per second), 60°C for 1 minute
(ramped to 60°C at 1 per second).
The dye-terminator removal process was fully automated using the Agencourt
CleanSEQ paramagnetic bead system on the Nanodrop II Liquid Handler (Innovadyne)
and the Biomek NXP liquid handling robot (Beckman Coulter). Initially ethanol and
CleanSEQ (Agencourt) reagent is added to the sequencing reaction. Sequencing
products are subsequently bound to magnetic beads. Contaminants are then separated
from sequencing products via the application of a magnetic field and washed with
ethanol. Sequencing products are then eluted from the magnetic particles in 0.1 mM
ethylenediaminetetraacetic acid (EDTA).
Manual mutation screening
When processing fewer than 20 amplicons, samples were processed manually using the
conditions described in the Polymerase Chain Reaction section above. Successful
amplification was verified by running 3 µl of PCR product on an agarose gel. The
removal of excess dNTPs and primers from the PCR product was performed using a
combination of two hydrolytic enzymes together with a buffer. Exonuclease I
(Escherichia coli) removes residual single-stranded primers and any extraneous single-
stranded DNA produced in the PCR. Shrimp alkaline phosphatase removes the
remaining dNTPs from the PCR mixture. 1.5 µl of shrimp alkaline phosphatase (USB
Corporation) and 0.5 µl of exonuclease I (Biolabs) was added directly to 5 µl of PCR[78]
product and incubated at 37°C for 15 minutes. After treatment the reaction is inactivated
by heating to 80°C for 15 minutes. Purified PCR products were typically submitted
either to The Wolfson Institute for Biomedical Research, UCL sequencing service or the
MRC CSC Genomics Laboratory DNA sequencing service at Imperial College London.
2.2.4 Plasmid Manipulation
Preparation of vectors and inserts
The coding sequence of POMGNT1 (NM_017739) had previously been cloned into the
high copy number pcDNA3.1/V5-His TOPO expression vector (Invitrogen) from
reverse transcribed total human brain RNA (ClonTech). This vector directs the
synthesis of a fusion protein tagged at its C-terminal end with the V5 epitope
(GKPIPNPLLGLDST).
Site-directed mutagenesis
The mutagenesis of POMGNT1 was achieved with a PCR reaction containing a proof
reading polymerase with a low amplification cycle number to maintain a high fidelity
PCR yield. Overlapping primers contained the desired base change (c.1666G>A
detected in patient A20) necessary to alter the amino acid sequence in the resulting
POMGNT1 protein (p.Asp556Asn). Oligonucleotides were designed with the
substitution located in the centre and flanked by twelve complementary
oligonucleotides. Primers used to mutate the cloned POMGNT1 are shown below with
mismatched primers indicated in red.
Forward primer (3’ to 5’) GCTGAGGTTCTGAACCACAGCAAGA
Reverse primer (3’ to 5’) TCTTGCTGTGGTTCAGAACCTCAGC
The PCR conditions were as follows; 2 μl (1U) of ProofStart DNA Polymerase
(Qiagen), 1 μl of forward and reverse primer (50 pmol/μl), 1 μl of 10 mM dNTP, 10 μl
of Q solution (Qiagen), 5 μl of buffer (Qiagen), 250 ng of plasmid DNA to a total of 50
μl with H20.[79]
PCR products were purified using Qiagen Quick columns following the manufacturer’s
recommended protocol. This system utilises the selective binding properties of a silica
membrane to facilitate the absorption of DNA in the presence of high concentrations of
salt whilst contaminants pass through the membrane. Excess primers, enzymes and
unincorporated nucleotides do not bind to the silica membrane but flow through the spin
column. Finally salts are washed away by both ethanol and buffers. 17 μl of cleaned
PCR product was subsequently treated with 1 μl of restriction enzyme DpnI (10 U) and
2 μl of buffer for 1 hour at 37°C to remove contaminating parental plasmid DNA. The
methylated template DNA is selectively digested leaving newly synthesised
unmethylated DNA undigested.
Plasmid DNA was transformed into chemically competent bacteria cells (please refer to
section 2.2.5). Cells grown on Luria-Bertani (LB) agar (Invitrogen) were selected by
ampicillin resistance and plasmids from candidate colonies were isolated from LB broth
(Invitrogen) by Qiagen Mini-prep or Qiagen Midi-prep kits. Plasmid DNA was
sequenced to confirm the presence of the desired mutation. The entirety of the plasmid
was subsequently sequenced to exclude the acquisition of mutations during multiple
rounds of replication.
2.2.5 Bacterial Manipulation
Storage of bacteria
The One Shot TOP10 Chemically Competent Escherichia coli (Invitrogen) cells were
used for the propagation of plasmid DNA. All plasmids used in this thesis carried the
ampicillin resistance gene. Antibiotic selection using ampicillin was applied at all stages
of growth. Bacterial transformants were grown in LB broth (Invitrogen) or on LB agar
(Invitrogen) containing 100 μg/ml ampicillin (SIGMA). Inoculated bacteria were stored
in 50% (v/v) glycerol (SIGMA) in LB broth with ampicillin at -80°C.
Transformation of competent bacteria by heat shock
Competent cells were thawed on ice in 50 μl aliquots. A total of 4 μl PCR product was
added and left on ice for a further 30 minutes, cells were then heat shocked at 42°C for[80]
30 seconds and then returned to ice for a further 2 minutes. The heat shocked cells were
then added to 250 μl of Super Optimal Broth medium (Invitrogen) and incubated at
37°C for 1 hour with 200 rotations per minute. Finally cells were spread on LB agar
plates containing 100 μl/ml ampicillin, left for 30 minutes at room temperature for the
suspension to become absorbed into the L-agar. Plates were then inverted and incubated
at 37°C over night.
Growth of inoculated bacterial cultures
Single colonies selected from a freshly streaked selective LB agar plate were used to
inoculate 5 ml of LB medium containing 100 µg/ml ampicillin. The propagation of a
desired clone was also performed by adding 25 µl of glycerol stock to 5 ml LB medium
containing 100 µg/ml ampicillin. Cultures were incubated for 12-16 hours at 37°C with
vigorous shaking at 180 rpm. Bacteria cells grown in LB broth were lysed and plasmid
DNA selectively isolated using Qiagen Mini-prep and Midi-prep systems.
Isolation of plasmid DNA
The QIAprep Spin Miniprep Kit DNA purification system (Qiagen) was routinely used
to prepare up to 20 μg of high copy plasmid DNA. The Qiagen HiSpeed Plasmid Midi
Kit purification system (Qiagen) was routinely used to prepare up to 100 μg of high
copy plasmid DNA. Plasmid DNA was isolated from bacterial cultures according to the
manufacturer’s recommended protocol.
The QIAprep Miniprep procedure is based on alkaline lysis of bacterial cells followed
by the adsorption of DNA onto silica in the presence of high salt. The silica membrane
allows the selective absorption of plasmid DNA in high salt conditions and elution in
low salt buffers. Contaminants such as endonucleases, salts, RNA, cellular proteins and
metabolites are not retained on the membrane.
The Qiagen Midiprep DNA purification system is based on a modified alkaline lysis
procedure, followed by the binding of plasmid DNA to Qiagen Anion-Exchange Resin
under appropriate low salt and pH conditions. Contaminants are removed by a medium[81]
salt wash and plasmid DNA is eluted in a high-salt buffer. The DNA is subsequently
concentrated and desalted by isopropanol precipitation.
2.2.6 Cell Culture
C2C12 cells are routinely used as a model of myogenic differentiation. Myoblasts can
be induced to fuse into myotubes upon confluence and lowering of serum medium
concentrations. These cells were originally obtained by Yaffe and Saxel through
selective serial passage of myoblasts cultured from the thigh muscle of C3H mice 70
hours after a crush injury (Yaffe and Saxel, 1977).
Fibroblast cell cultures for patient A20 had previously been derived from a skin biopsy
and processed by the biopsy team at the Dubowitz Neuromuscular Centre.
Peripheral blood lymphocytes from patient C1-1 and C1-4 had previously been
submitted to the European Collection of Cell Cultures (Health Protection Agency) for
transformation with the EBV virus. Subsequent lymphoblastoid cells were stored in the
Health Protection Agency’s Human Genetic Collection. Table 4 details those cell lines
used from both affected and unaffected individuals.[82]
Individual ECACC cell line ID ECACC Collection Age at sampling Gender Ethnic origin
Patient C1-4 (pedigree 1) FG0012 Human Genetic Collection 08.05 Male Arabic
P
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d
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e
e
1
Patient C1-1 (pedigree 1) FG0013 Human Genetic Collection 11.05 Female Arabic
Unaffected C0106 Human Random Collection 24 Male UK Caucasian
Unaffected C0126 Human Random Collection 24 Female UK Caucasian
U
n
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e
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t
e
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l
s
Unaffected sibling of CB0409
(condition; Psoriasis)
CB0411 Human Genetic Collection 13.02 Female UK Caucasian
Table 3. Lymphoblastoid cell lines sourced from the European Collection of Cell Cultures (ECACC).[83]
Growth conditions
C2C12 and fibroblast cell lines were routinely grown in a monolayer in 75 cm
2 tissue
culture flasks at 37°C in a humid atmosphere maintained at 5% (v/v) CO2. Cells were
cultured in growth medium; Dulbecco’s modified Eagle’s medium (DMEM) (SIGMA)
supplemented with 20% (v/v) Fetal Bovine Serum Gold (PAA) and 2 mM L-glutamine
(SIGMA). Cells were typically seeded at 1/10 dilutions and passaged once a week as
follows; the medium was removed from the flask and the cells were washed with 5 ml
of DMEM. 2 ml of trypsin-EDTA solution was added to the flask and cells were
returned to the incubator for 2-5 minutes. The majority of cells disassociate from the
plastic during this time and any remaining adherent cells were dislodged by gentle
tapping. 5 ml of growth medium was added to neutralise the trypsin. The cell
suspension was subsequently aerated by vigorous pipetting. A suitable dilution was
made by adding part of the suspension to 10 ml of growth medium and incubated as
normal. C2C12 cells were differentiated with fusion medium upon confluence; DMEM
supplemented with 2% Horse Serum (PAA) and 2 mM L-glutamine (SIGMA).
Lymphoblastoid cells were grown in suspension in Roswell Park Memorial Institute
(RPMI) growth medium at 37°C in a humid atmosphere maintained at 5% (v/v) C02.
The ampoule of frozen cells was added to 10 ml of RPMI in a 25 cm
2 tissue culture
flask and cultured over night. A further 10 ml of RPMI was added the following day.
On day three the cells were seeded at ¼ in 75 cm
2 tissue culture flasks and harvested 24
hours later.
Freezing and thawing cells
C2C12 and fibroblasts cells were treated with trypsin-EDTA, as described above, and
counted in a hemocytometer. C2C12, fibroblasts and lymphoblastoid cell suspensions
were centrifuged at 1500 rpm for 5 minutes and pellets re-suspended in freezing
medium (90% Fetal Bovine Serum (PAA), 10% DMSO (Sigma)). Approximately one
million cells were frozen per 1 ml of freezing medium. The cells were frozen in a
cryogenic chamber (surrounded by isopropanol) at -80°C overnight and transferred to
liquid nitrogen storage the following day.[84]
When thawing cells, vials were removed from liquid nitrogen storage and thawed
rapidly at 37°C in the incubator. Cells were re-suspended slowly in 10 ml growth
medium and transferred to a flask. Once C2C12 and fibroblasts cells had adhered to the
plastic the culture medium was replaced with fresh growth medium.
2.2.7 Transient Transfections
Transient transfections were performed using the lipid based transfection reagents Gene
Juice (Novagen) and Lipofectamine 2000 (Invitrogen) allowing efficient delivery of
nucleic acids ranging from small RNAs to large plasmids. All transfection experiments
were performed at least 3 times.
Short interfering RNA
Short interfering RNA (siRNA) oligonucleotides specific for mouse Pomt1, Gyg and
β3gnt1 were obtained from Ambion. A list of siRNA oligonucleotides used is shown in
Table 4. A total of 100,000 cells were plated in 6 well culture dishes containing cover
slips and cultured overnight in 2 ml of supplemented DMEM to reach 70% confluence
the following day. Cells were transiently transfected using Lipofectamine 2000 reagent
(Invitrogen) in serum-free media (Opti-MEM, Invitrogen) using the following protocol;
both 100 μM of RNAi and 5 μl Lipofectamine 2000 reagent were diluted in 500 μl Opti-
MEM and incubated separately for 5 minutes. The diluted RNAi and Lipofectamine
were then combined. All incubations were performed at room temperature. Culture
medium was removed from the cells and the cells were washed with Opti-MEM prior to
the addition of the mixture. Cells were transfected 24 hours after plating and then re-
transfected 72 hours after plating. Cells were harvested 96 hours after plating in the
appropriate buffer for western blotting or Real Time PCR analysis.[85]
Silencer(R) Select Pre-designed siRNA
Protein (encoding gene) *
siRNA ID ** Sense Antisense
s97376 CGUGGAAUCUGAUCGGAGAtt UCUCCGAUCAGAUUCCACGcg
Protein-O-mannosyltransferase 1 (Pomt1)
s97374 CCCUGGUUGUAGCAUGGUAtt UACCAUGCUACAACCAGGGca
s77650 CCCUCCAUUGAAACGUAUAtt UAUACGUUUCAAUGGAGGGtt
Glycogenin 1 (Gyg1)
s77652 GGACAGUGGUGAUUCUGCUtt AGCAGAAUCACCACUGUCCaa
s99324 CCAGCGCAAUAAGAUCCUUtt AAGGAUCUUAUUGCGCUGGtt UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 (β3gnt1) s99323 GAAUGCCGAUGAACAAGAAtt UUCUUGUUCAUCGGCAUUCgg
Table 4. siRNA oligonucleotides.
Probes for specific knockdown of mouse Pomt1, Gyg1 and β3gnt1. * Gene symbols and names as per HUGO nomenclature
(www.genenames.org/). ** siRNA identification code (ID) (www.ambion.com).[86]
Plasmid transfection
Cells were plated in 6 well dishes on round glass coverslips (10 mm diameter) and
incubated in growth medium to reach 70% confluence. Cells were transiently
transfected using Gene Juice (Novagen) in Opti-MEM using the following protocol; 3
μl of Gene Juice was diluted in 20 μl of Opti-MEM and incubated for 5 minutes at room
temperature. 0.5 μg of plasmid was then added to the above mix and incubated for 15
minutes at room temperature. Culture medium was removed from the cells and the cells
were washed with Opti-MEM prior to the addition of the mixture. Cells were
transfected for 24 hours before transferring to growth medium. After four days cells
were harvested in the appropriate buffer for western blotting or fixed in 2%
paraformaldehyde for immunohistochemical analysis.
2.2.8 Protein Manipulation
Preparation of cell homogenates
Fibroblast cell homogenates were sent to Harry Schatner’s laboratory in the Department
of Structural Biology and Biochemistry in Toronto, Canada to assay patient A20’s
POMGNT1 function (please refer to section 3.2.3). A total of four 175 cm
2 flasks were
grown as described above. Once confluent, cells were washed with Phosphate Buffered
Saline (PBS) before being scraped and transferred to a 50 ml centrifuge tube. Cells were
subsequently washed with PBS to ensure the removal of serum media. The cells were
then divided into 1.5 ml microcentrifuge tubes and centrifuged at 1500 rpm for 5
minutes to form pellets. Pellets were stored at -80°C and transported on dry ice.
Protein extraction from cultured cells
To inhibit contaminating proteases, cellular proteins were extracted in lysis buffer
consisting of 75 mM Tris-HCl, 1% sodium dodecyl sulphate (SDS) plus Complete
Protease Inhibitor Cocktail (Roche). One complete Mini tablet was dissolved in 750 μl
H20, 50 μl aliquots were stored at -20 for a maximum of 12 weeks. A total of 35 μl of
protease inhibitor cocktail solution was added to a 500 μl aliquot of sample buffer. Cells
were dislodged from the plastic with protease inhibitor and a plastic cell scraper (30 μl[87]
or 70 μl of protease inhibitor was used for a 75 cm
2 or 175 cm
2 culture flask
respectively). The cells were then boiled for 3 minutes in a 1.5 screw top tube followed
by centrifugation (14,000 rpm) for 3 minutes at 4°C. The supernatant was transferred to
a new tube and treated with 1 U of DNaseI for 20 minutes at room temperature. Protein
extractions were then stored at -80°C.
SDS poly-acrylamide gel electrophoresis
Proteins were resolved using the NuPAGE Bis-Tris system in conjunction with the
XCell SureLock™ Mini-Cell system (Invitrogen Life Sciences) according to the
manufacturer’s protocol.
Corresponding amounts of sample (typically 21.25 μl) and 4X NuPAGE LDS sample
buffer were mixed to give a volume of 30 μl. 5 μl of NuPAGE reducing agent was
added to each sample (0.5M DTT) immediately prior to heating. Samples were then
boiled for 3 minutes and a total of 35 μl loaded into each well. The migration of proteins
was estimated by comparison to markers run simultaneously alongside samples; 10 μl of
SeeBlue Plus2 Pre-Stained Standard was routinely used.
The pre-cast NuPAGE Bis-Tris-HCl buffered (pH 6.4) 4-12% polyacrylamide gels were
removed from their pouches and rinsed with H20. The tape and comb were gently
removed and sample wells rinsed repeatedly with 1X NuPAGE SDS Running Buffer.
Once the gel cassette and buffer core were assembled in the Mini-Cell the upper
chamber was filled with 200 ml NuPAGE MOPS SDS Running Buffer. 500 μl of
NuPAGE antioxidant was added to the running buffer in the upper chamber to ensure
that samples did not re-oxidise during electrophoresis. The lower chamber was filled
with 600 ml NuPAGE MOPS SDS Running Buffer. Denaturing electrophoresis was
carried out at 200 V at 4°C until the Myoglobin Red (19 kDa) had migrated to the
bottom of the gel (Figure 12). The cassette was subsequently removed from the Mini-
Cell system, the plates separated and the gel removed for processing.[88]
Figure 12. Migration of bands in the SeeBlue Plus2 Pre-Stained Standard (NuPAGE
MOPS system).
The apparent molecular weights in kDa are illustrated on the left. * The membrane was
cut horizontally at the 64 kDa protein band to allow the staining of both α and β-
dystroglycan within a single lane. ** Electrophoresis was performed until the 19 kDa
protein band had migrated to the bottom of the gel. Image adapted from Invitrogen.com.[89]
Western transfer
Proteins were transferred to a nitrocellulose membrane using the NuPAGE XCell II™
blotting apparatus. Blotting pads, filter paper and Hybond-Electrochemiluminescence
(ECL) nitrocellulose membrane (Amersham Biosciences) were soaked in 1X NuPAGE
Transfer buffer (with the addition of methanol as per manufacturer’s protocol). The gel
was transferred from the cassette to a piece of filter paper and the pre-soaked membrane
placed over the gel. The gel and membrane were sandwiched between filter paper and
blotting pads in the correct orientation to ensure the gel is closest to the cathode core.
The blot module was then held closely together and placed in the lower buffer chamber
with the gel tension wedge locked into place. The blot module was filled with 1x
NuPAGE Transfer Buffer until the gel / membrane assembly was covered. The outer
chamber was filled with H20 and the transfer performed at 30 V for 2 hours 30 minutes
at 4°C. The membrane was then inspected for the presence of the SeeBlue Plus2 Pre-
Stained Standard to confirm the transfer of proteins.
Immunoblotting
Where appropriate, the nitrocellulose membrane was cut vertically to allow staining
with a number of different antibodies. In addition the membrane was typically cut
horizontally at approximately 64 kDa to permit the staining of α and β-dystroglycan
within the same well (Figure 12). Nitrocellulose strips were blocked overnight at 4°C.
The membrane was sequentially probed with the appropriate antibodies and buffers at
room temperature for 1 hour. After each antibody incubation period the nitrocellulose
membrane was washed in buffer alone for 3 x 10 minutes at room temperature. All
blocking, washing and incubations were carried out with gentle shaking.
For glycosylated α-dystroglycan detection the nitrocellulose membrane strips were
blocked in 3% bovine serum albumin (BSA) (v/w) (IgG- and protease-free, Jackson
Laboratories) IIH6 buffer (20 mM Tris 0.1 NaCl, pH 7.4). The primary antibody, IIH6
(Millipore; 1/2000) was diluted in 3% BSA (w/v) IIH6 buffer. The secondary antibody,
Polyclonal Rabbit anti-mouse IgM (Dako; 1:2000) and tertiary antibody Streptavidin
horseradish peroxidise (HRP) (Dako; 1:10,000) were incubated in IIH6 buffer only.[90]
For β-dystroglycan detection the nitrocellulose membrane strips were blocked in 10%
skimmed milk powder (w/v) (Fluka) Tris-buffered saline with 0.5% Tween 20 (TBST)
(v/v). The primary antibody, 43DAG/8D5 (Vector Laboratories; 1:150) was incubated
in 5% skimmed milk powder (w/v) TBST. The secondary antibody, anti-mouse Ig
biotinylated species specific whole antibody (Amersham; 1:2000) and tertiary antibody
HRP-Streptavidin (DAKO; 1:10,000) were incubated in TBST only.
For V5 recombinant fusion protein detection the nitrocellulose membrane strips were
blocked in 3% BSA (w/v) TBST. The primary antibody Anti-V5 (Invitrogen; 1:10,000)
was incubated in 3% BSA (v/w) TBST. The secondary antibody anti-rabbit HRP
(DAKO; 1:50,000) was incubated in TBST only.
For myogenin detection the nitrocellulose membrane strips were blocked in 10%
skimmed milk powder (w/v) TBST. The primary antibody F5D (Developmental Studies
Hybridoma Bank; 1:500) was incubated in 5% skimmed milk powder (w/v) TBST. The
secondary antibody anti-mouse Ig biotinylated species specific whole antibody
(Amersham; 1:2000) and tertiary antibody HRP-Streptavidin (DAKO; 1:1000) were
incubated in TBSB only.
After washing, membranes were visualized using chemiluminescence (ECL+Plus,
Amersham), according to manufacturer’s instructions. Film was typically processed in a
Xograph Compact X4 film processor (Xograph Imaging Systems).
Stripping and re-probing western blot membrane
Membrane stripping describes the complete removal of bound reagents such as ECL
solution, antibodies and blocking solution from the WB nitrocellulose membrane. The
membrane was submerged in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS,
62.5 mM Tris-HCl pH 6.7) and incubated at 50°C for 30 minutes with occasional
agitation in a fume hood. The membrane was then washed for 2 x 10 minutes in large
volumes of TBST or IIH6 buffer (as appropriate) at room temperature. Subsequent
blocking and immunodetection was then carried out as outlined above.
Immunohistochemistry[91]
C2C12 cells grown on coverslips were transfected with wild-type and mutant
pcDNA3.1/V5-His TOPO expression vectors (as described above). Cells were washed
in PBS before being fixed in 2% paraformaldehyde (dissolved in PBS+NaOH adjusted
to pH 7.4 with HCl) for 10 minutes, followed by washing twice in PBS for 10 minutes.
Fixed cells could then be stored at 4°C in PBS for a few days if necessary. After
fixation the cells were permeabilized in PBS with 0.05% Triton X-100 (v/v) (Sigma) for
5 minutes. For double labelling, cells were first incubated for 1 hour with monoclonal
anti-GM130 (BD Biosciences; 1:500), a Golgi apparatus marker, followed by an anti-
mouse conjugated to Alexa 594 (Molecular Probes; 1:500) for 30 minutes. After
washing, fluorescein isothiocyanate-conjugated goat anti-V5-His (Bethyl Lab; 1:50)
was applied for 1 hour. Cell nuclei were counterstained with Hoechst 33342 (Molecular
Probes; 1:2000). All dilutions and washings were made in phosphate-buffered saline,
and incubations were performed at room temperature. Coverslips were mounted in
aqueous mountant and viewed with epifluorescence using a Leica Diaphot microscope
and digitally captured using Metamorph (Universal Imaging).
Antibodies
The monoclonal mouse anti-IIH6 antibody is specific to an unknown carbohydrate
epitope present on α-dystroglycan was originally obtained from female BALB/c mice
immunized with purified rabbit skeletal muscle sarcolemma membranes and boosted
with dystrophin-glycoprotein complex (Ervasti and Campbell, 1991). For western
blotting IIH6 was purchased from Millipore whereas for immunocytochemical analysis
the antibody was a kind gift from Kevin Campbell.
The monoclonal mouse anti-β-dystroglycan antibody (Vector laboratories clone
43DAG/8D5) is a synthetic peptide containing 15 of the last 16 amino acids at the end
of the C-terminal region of the human dystroglycan molecule (PKNMTPYRSPPPYVP).
The polyclonal rabbit anti-V5 antibody (Invitrogen) allows the detection of recombinant
fusion protein by recognising the V5 tag (IPNPLLGLD).[92]
The monoclonal mouse anti GM130 (BD Bioscience) antibody allows the detection of
Golgi apparatus matrix protein (130 kDa). GM130 recognises a protein isolated from
the Triton™ X-100-insoluble Golgi matrix and peripherally associated with the cis-
compartment, as demonstrated by co-localization with syntaxin5.
2.2.9 Statistical Analysis
Where specified, experiments were performed in triplicate and expressed as the mean ±
the standard error of the mean (SEM) of three independent samples. For each Real Time
PCR experiment, individual sample values represent the average of three samples.
Analyses were interpreted with the use of unpaired Student’s t-test comparing the effect
against appropriate controls. A P value of less than 0.05 was considered to indicate
statistical significance. Statistical analyses were performed via excel.
2.2.10 Bioinformatics
The following bioinformatics packages were used in addition to those described above;
Genomic sequences were acquired from the Ensembl Genome Server
(http://www.ensembl.org/index.html) and from the databases at NCBI
(http://ncbi.nlm.nih.gov). Protein homology plots were produced by multiple alignments
using ClustalW (www.ebi.ac.uk/clustalw/) within the BioEdit platform
(www.mbio.ncsu.edu/BioEdit/bioedit.htm). Figures depicting linkage regions were
manipulated using the UCSC Genome Browser (genome.ucsc.edu/). Features assigned
within linkage regions were displayed using ‘Custom Tracks’ and the ‘RefSeq Genes’
track. Phylogenetic trees were constructed with TreeFam (www.TreeFam.org) (Li et al.,
2006; Ruan et al., 2008). Endeavour bioinformatics software was used to prioritise
candidate genes (www.esat.kuleuven.be/endeavour) (Aerts et al., 2006). The following
data sources were used for ranking; Annotation (EnsemblEst, GeneOntology, Interpro,
Kegg, and Swissprot); Blast; CisRegModule; Expression (SonEtAl and SuEtAl);
Interaction (Bind, BioGrid, Hprd, InNetDb, Intact and Mint); Motif; Precalculated
Ouzounis and Prospectr and literature. Candidate genes were classified by their
biological function using the Panther data analysis tool (http://www.panther.org)
(Thomas et al., 2003). Subcellular localisations were annotated via the Universal
Protein Resource Knowledge Base (UniProtKB) (www.uniprot.org). Protein domains[93]
were predicted by the Eukaryotic Linear Motif (ELM) server (http://elm.eu.org)
(Puntervoll et al., 2003).[94]
CHAPTER 3: REFINING GENOTYPE-PHENOTYPE
CORRELATIONS[95]
3 REFINING GENOTYPE-PHENOTYPE CORRELATIONS
3.1 INTRODUCTION
Muscular dystrophy syndromes associated with the hypoglycosylation of α-
dystroglycan vary extensively in phenotypic severity. Historically, subsets of patients
with a particular clinical presentation in specific geographical regions were studied to
uncover their underlying molecular defects. As mutations were detected, specific genes
became associated with discrete clinical phenotypes. This is best represented by the
research performed on patients with FCMD and MEB. FCMD was described within the
Japanese population where, in the majority of cases, it is caused by a homozygous 3 kb
insertion mutation in the 3’ UTR of the gene FKTN (Kobayashi et al., 1998). MEB was
originally described within the Finnish population in association with mutations in
POMGNT1 (Yoshida et al., 2001). WWS was however described worldwide and
originally found to be associated with mutations in POMT1 and POMT2 (Beltran-
Valero de Bernabe et al., 2002; Currier et al., 2005; van Reeuwijk et al., 2005b). In
addition, MDC1C and MDC1D are two rare congenital dystroglycanopathy syndromes,
secondary to mutations in FKRP and LARGE respectively (Brockington et al., 2001a;
Longman et al., 2003).
The increased availability of mutation analysis in patients with a dystroglycanopathy
has subsequently led to a widening of the clinical spectrum observed for several of these
genes. This is best exemplified by the range of phenotypes resulting from mutations in
FKRP. Following the initial description of its involvement in MDC1C (Brockington et
al., 2001a), it was subsequently shown to cause a very common and relatively mild
variant, LGMD2I (Brockington et al., 2001b), and more recently CMD variants with
associated mild structural brain (MDC1C and cerebellar cysts (Mercuri et al., 2006;
Topaloglu et al., 2003)) or severe brain and eye involvement resembling WWS and
MEB (Beltran-Valero de Bernabe et al., 2004; Mercuri et al., 2006).
It has also been documented that genes other than FKRP are involved in both milder
and more severe phenotypes than originally reported. This includes the finding of FKTN
mutations in two families with WWS as well as the involvement of POMT1 in patients[96]
with LGMD2K (LGMD with associated microcephaly and mental retardation) (Balci et
al., 2005; de Bernabe et al., 2003).
All previous studies have been conducted on a small number of families or individuals.
This causes inevitable difficulties in applying mutation frequencies to the general
population. In addition, such reports make it problematic to establish: 1) whether the
described clinical spectrum is truly representative of the phenotypic variability and 2)
how common the originally described core phenotypes are for each of these genes.
In order to address these points, we have systematically analysed a large population of
patients with a dystroglycanopathy phenotype for mutations in the associated genes. As
the spectrum of phenotypes secondary to FKRP involvement had been extensively
reported previously, 92 patients were studied in whom involvement of this gene had
been excluded before proceeding with analysis of POMT1, POMT2, POMGNT1, FKTN
and LARGE.
3.2 RESULTS
3.2.1 Clinical Findings
Patient cohort A comprised of 92 probands (patients A1-A92) from a range of
ethnicities, the inclusion criteria of which is detailed in section 2.1.1. As previously
stated, clinical data was analysed by Professor F Muntoni and Dr E Clement and muscle
pathology was evaluated by Professor C Sewry, Dr L Feng and Dr C Jimenez-
Mallebrera.
Patients were classified as having either a CMD or LGMD phenotype and further
subdivided according to the degree of structural and functional brain involvement.
CMD was defined as onset of weakness prenatally or within the first 6 months of life.
LGMD was defined by later onset weakness, specifically after having acquired
ambulation. The cohort consisted of 64 patients with CMD, 25 patients with LGMD and
included a total of 59 patients with brain involvement. In three cases the clinical
information available was insufficient to determine phenotypic classification. Patients
were divided into 1 of 7 broad phenotypic categories described below:[97]
1) WWS (and WWS-like): Onset is prenatal or at birth. Patients assigned to this
category had severe structural brain abnormalities including complete agyria or severe
lissencephaly with only rudimentary cortical folding, marked hydrocephalus, severe
cerebellar involvement and complete or partial absence of the corpus callosum (Figure
13). Eye abnormalities including congenital cataracts, microphthalmia and buphthalmos
were common. When MRI evidence was not available, death before 1 year of age was
taken as suggestive of this category if other clinical findings were supportive (Cormand
et al., 2001). Motor development was typically absent in these patients. Five patients
were assigned to this group.
2) MEB/FCMD-like: These categories were merged due to the overlapping phenotypic
features. Included in this group were CMD with structural brain defects less severe than
that seen with WWS. MRI findings include pachygyria with preferential frontoparietal
involvement, polymicrogyria, cerebellar hypoplasia, cerebellar dysplasia and frequent
flattening of the pons and brainstem (Figure 13). Eye abnormalities were often present
in this group and include congenital glaucoma, progressive myopia, retinal atrophy and
juvenile cataracts. Individuals may, rarely, acquire the ability to walk although this is
delayed. Rarely patients manage to learn a few spoken words. Thirty patients were
assigned to this group, including one in whom the clinical information was limited.[98]
A B
Figure 13. Brain MRI scans from patients with a severe dystroglycanopathy.
A) The brain MRI of a patient with WWS showing complete agyria. B) The brain MRI
of a patient with MEB showing simplified gyral patterning with shallow sulci in the
posterior temporal and parietal regions. Images from Beltran et al. (Beltran-Valero de
Bernabe et al., 2004). Permission to reproduce this figure has been granted by BMJ
Publishing Group Ltd.[99]
3) CMD-CRB (CMD with cerebellar involvement): This category included CMD
with mental retardation and cerebellar involvement on MRI scan as the only structural
abnormality. Cerebellar abnormalities may include cysts, which are described relatively
frequently in individuals with FKRP gene defects or cerebellar hypoplasia or dysplasia
(Mercuri et al., 2006). Four patients were assigned to this group.
4) CMD-MR (CMD with mental retardation): CMD with mental retardation and a
structurally normal brain. Patients with isolated microcephaly or minor white matter
changes on MRI are included in this group. Fifteen patients were assigned to this group,
including two with limited clinical information.
5) CMD-no MR (CMD with no mental retardation): Several patients within this
group have had no neuroimaging but had entirely normal intellectual function. Ten
patients were assigned to this group, one with limited information.
6) LGMD-MR (LGMD with mental retardation): LGMD with mental retardation
and a structurally normal brain. Patients with minor white matter abnormalities and
microcephaly were included in this group. This category includes patients with a
phenotype resembling LGMD2K (Balci et al., 2005). Five patients were assigned to this
group.
7) LGMD-no MR (LGMD with no mental retardation): LGMD with no mental
retardation. This category includes the LGMD phenotypes resembling LGMD2I and 2L
(Brockington et al., 2001b; Godfrey et al., 2006). Twenty patients were assigned to this
group, six with limited clinical information.
The division of phenotypes within the cohort is shown in Table 8. Detailed clinical
information for those patients in whom pathogenic mutations were detected is contained
in Table 5.[100]
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1 LOW WWS P 4000 NS Y Y Sc, RS Poor
visual
attention
LL>UL L Y H, CHy, WM, Lis Gastrostomy
2 LOW MEB-FCMD P 3500 N/A Y N/A N/A CG N/A L Y H, BS,WM,CC,CHy N/A
3 LOW LGMD-MR I 2000 W N/A Y U N/A N/A L Y Normal N/A
4 LOW CMD-MR I 7800 NW
2yr
N/A N/A U U N/A L N/A WM N/A
5 LOW LGMD-MR I 4000 W N Y U U N/A L Y Normal N/A
6 LOW LGMD-MR 3Yr 8000 W Y N/A U N/A L Y WM- minimal N/A
7 LOW CMD-MR I 3600 St N Y U U N/A L Y Normal N/A
8 LOW CMD-MR 4m 18000 W N/A Y RS N/A N/A L Y WM- minimal Choreic Movement
disorder
9 LOW MEB-FCMD N 5500 S Y Y RS, Sc N/A N/A L Y WM, BS N/A
10 LOW MEB-FCMD 4Yr 5200 NW N Y U N/A L Y Encephalocele N/A
11 LOW MEB-FCMD 7m N/A NS Y N U Hm N/A N/A H, WM,CC, N/A[101]
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12 LOW MEB-FCMD N 3100 NS Y N/A RS UL>LL L Y WM N/A
13 N/A MEB-FCMD 8m W N/A Y U My UL>LL L N
WM , CDys,
CC,PMG
N/A
14 LOW MEB-FCMD N 6000 S Y Y Sc CC N/A L Y BS,H,WM SE, RIP age 11yr
15a N/A CMD-CRB I 4700 W Y Y N/A N/A UL>LL L Y N/A N/A
15b N/A CMD-CRB I 5200 S N/A N/A N/A N/A N/A L N/A CHy
Micropenis and
cryptorchidism
16 LOW LGMD-MR 18m 1900 W N Y U N/A N/A L N/A NO MRI RBBB on ECHO
17 LOW MEB-FCMD N 2000 NS Y Y N/A My UL,LL L Y CHy, H Macroglossia, **
18 LOW MEB-FCMD I 780 NW N N N/A CG N/A L N/A BS,CC,WM,H N/A
19 LOW MEB-FCMD P 1000 W Y Y U OA, My N/A L N WM,CC
SE, feeding
difficulties
20 LOW LGMD-no MR 12 Yr 12000 R N Y U My LL>UL NI N N/A
21 LOW MEB-FCMD N 1200 NONE N N U RD N/A L N/A H,WM,CC
SE, feeding
difficulties.[102]
P
a
t
i
e
n
t
α
-
d
y
s
t
r
o
g
l
y
c
a
n
e
p
i
t
o
p
e
s
t
a
i
n
i
n
g
P
h
e
n
o
t
y
p
e
a
A
g
e
a
t
o
n
s
e
t
b
C
K
M
o
t
o
r
a
b
i
l
i
t
y
c
C
o
n
t
r
a
c
t
u
r
e
s
d
H
y
p
e
r
t
r
o
p
h
y
e
S
p
i
n
e
f
E
y
e
s
g
W
e
a
k
n
e
s
s
h
I
Q
i
M
i
c
r
o
c
e
p
h
a
l
y
j
M
R
I
k
O
t
h
e
r
l
22 LOW MEB-FCMD 12m 2800 R N N/A U Pt, RA N/A L N/A CHy, CC, WM,H
Dyspraxia, feeding
difficulties, SE
23 LOW MEB-FCMD N/A N/A N/A N/A N/A N/A N/A N/A
N/
A
N/A H,CC,WM N/A
24 N/A WWS N 1300 NS N/A N/A U N/A N/A L N/A CC,CHy, WM, H,Lis N/A
25 LOW WWS P 5700 NONE Y RDy L H,WM,CHy, Lis
Feeding difficulties,
RIP 8 weeks
26 LOW CMD-no MR 3Yr 3200 S N N U U G NI N/A WM-MILD Hypothyroid
27 N/A MEB-FCMD I 4000 S N Y U U N/A L N/A CC,WM,H
28 LOW WWS N 7000 N/A Y Y U RD,Mo N/A N/A WM,CHy, BS, H Dysmorphic
29a LOW LGMD-no MR 4m 10000 W N Y N/A N/A UL>LL NI N N/A Steroid responsive
29b LOW LGMD-no MR 4m 13000 W N Y U U LL>UL NI N Normal Steroid responsive
30 LOW LGMD-no MR 10m 60000 W N Y U U LL>UL NI N H-MILD Steroid responsive
31a LOW LGMD-no MR 4yr 9000 R Y N/A U N/A N/A NI N/A N/A N/A[103]
Table 5. Clinical characteristics of 33 individuals from 31 families in whom mutations were detected.
aWWS; Walker-Warburg syndrome, MEB/FCMD; muscle-eye-brain/Fukuyama congenital muscular dystrophy, CMD-MR; congenital muscular
dystrophy with mental retardation, CMD-no MR; congenital muscular dystrophy with no mental retardation, CMD-CRB; congenital muscular
dystrophy with cerebellar involvement, LGMD-MR; limb girdle muscular dystrophy with mental retardation, LGMD-no MR; limb girdle
muscular dystrophy with no mental retardation.
bP; prenatal onset, N; neonatal onset, I; infant onset, Yr; years, m; months.
cW; walk, S; sit, St;
stand, R; run, Prefix N; never.
d-e Y; yes, N; no.
f RS; rigid spine, Sc; scoliosis, U; unaffected.
g CG; congenital glaucoma, RD; retinal
detachment, RA; Retinal Atrophy, CC; Congenital cataracts, OA; optic atrophy, My; myopia, Mo; microphthalmia, Pt; ptosis, U; unaffected,
Hm; hypermetropia, RDy; retinal dysplasia.
h UL; Upper limbs, LL; lower limbs, G; generalised,
i NI; normal intelligence, L; low,
j Y; yes, N;
no,
k H; Hydrocephalus, CC; cerebellar cysts, BS; brainstem involvement, WM; white matter abnormality, CHy; cerebellar hypoplasia, Lis;
lissencephaly, CDys; cerebellar dysplasia.
lSE; seizures, CDH; congenital dislocation of hip, RBBB; Right bundle branch block.[104]
3.2.2 Mutation Analysis
I originally initiated the mutation screening of the POMT1, POMT2, POMGNT1,
LARGE and FKTN in the ninety two patients described here as part of my Pre-
registration clinical scientist training at Guy’s DNA Laboratory prior to undertaking my
PhD at University College London. The completion, characterisation and interpretation
of these data, however, constituted a large proportion of my PhD studies and have
therefore been included within this thesis.
A brief description of the mutation screening protocol has been included below for
clarity: Genomic DNA was extracted in the referring centre's laboratory using standard
methods. The complete coding regions, including intron/exon boundaries of POMT1,
POMT2, POMGNT1, FKTN and LARGE were amplified by PCR. Amplicons were
screened for mutations using a combination of uni-directional sequencing (standard
dideoxynucleotide methodology) and heteroduplex analysis (methods described in
(Clement et al., 2008b; Godfrey et al., 2007; Godfrey et al., 2006)). Where available,
parental DNA was studied once a sequence alteration was identified in the proband. In
two families, further segregation analysis was carried out to investigate the potential
pathogenicity of unclassified variants. In families where a de novo mutation was
suspected, paternity was confirmed using 11 STR markers (data not shown). Mutation
nomenclature is based on the following GenBank Accession numbers; POMT1;
NM_007171.2, POMT2; NM_013382.3, POMGNT1; NM_017739.1, FKTN;
NM_006731.1 and LARGE; NM_133642.2, with nucleotide number 1 corresponding to
the first base of the translation initiation codon.
Mutation screening of POMT1, POMT2, POMGNT1, FKTN and LARGE was performed
on 92 probands in whom FKRP mutations had been previously excluded. Homozygous
and compound heterozygous mutations were detected in a total of 31 probands (34
individuals from 31 families). Thirty seven different mutations were identified, 32 of
which had not been previously reported. Pathogenic mutations are summarized in Table
6 and the comparative mutation frequencies between genes are represented in Table 8
and are represented schematically in Figure 14.[105]
For the purposes of this study, I classified all insertions and deletions, splice site and
nonsense mutations as well as previously published mutations as pathogenic. Both
exonic and intronic sequence alterations were categorized as polymorphisms if they
were present on The Single Nucleotide Polymorphism database (dbSNP)
(http://www.ncbi.nlm.nih.gov), the Leiden database (http://www.dmd.nl) or present as
an additional change in a patient with two proven pathogenic mutations (polymorphisms
are shown in appendix Table 1). Amino acid substitutions were classified as pathogenic
if they were detected in conjunction with a clearly pathogenic mutation or if they have
been shown to segregate with disease in a large pedigree (Patients A15 and A20). In
addition, two patients with homozygous missense mutations and one patient with
compound heterozygous missense mutations have been included in Table 5 as they are
non-conservative amino acid changes that affected an evolutionary conserved amino
acid residue (patient A16, patient A18 and patient A27) (Figure 15). Patients in whom
only a single sequence alteration was detected are summarised in Table 7. We have
been unable to determine whether these are rare polymorphisms or pathogenic
alterations in patients who harbour a second undetectable mutation. These six patients
have not been included in the 34% of patients detected with mutations. Patient A25 has
been included in Table 5, Table 6 and Table 8 despite the absence of a second
detectable mutation due to the presence of a nonsense mutation.[106]
Patient Gene Exon/intron Nucleotide change Predicted amino acid change Mutation type References
1
POMT1
POMT1
20
20
c.2179_2180delTC
c.2179_2180delTC
p.Ser727fs
p.Ser727fs
Frameshift
Frameshift
Novel
Novel
2
POMT1
POMT1
20
20
c.2179_2180delTC
c.2179_2180delTC
p.Ser727fs
p.Ser727fs
Frameshift
Frameshift
Novel
Novel
3
POMT1
POMT1
7
7
c.598G>C
c.598G>C
p.Ala200Pro
p.Ala200Pro
Missense
Missense
Leiden database
Leiden database
4
POMT1
POMT1
18
3
c.1847_1849delGGT
c.193G>A
p.Trp616del
p.Gly65Arg
Deletion
Missense
Novel
Leiden database
5
POMT1
POMT1
11
19
c.1081C>T
c.2005G>A
p.Gln361X
p.Ala669Thr
Nonsense
Missense
Novel
Novel
6
POMT1
POMT1
6
18
c.517_523delTTCTTCAinsG
c.1868G>C
p.Phe173_Asn175delinsAsp
p.Arg623Thr
Insertion/deletion
Missense
Novel
Novel
7
POMT1
POMT1
7
7
c.598G>C
c.598G>C
p.Ala200Pro
p.Ala200Pro
Missense
Missense
Leiden database
Leiden database
8
‡ POMT1
POMT1
5
7
c.427G>T
c.598G>C
p.Glu143X
p.Ala200Pro
Nonsense
Missense
Novel
Leiden database
9
‡ POMT2
POMT2
21
21
c.2150T>C
c.2177G>A
p.Phe717Ser
p.Gly726Glu
Missense
Missense
Novel (de novo)
Leiden database
10
POMT2
POMT2
19
19
c.1997A>G
c.1997A>G
p.Tyr666Cys
p.Tyr666Cys
Missense
Missense
Novel
Novel
11
POMT2
POMT2
19
11
c.1997A>G
c.1238G>C
p.Tyr666Cys
p.Arg413Pro
Missense
Missense
Novel
Novel[107]
Patient Gene Exon/intron Nucleotide change Predicted amino acid change Mutation type References
12
‡ POMT2
POMT2
20
9
c.2047A>C
c.1051delG
p.Thr683Pro
p.Ala351fs
Missense
Frameshift
Novel
Novel
13
POMT2
POMT2
5
19
c.593T>A
c.1997A>G
p.Ile198Asn
p.Tyr666Cys
Missense
Missense
Novel
Novel
14
POMT2
POMT2
10
5
c.1117G>T
c.593T>A
p.Val373Phe
p.Ile198Asn
Missense
Missense
Novel
Novel
15a, 15b *
POMT2
POMT2
19
19
c.1997A>G
c.1997A>G
p.Tyr666Cys
p.Tyr666Cys
Missense
Missense
Novel
Novel
16
POMT2
POMT2
5
21
c.551C>T
c.2243G>C
p.Thr184Met
p.Trp748Ser
Missense
Missense
Novel
Novel
17
POMT2
POMT2
9
21
c.1057G>A
c.2177G>A
p.Gly353Ser
p.Gly726Glu
Missense
Missense
Novel
1
Novel
1
18
POMGNT1
POMGNT1
6
6
c.526A>C
c.526A>C
p.Thr176Pro
p.Thr176Pro
Missense
Missense
Novel
Novel
19
POMGNT1
POMGNT1
7
17
c.652+1G>A
c.1469G>A
Donor splice site
p.Cys490Tyr
Splice site
Missense
Novel
Leiden database
20 *
† POMGNT1
POMGNT1
20
20
c.1666G>A
c.1666G>A
p.Asp556Asn
p.Asp556Asn
Missense
Missense
Novel
2
Novel
2
21
POMGNT1
POMGNT1
17
17
c.1539+1G>A
c.1539+1G>A
Donor splice site
Donor splice site
Splice site
Splice site
Leiden database
Leiden database
22
POMGNT1
POMGNT1
12
17
c.1100G>A
c.1539+1G>A
p.Arg367His
Donor splice site
Missense
Splice site
Novel
Leiden database[108]
Patient Gene Exon/intron Nucleotide change Predicted amino acid change Mutation type References
23
POMGNT1
POMGNT1
20
20
c.1785+2T>G
c.1785+2T>G
Donor splice site
Donor splice site
Splice site
Splice site
Novel
Novel
24
POMGNT1
POMGNT1
17
17
c.1425G>A
c.1425G>A
p.Trp475X
p.Trp475X
Nonsense
Nonsense
Novel
Novel
25 LARGE 13 c.1548C>G p.Trp516X Nonsense Novel
26
FKTN
FKTN
8
8
c.920G>A
c.920G>A
p.Arg307Gln
p.Arg307Gln
Missense
Missense
Leiden database
Leiden database
27
FKTN
FKTN
8
8
c.915G>A
c.915G>A
p.Trp305Cys
p.Trp305Cys
Missense
Missense
Novel
Novel
28
FKTN
FKTN
8
8
c.919C>T
c.919C>T
p.Arg307X
p.Arg307X
Nonsense
Nonsense
Novel
Novel
29a, 29b
† FKTN
FKTN
8
9
c.920G>A
c.1167dupA
p.Arg307Gln
p.Phe390fs
Missense
Frameshift
Novel
3
Leiden database
3
30
‡† FKTN
FKTN
9
10
c.1167dupA
c.1363delG
p.Phe390fs
p.Asp455fs
Frameshift
Frameshift
Leiden database
3
Novel
3
31a, 31b
FKTN
FKTN
4
7
c.340G>A
c.859delA
p.Ala114Thr
p.Thr286fs
Missense
Frameshift
Novel
Novel[109]
Table 6. A summary of pathogenic mutations detected in this study.
Probands are numbered. Affected siblings are indicated with letters.
*Family studies carried out to investigate segregation of the variant through
the pedigree.
†Functional characterisation described in section 3.2.3.
‡Functional characterisation described in section 3.2.4.
†Functional
characterisation described in section 3.3.1. The following patients have been reported individually;
1 Patients previously described in Mercuri et
al. 2006.
2 Patients previously described in Clement et al. 2007.
3 Patients previously described in Godfrey et al. 2006.[110]
Patient Gene Exon/intron Nucleotide change Predicted amino acid change Mutation type References
32 POMT1 9 c.905T>G p.Phe302Cys missense Novel
33 POMT1 20 c.2203C>T p.Arg735Cys missense Novel
34 POMT1
POMT1
20
20
c.2248+5A>G
c.2248+5A>G
intronic
intronic
intronic
intronic
Novel
Novel
35 POMT1 20 c.2246G>A synonymous synonymous Novel
36 LARGE 4 c.309C>A synonymous synonymous Novel
37 LARGE 12 c.1431C>T synonymous synonymous Novel
38 LARGE 13 c.1640G>A p.Arg547His missense Novel
39, 40 LARGE 14 c.1827A>T synonymous synonymous Novel
Table 7. Summary of unclassified variants.[111]
WWS MEB/FCMD CMD-CRB CMD-MR CMD-no MR LGMD-MR LGMD-no MR Total
POMT1 1 1 - 3 - 3 - 8
POMT2 - 6 2 - - 1 - 9
POMGNT1 - 6 - - - - 1 7
FKTN 1 1 - - 1 - 3 6
LARGE 1 - - - - - - 1
Mutation detected 3 (60%) 14 (47%) 2 (50%) 3 (20%) 1 (10%) 4 (80%) 4 (20%) 31 (34%)
Patient total 5 30 4 15 10 5 20 92
*
Table 8. The phenotypic distribution of patients within the cohort, the frequency of mutations in each of the five glycosyltransferase genes
analysed and the comparative mutation frequencies for individual clinical categories.
WWS; Walker-Warburg syndrome, MEB/FCMD; muscle eye brain syndrome/ Fukuyama congenital muscular dystrophy, CMD-CRB;
congenital muscular dystrophy with cerebellar involvement, CMD-MR; congenital muscular dystrophy with mental retardation, CMD-no MR;
congenital muscular dystrophy with no mental retardation, LGMD-MR; limb girdle muscular dystrophy with mental retardation, LGMD-no MR;
limb girdle muscular dystrophy with no mental retardation.
* Includes three patients not assigned a clinical classification due to insufficient
clinical information.[112]
A variety of mutation types were identified; 37 missense mutations; 7 nonsense
mutations; 9 frameshift mutations; 1 insertion/deletion mutation; 1 deletion and 6 splice
site mutations. No mutation hotspots were identified in any of these five genes (Figure
14). From a total of 37 different mutations, eight were found to be recurrent within the
cohort. The p.Ala200Pro mutation in POMT1, previously described as prevalent within
the Turkish population, was detected in three patients, two of Turkish origin and one of
Greek decent (patients A3, A7 and A8 respectively) (Balci et al., 2005). The POMGNT1
donor splice site mutation c.1539+1G>A found to account for the enrichment of MEB
within the Finnish population was detected in two patients (patients A21 and A22
respectively) (Diesen et al., 2004). Three further novel mutations were detected more
than once, specifically the p.Tyr666Cys mutation in POMT2 which was found both in
the homozygous and heterozygous state in four patients. Segregation of this novel
missense mutation was studied in a large pedigree and was found to segregate with the
disease (patient A15). Parental samples where studied for 11 probands to ensure that
compound heterozygous mutations were in trans and that apparent homozygous
mutations in the proband were not masking undetected deletions. Where parental DNA
was tested (22 families in total) a single paternal mutation was found to occur de novo
(POMT2; c.2150T>C; p.Phe117Ser). A relatively similar frequency of patients with
mutations detected in POMT1, POMT2, POMGNT1 and FKTN was detected (Table 8).
In contrast, only a single patient was found to have a pathogenic mutation in LARGE
although we were unable to identify a second mutation (patient A25).[113]
Figure 14. Distribution of mutations in POMT1, POMT2, POMGNT1, FKTN and
LARGE.
White boxes represent individual coding exons, dark grey boxes indicate non-coding
exons. All exons are numbered accordingly. The size of the box corresponds to the
number of base pairs within each exon. Mutation types and locations are represented by
symbols above the appropriate exon; circles represent missense mutations; triangles
represent nonsense mutations; squares represent frameshift mutations; diamonds
represent splice site mutations; crosses represent in frame deletions. Dark symbols
indicate mutations found only in the homozygous state, white symbols indicate
mutations found only in the heterozygous state and mixed symbols indicate mutations
found in both states.[114]
Patient A16 POMT2; c.2243G>C; p.Trp748Ser (exon21)
Homo VGPLAQDPQSPMAGLRWLDSWDF
Pan VGPLAQDPQSPMAGLRWLDSWDF
Macaca VGPLAQDPQSPMAGLRWLDSWDF
Mus VGPLAQEPESPMAGLRWLESWDF
Canis VGPLAQDPGSPMAGLRWLESWDF
Felis VGPLAQDPRSPMAGLRWLESWDF
Equus VGPLAQDPRSPMAGLRWLESWDF
Bos VGPLAQDPRSPMAGLRWLESWDF
Echinops VGPLAQNPLSPMAGLRWLESWDF
Monodelphis VGPLAQDPQSPMAGLKWLETWEF
Ornithorhynchus VGPLAQDPHSPMAGLRWLDSWEF
Gallus IGPMASDPSSPMAGLRWMDSWEF
Patient A16 POMT2; c.551C>T; p.Thr184Met (exon5)
Homo LDLSKSLSAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Pan LDLSKSLSAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Macaca LDLSKSLSAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Mus LDLSKSFPAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Canis LELSKSFPAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Felis LELSNSLPAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Equus LELSKSLPAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Bos LELSRSLSAALLTAALLTFDTGCLTLSQYILLDPILMFFIM
Echinops LELSKSLPAALLTAALLTFDTGCLTLSQYILLDPILLFFIM
Monodelphis LELSRSQPAALLAAALLTFDTGCLTLSQYILLDPILMFFIM
Ornithorhynchus LELTKSLPAALLAAALLTFDTGCLTLSQYILLDPILMFFIM
Gallus LELSKSLPAALLTAFILIFDTGCITLSQYILLDPILMFFLM
Patient A18 POMGNT1; c.526A>C; p.Thr176Pro (exon 6)
Homo EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Pan EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Macaca EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Mus EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Canis EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Felis EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Equus EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Bos EDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSL
Echinops EDEAMVLFLNMVAPGRVLICTIKDEGSFHLKDTAKALLRSL
Monodelphis EDEAMVLFLNMVAPGRVIICTVKDEGSFHLKDTAKALLRSL
Ornithorhynchus EDEAMVLFLNMVAHGRVLIFTIKDEGSFHLKEPAKALLSSL
Gallus EDEAMVLFLNMVARGRILIFTIKDEGSFHLKETAKNVLKSL
Patient A27 FKTN; c.915G>A; p.Trp305Cys (exon 8)
Homo AKTLNKLGVPFWLSSGTCLGWYRQCNIIPYSKDVDLGIFIQ
Pan AKTLNKLGVPFWLSSGTCLGWYRQCNIIPYSKDVDLGIFIQ
Macaca AKTLNKLGVPFWLSSGTCLGWYRQCNIIPYSKDVDLGIFIQ
Mus AKTLKDLGVPFWLSSGTCLGWYRQCGIIPYSKDVDLGIFIQ
Canis AKTLKKLGVQFWLSSGTCLGWYRQCNIITYSKDVDLGIFIQ
Felis ARNVKKLGVRFWLNSGTCLGWYRQCNIIPYSKDVDLGIFIQ
Equus ARTLKKLGVRFWLSSGTCLGWYRQCNIIPYSKDVDLGIFIQ
Bos AKTLKKLGVRFWLSSGTCLGWFRQCSIIPYSKDVDLGIFIQ
Echinops AKTLKKLGIRFWLSSGTCLGWYRQCNIIPYSKDVDLGIFIQ
Monodelphis -----------------------------------------
Ornithorhynchus ALTLQSLGVRFWLSSGTCLGWYRQCNIIPYSRDVDLGIFIQ
Gallus ALTLNNLGVKFWLSSGTCLGWYRQCNVIPYSKDVDLGIFIR
Figure 15. Protein alignment (homology) plots of POMT2, POMGNT1 and FKTN.
A total of 12 vertebrate species are shown. The complete conservation of sequence
variants detected in patients A16, A18 and A27 is indicated by arrows and are flanked
by 40 amino acids.[115]
Genotype-phenotype correlations
The spectrum of phenotypes associated with mutations in POMT1 included WWS (1
case), MEB-FCMD (1 case), CMD-MR (3 cases) and LGMD-MR (3 cases). POMT2
mutations were observed in patients with MEB-FCMD (6 cases), CMD-CRB (2 cases)
and LGMD-MR (1 case). Six patients with POMGNT1 mutations had WWS and a
single case had LGMD-no MR. Phenotypes associated with mutations in FKTN were
detected in patients with WWS (1 case), MEB-FCMD (1 case), CMD-no MR (1 case)
and LGMD-no MR (3 cases). A mutation in LARGE was detected in a single patient
with WWS (Table 5).
No clear difference in phenotype was observed between patients with and without
mutations in any of these genes. The phenotypic spectrum of patients without
identifiable mutations was similar to that of patients with mutations.
3.2.3 Functional Characterisation of the POMGNT1 Variant p.Asp556Asn
The detection of a homozygous POMGNT1 non-synonymous variant in a patient with
LGMD-no MR warranted further investigation (patient A20, c.1666G>A;
p.Asp556Asn). Thus far mutations in this gene have not been described in patients
without associated brain involvement.
The sequence change was found to segregate with disease in all family members tested.
This substitution causes a non-conservative amino acid change that affects an
evolutionary conserved amino acid residue within the catalytic domain (Figure 16).[116]
A
B
Figure 16. Sequence analysis: POMGNT1 variant c.1666G>A; p.Asp556Asn.
A) The arrow indicates patient A20. Circles denote females and the square denotes a
male. Fully shaded shapes indicate homozygosity for the POMGNT1 variant, semi
shaded shapes indicate carriers of this variant. B) Electropherograms showing the
sequence variation in POMGNT1. An asterisk denotes the homozygous mutation
(c.1666G>A) that leads to a predicted amino acid change (p.Asp556Asn).[117]
Subcellular localisation of mutant POMGNT1 constructs
To observe the effects of the variant found in patient A20 on POMGNT1 expression and
localization, I introduced the c.1666G>A; p.Asp556Asn variant into the wild-type
POMGNT1 tagged construct. The mutant construct appeared to be expressed at levels
similar to the wild-type construct and retained co-localization with the Golgi apparatus
marker GM130 in transfected myotubes (Figure 17).[118]
Figure 17. Double labelling of POMGNT1-V5 constructs and GM130 on transfected
C2C12 myotubes.
The merged images (c and f) indicate that both wild-type (a-c) and mutant POMGNT1
(c.1666G>A; p.Asp556Asn) constructs (d-f) colocalize with the Golgi apparatus marker
GM130. Green channel; anti-V5 antibody; red channel; anti-GM130 antibody; blue
channel; Hoechst 33342 nuclear stain. Scale bar; 10µm.[119]
Investigating the creation of a novel N-glycosylation site
The c.1666G>A alteration results in a substitution of aspartic acid with an asparagine
residue at position 556. This alteration creates a potential N-glycosylation site (Asn-X-
Ser/Thr-X-, where X is any amino acid except proline) in the protein which is predicted
to have no other such sites (Asp-His-Ser-Lys to Asn-His-Ser-Lys). To observe the
effects of the variant detected in patient A20 on POMGNT1 expression and localisation,
I transfected C2C12 cells with human V5-tagged wild type and mutant (c.1666G>A;
p.Asp556Asn) POMGNT1. Protein extracts from these cells were analysed by western
blotting using a V5-specific antibody. No difference in molecular weight of mutant and
wild type protein was observed in this system indicating that this mutation does not
induce aberrant N-glycosylation at this site (Figure 18).[120]
A
B
Figure 18. Investigating the creation of a novel N-glycosylation site in POMGNT1.
C2C12 cells were transfected with wild-type (WT) and mutant POMGNT1
(c.1666G>A; p.Asp556Asn) V5-tagged constructs. A) Proteins were resolved by SDS-
PAGE and immunoblotted with an antibody to V5. MW, molecular weight in kDa.
POMGNT1 V5-tagged protein is indicated by an asterisk, whilst the band below this is a
non specific band. * Indicates transfected V5-tagged POMGNT1. Vertical bar
(approximately 3 mm) indicates the predicted change in migration of V5-tagged
POMGNT1 if aberrantly N-glycosylated. B) Graph showing calculations of predicted
change in migration of POMGNT1 if aberrantly N-glycosylated (Vogt et al., 2005).[121]
Collaborative functional investigations; kinetic analysis
Quantifying the pathological consequence of POMGNT1 mutations has been facilitated
by the development of a functional assay measuring POMGNT1 enzyme activity. This
assay enables the detection of pathogenic POMGNT1 alterations in both individuals
with MEB as well as carriers of these mutations. Its implementation and has been used
as a successful adjunct to diagnosis. In a collaborative study with Professor Harry
Schachter’s group in the department of Structural Biology and Biochemistry in Toronto,
Canada, skin fibroblasts from patient A20 were analysed by methods previously
described (Vajsar et al., 2006; Zhang et al., 2003). Conventional enzyme assays
measuring apparent Vmax values detected no significant difference between controls
and patient A20. During a more detailed analysis of patient 20’s fibroblasts, POMGNT1
activity was measured at four different substrate concentrations. An altered kinetic
profile of the mutant enzyme was subsequently detected. The apparent Km for UDP-
GlcNAc is substantially higher and the Vmax for Manα1-O-benzyl is substantially lower
than in the control sample. Detailed descriptions of these results have been reported in
Clement et al (Clement et al., 2008b).
Prevalence of the POMGNT1 sequence change c.1666G>A
The POMGNT1 sequence change c.1666G>A; p.Asp556Asn was excluded as a
common polymorphism as it was not found in the dbSNP yet I detected the variant in 1
of 150 white European control chromosomes (please refer to section 2.1.1).
3.2.4 Further Collaborative Functional Investigations
Where available, fibroblasts from patients with detected sequence alterations were sent
for analysis in Professor Kevin Campbell’s laboratory (Howard Hughes Medical
Institute, Department of Physiology and Biophysics, Department of Neurology,
University of Iowa, USA). A complementation assay was performed by viral
transfection of wild type constructs containing either human POMT1, POMT2,
POMGNT1, FKTN or FKRP. Successful complementation was observed as a restoration
of immunoreactivity to IIH6 on western blot. Fibroblasts from patients A8, A9, A12 and
A30 were analysed.[122]
As predicted, complementation was successful in cell lines from patient’s A8, A12 and
A30 using plasmids for POMT1, POMT2 and FKTN respectively. All three patients
harboured a mutation predicted to cause nonsense mediated decay. Patient A9, with two
missense changes in POMT2 was confirmed as having a POMT2 defect.
3.3 DISCUSSION
Dystroglycanopathies are a recently defined, common group of muscular dystrophies
encompassing an extremely wide spectrum of clinical severity and are caused by
mutations in at least six genes encoding putative or demonstrated glycosyltransferases.
The comparatively small coding region of FKRP has facilitated the rapid correlation
between genotype and phenotype, allowing the discovery of pathogenic mutations in
patients with LGMD2I, MDC1C, MEB-like and WWS-like disorders. However, there
was no information regarding the frequency of involvement or the genotype-phenotype
relationships for the remaining five glycosyltransferase genes in a large and unbiased
population.
In this study we have systematically screened for mutations in POMT1, POMT2,
POMGNT1, FKTN and LARGE in patients in whom we had previously ruled out FKRP
gene involvement. Mutations were detected in 34% of these patients.
3.3.1 Genotype-Phenotype Correlations
Protein-O-mannosyltransferase 1 (POMT1)
Mutations in POMT1 have previously been reported in patients with WWS, CMD-MR
and LGMD-MR (LGMD2K). Within our cohort, all patients with mutations in POMT1
had evidence of functional brain involvement either with no clear associated structural
brain abnormalities (3 patients with LGMD2K (LGMD MR), and 3 patients with CMD-
MR), or more severe conditions with structural brain defects (one patient with WWS,
and one individual with a MEB-like phenotype). This suggests that the majority, if not
all patients with POMT1 mutations have either functional or structural central nervous
system involvement, including those patients with relatively mild muscle weakness.[123]
This is in contrast to patients in the present study with mutations in FKTN and to that
previously reported for FKRP mutations.
Protein-O-mannosyltransferase 2 (POMT2)
Mutations in POMT2 were confined to patients with evidence of brain involvement.
Nine patients had pathogenic POMT2 mutations; 6 with a MEB-FCMD phenotype, 2
with a CMD-CRB phenotype and a single patient with LGMD-MR. This latter patient
has learning difficulties and remains ambulant at age 20 having presented, at 18 months
of age, with developmental delay (patient A16). These findings indicate that like
POMT1, the majority or all patients with mutations in POMT2 have evidence of central
nervous system involvement. In addition, we have identified the mildest phenotype
associated with mutations in POMT2 reported to date in an individual with LGMD-MR.
Protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase (POMGNT1)
To date POMGNT1 mutations have been described in patients with a phenotype
consistent with MEB, although rare cases with more severe clinico-radiological
features, resembling WWS, have also been reported (Taniguchi et al., 2003; Yoshida et
al., 2001). The majority of patients in this study had an MEB- like disorder suggesting
that POMGNT1 mutations more frequently give rise to congenital disorders with
associated structural brain involvement. A single patient possessing a LGMD phenotype
and entirely normal intellectual function harboured a homozygous missense change.
Applying the initial classification system, this variant was included in the mutation table
yet further functional investigations uncovered a more complicated profile (please refer
to section 3.3.2).
Like-glycosyltransferase (LARGE)
We were only able to identify a single potentially pathogenic LARGE mutation in a
patient with typical WWS phenotype who died in the first few months of life (patient
A25). Absent immunofluorescence staining was demonstrated on this patient’s skeletal
muscle biopsy using antibodies which recognise the glycosylated epitope of α-[124]
dystroglycan. Unfortunately neither sufficient DNA nor frozen muscle from this patient
was available to investigate the presence of a second, as yet undetected, mutation.
Fukutin (FKTN)
Mutations in FKTN, typically associated with FCMD in Japan were found in six
patients, none of whom are of Japanese origin. Only two of these patients had structural
brain involvement; one patient affected by WWS (patient A28) and one by a MEB-
FCMD phenotype (patient A27). The remaining patients had no structural brain
involvement; one case had CMD-no MR (patient A26) and never acquired the ability to
walk but has normal IQ and 5 individuals from 3 families have entirely normal intellect
and a mild LGMD phenotype (LGMD2L) (patients A29, A30, and A31). Interestingly
in two of these families (A29 and A30), a dramatic response to steroid therapy was
noted (Godfrey et al., 2006). In striking contrast to what has previously been reported in
FCMD, none of these 5 patients have evidence of central nervous system involvement.
Our findings together with the recent description by Murakami et al. of individuals with
FKTN mutations presenting with a predominant cardiomyopathy, suggest that the
majority of mutations outside Japan give rise to conditions milder than FCMD and are
not usually associated with structural brain involvement (Murakami et al., 2006).
Further functional investigations were carried out on two mutations detected in patients
A29 and A30 by members of the Dubowitz Neuromuscular Centre; p.Arg307Gln and
Asp455fs were introduced into a wild type FKTN tagged construct. Both mutations
appeared to be expressed at levels similar to the wild-type construct and retained co-
localisation with the Golgi apparatus marker GM130 (data not shown). Detailed
descriptions of these have been reported in Godfrey et al. (Godfrey et al., 2006).
Mutation frequencies
Mutations in POMT2 were the most prevalent with 9 cases, followed by POMT1 with 8
cases, POMGNT1 with 7 cases, FKTN with 6 cases and finally LARGE with only a
single case.[125]
Members of the Dubowitz Neuromuscular Centre had previously identified FKRP
mutations in 79 patients. Approximately 75% of these patients have a LGMD2I
phenotype (Beltran-Valero de Bernabe et al., 2004; Brockington et al., 2001a; Mercuri
et al., 2006; Topaloglu et al., 2003). The relative frequency of FKRP involvement needs
to be considered with caution as it clearly reflects the genetic origin of patients studied
within the Dubowitz Neuromuscular Centre. For example screening of 79 Australian
LGMD dystroglycanopathy patients detected only two FKRP mutations. However,
when amalgamating these results, it remains clear that FKRP mutations are the most
frequent in this group of conditions. Both our department and others have previously
published extensively on the spectrum of these mutations (Brockington et al., 2001a;
Brockington et al., 2001b; Harel et al., 2004; Lin et al., 2007; Mercuri et al., 2003;
Mercuri et al., 2006; Topaloglu et al., 2003; Vieira et al., 2006).
Genotype-phenotype correlations
Pathogenic mutations were detected in 3 of 5 patients with WWS syndrome (60%), 14
of 30 patients with a MEB/FCMD phenotype (47%), 2 of 4 patients with CMD-CRB
(50%), 3 of 15 patients with CMD-MR (20%), 1 of 10 patients with CMD-no MR
(10%), 4 of 5 patients with LGMD-MR (80%), and 4 of 20 patients with LGMD-no MR
(20%) (Table 7).
Patients with associated structural brain defects belonging to the severe end of the
clinical spectrum showed no apparent difference in their pattern of skeletal muscle
weakness or central nervous system involvement in relation to the gene involved.
However, the 4 LGMD patients with associated MR and microcephaly all had mutations
in either POMT1 or POMT2. No mutations were identified in the remaining patients.
Conversely a number of patients with more severe muscle weakness and no brain
involvement (CMD-no MR) were found to have mutations in FKTN, similar to that
previously described in MDC1C (Brockington et al., 2001a). This suggests that there
may be a hierarchical involvement of muscle and brain arising from individual gene
mutations, with POMT1 and POMT2 being associated with significant central nervous
system involvement even in patients with relatively mild weakness and who remain
ambulant (LGMD2K). This does not appear to be a feature of FKTN or FKRP. These
results suggest that in some individual subcategories certain genes are more likely to be[126]
involved than others and this should be taken into account when undertaking mutation
analysis in the dystroglycanopathies.
3.3.2 Functional Investigations
Without further RNA studies and functional biochemical analysis it is difficult to
determine the pathogenicity of unclassified variants. This is exacerbated by the
abundance of missense variants within these genes.
Further functional characterisation of the POMGNT1 variant p.Asp556Asn was
performed by me and others. This variant was detected in a patient with LGMD yet no
associated brain involvement. Several lines of evidence initially suggested that the
alteration identified in patient A20 was pathogenic. The variant was found to segregate
with the disease in this large family. This substitution causes a non conservative amino
acid change that affects an evolutionary conserved amino acid residue (Figure 19). The
mutation causes a reversal of amino acid polarity in the substrate specific domain of
POMGNT1 which may be expected to have functional consequences. In addition, the
detailed enzymatic studies offer support for this theory. POMGNT1 activity was
observed in the patient’s fibroblasts yet differs in its kinetics from that of controls. This
altered kinetic profile is less marked than in patients with MEB and in keeping with the
relatively mild phenotype in our patient.[127]
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Homo KEAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLM
Pan KEAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Macaca KEAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Otolemur KEAYEVEIHRLLSEAEVLDHSRNPCEDSFLPDTEGHTYVAFIQMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Rattus KEAYEVEIHRLLSEAEVLDHSKDPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Mus KEAYEVEIHRLLSEAEVLDHSKDPCEDSFLPDTEGHTYVAFIRMETDDDFATWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Cavia KEAYEAEIHRLLSGAEILDHSKNPCEDSFLPDTEGHTYVAFIQMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Sorex KEAYEVEIHRLLSEAEVLDHTRNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Erinaceus KEAYEVEIHRLLSEATVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHCGLWRLFRKKNHFLV
Canis KEAYEVEIHRLLSEAEVLDHSRNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Felis KEAYEAEIHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFITWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Equus KDAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Bos KDAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLRIWDLDVRGNHRGLWRLFRKKNHFLV
Monodelphis KDAYEAEVLRLLSEAEVLDHSKDPCEDSFVPDTEGRTYVTFIRMEQDNDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLV
Xenopus KDAYEIEIHRILSEAEILDHSKNPCEDSFIPDTEGKTYVMYIKMEQEADFTTWTQLAKCLHIWDLDVRGNHKGLWRLFRKKNHFLV
Tetraodon KDSYEVEIQNLLREAEVLDHTKDPCEDSFLPDAEGKTYVMFIKMDTDTDTSTWTELAKCLHVWDLDVRGYHRGLWRLFRKRNHLLV
Figure 19. Sequence analysis POMGNT1 variant p.Asp556Asn.
A) Location of an amino acid change in the catalytic substrate specificity domain of
POMGNT1. Human POMGNT1 is composed of a cytoplasmic domain (CD, amino
acids 1-38), a transmembrane domain (TD, amino acids 39-59), a stem domain (amino
acids 60-301) and a catalytic domain (amino acids 302-660). * Indicates the position of
the patient mutation (p.Asp556Asn). B) Panel shows a protein alignment (homology)
plot of the catalytic domain of POMGNT1 in 16 vertebrate species, with complete
conservation of Asp556Asn (arrow).[128]
It is interesting to note that this mutation does not affect either the expression or
subcellular localisation of a recombinant form of POMGNT1. The p.Asp556Asn
mutation introduces a potential N-glycosylation site (Asn-X-Ser) into the protein which
is predicted to have no other such sites. Vogt et al. reported that an unexpectedly high
proportion of pathogenic mutations lead to the creation of N-glycosylation sites (Vogt et
al., 2005). The authors demonstrated that the pathogenic effect of mutations in IFNγR2 
was a direct consequence of the addition of N-linked carbohydrate. Although this study
focussed on those proteins that undergo trafficking through the ER, some
transmembrane proteins lacking a signal peptide or signal anchor can also be subjected
to gains in glycosylation (Hammerle et al., 2000). It may be hypothesised that the
presence of an N-glycan on POMGNT1 within the substrate specific region of the
catalytic domain may cause defective enzyme folding resulting in an active but
inefficient enzyme. However no change in molecular weight on western blot was
detected between wild-type and mutant POMGNT1 constructs, therefore it is unlikely
that this protein is aberrantly glycosylated. The N-glycosylation consensus sequence
described is a prerequisite for modification; however not all of these sequons are
glycosylated. In silico analysis to examine the sequence context of Asn-X-Ser sequon
by NetNGlyc Server 1.0 (Technical University of Denmark) did not predict N-
glycosylation at this site, adding to evidence that this variant does not cause the addition
of aberrant carbohydrate moieties.
Subsequent to the publication of this study, we became aware that this sequence change
had been detected within a French family. Both a patient with MEB disease and her
apparently unaffected sibling were both homozygous for this change. In addition, this
variant was detected in 8 out of 218 alleles from healthy French controls (Celin
Bouchet, unpublished observation). This is surprising in view of our findings but, if
confirmed will effectively exclude the p.Asp556Asn as being pathogenic. It therefore
remains to be established whether the altered kinetic profile detected in POMGNT1 is a
polymorphism or contributes to the patient’s phenotype. Indeed the alteration in
POMGNT1 kinetics may be due to a secondary effect of an as yet unidentified gene
defect. We are currently awaiting a fibroblast cell line from the unaffected French
sibling to ascertain POMGNT1 function.[129]
Functional characterisations were performed on a further four patient fibroblast cell
lines by collaborators in America. Members of Professor K Campbell’s department
were able to confirm POMT1, POMT2 and FKTN defects in four patients using a
complementation assay. However, this approach was not useful to confirm/exclude the
pathogenesis of a POMGNT1 defect in patient A20’s fibroblasts. To perform the assay,
a dramatic reduction in immunoreactivity to the monoclonal antibody IIH6 is required.
The mild reduction in α-dystroglycan epitope staining in patient A20’s fibroblasts was
not sufficient to detect a quantifiable improvement when transfected with a panel of
virus.
The application of functional data to ascertain the pathological consequences of
unclassified variants is an especially valuable tool in clinically and genetically
heterogeneous disorders. Nevertheless, the investigation of the p.Asp556Asn variant in
POMGNT1 yielded a complex profile and highlights the difficulty in interpreting data in
patients with atypical clinical presentations.
3.3.3 Conclusions
The results of this study demonstrate that the phenotypic spectrum of disorders
associated with mutations in six of the known glycosyltransferase genes is significantly
wider than initially suspected. In part this is due to the high prevalence of founder
mutations within specific populations (Diesen et al., 2004; Kobayashi et al., 1998). We
have expanded the clinical phenotypes associated with mutations in POMT1, POMT2,
FKTN and LARGE. Despite this we have not observed a full spectrum of phenotypes
associated with each gene, in particular POMT1, POMT2 and LARGE. Numerous
patients with clinicopathological features indistinguishable from the ones detailed in
this study were not found to have mutations in any of the genes analysed.
This large and unbiased study redefines the clinical spectrum associated with each of
the glycosyltransferases genes included. It identifies the frequency of individual gene
defects and suggests that, after the exclusion of FKRP, the majority of patients with a
dystroglycanopathy do not harbour mutations in any of the known genes. This work
therefore suggests that further, as yet unknown genes will be involved in the[130]
pathogenesis of the dystroglycanopathies. The identification of these genes will provide
important information defining the pathway of glycosylation of α-dystroglycan.[131]
CHAPTER 4. CANDIDATE GENE ANALYSIS[132]
4 CANDIDATE GENE ANALYSIS
4.1 INTRODUCTION
At the time the study in chapter 3 was performed, pathogenic mutations had been
identified in a total of six genes responsible for dystroglycanopathies. After the
exclusion of FKRP, mutation screening of POMT1, POMT2, POMGNT1, FKTN and
LARGE in a large cohort identified mutations in approximately a third of all cases.
These findings reported for the first time the proportion of patients in whom a molecular
diagnosis remains undefined. In addition it was noted that those patients without an
identifiable mutation were clinically and pathologically indistinct from those with
identified mutations. A clear limitation of this analysis is that only coding exons and
bordering intronic splice sites were sequenced. It is therefore possible that some patients
in cohort A (those screened in chapter 3) may instead harbour pathogenic structural or
regulatory region defects in the genes studied. It is however, unlikely that these
pathogenic variants account for a considerable proportion of patients in whom a gene
defect remains undefined. It would be expected that if these mutations were highly
prevalent within our population, an abundance of patients would have been identified as
heterozygous for one clearly pathogenic mutation, but with no detectable second
mutation. Only a single such case was identified in cohort A (patient A25). Therefore
the high proportion of cases with no identifiable mutation strongly suggests that novel
genes are likely to be involved in the pathogenesis of dystroglycanopathies. The
challenge has therefore shifted focus to investigate novel genes. The identification of
genetic defects in these patients would not only yield novel insights into the pathway of
α-dystroglycan glycosylation but would improve the diagnosis, classification and
counselling of patients and their families.
In the past, the analysis of linkage data from patient cohorts with specific clinical
presentations has yielded fruitful results, specifically led to the identification of
mutations in FKTN and POMGNT1 (Kobayashi et al., 1998; Yoshida et al., 2001). The
success of these studies relied on the elevated prevalence of specific mutations within
distinct populations. The relatively high incidence of specific clinical phenotypes in
Caucasian, Japanese and Finnish populations demonstrates the importance of founder
effects in the aetiology of these diseases (Brockington et al., 2001b; Kobayashi et al.,[133]
1998; Yoshida et al., 2001). Despite the success of this approach, those patients with no
detectable mutations (described in chapter 3) are both clinically and ethnically diverse.
This indicates that their underlying genetic defects are unlikely to be caused by a single
mutation residing in a novel gene derived from a common ancestral chromosome. In
support of this, evidence from homozygosity mapping performed on eleven unrelated
consanguineous families with WWS failed to pinpoint a single loci indicating the
presence of extensive genetic heterogeneity (van Reeuwijk et al., 2005b). The prospect
remains that a large number of defective genes underlie the pathogenesis in these
unresolved dystroglycanopathy cases. The contribution of novel genes could reflect that
of LARGE, where the number of patients reported in the literature with mutations in this
gene remains extremely low, despite its identification more than seven years ago
(Longman et al., 2003; van Reeuwijk et al., 2007). The anticipated level of
heterogeneity therefore challenges the appropriateness of using standard mapping
strategies to identify novel genes, especially those involving the pooling of linkage data
from a number of small pedigrees.
With such clinical, ethnic and presumed genetic heterogeneity within a cohort of
sporadic cases, whole genome candidate gene analysis presents as an appropriate
alternative strategy. Within the dystroglycanopathies alone, this methodology has
proved successful in leading to the identification of mutations in FKRP, POMT1,
POMT2 and more recently, DPM3. This chapter describes the application of this
approach to our cohort of molecularly unresolved dystroglycanopathy cases. I
systematically screened a cohort of patients for mutations in a panel of candidate genes
selected using a variety of rationales. In addition I functionally assessed the
involvement of a subset of these genes in the pathway of α-dystroglycan glycosylation.
4.2 RESULTS
4.2.1 Clinical Findings
Patient cohort B comprised of 37 probands (patients B1-B37) from a range of
ethnicities, the inclusion criteria of which is detailed in section 2.1.1. As previously
stated, clinical data was analysed by Professor F Muntoni and Dr E Clement. Patients
were classified into 1 of 7 broad clinical categories as described in section 3.2.1. The[134]
cohort consisted of total of 22 patients with CMD and 15 patients with LGMD. A total
of 21 patients had brain involvement. The division of phenotypes within the cohort is
shown in Table 9.[135]
Table 9. Clinical classifications of 37 patients within cohort B.
CMD; Congenital Muscular Dystrophy, LGMD; Limb Girdle Muscular Dystrophy.
Phenotypic category Hypoglycosylation of
α-dystroglycan
Muscle unavailable for
α-dystroglycan studies Total
Walker-Warburg syndrome 1 1 2
Muscle eye brain disease/Fukuyama CMD 8 2 10
CMD cerebellar involvement 1 1 2
CMD mental retardation 3 2 5
CMD no mental retardation 3 0 3
LGMD mental retardation 1 1 2
LGMD no mental retardation 9 4 13
Total 26 11 37[136]
4.2.2 Identification of Novel Candidate Genes
I selected a total of seven genes as potential candidates for dystroglycanopathy (Table
12). The existence of naturally occurring and engineered animal dystroglycanopathy
models provided a solid source of candidate genes. The analysis of functional
candidates as well as the use of a bioinformatics approach identified a further four
genes.
Animal models
Hypoglycosylation of α-dystroglycan has been demonstrated in a naturally occurring
muscular dystrophy chicken (Saito et al., 2005). This was observed using the same
monoclonal antibody routinely used in the diagnosis of dystroglycanopathy patients
(Ervasti and Campbell, 1991; Saito et al., 2005). Linkage studies identified a
homozygous region spanning approximately 1 Mb on chicken chromosome 2q
containing only seven genes (Matsumoto H, 2007). A single homozygous missense
alteration (c.1321G>A; p.Arg441Gln) was identified in the gene encoding ubiquitin
ligase WW domain-containing protein 1 (Wwp1), although the pathogenic effect of this
novel sequence variant has yet to be demonstrated (Matsumoto et al., 2008). E3
ubiquitin ligases are thought to function in the ubiquitin proteasome system; the major
pathway responsible for protein degradation in eukaryotic cells through its ability to
selectively target proteins for destruction. Ubiquitination is catalysed by three enzymes
acting in a cascade; a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme
(E2) and a ubiquitin protein ligase (E3). The E3 ubiquitin ligase provides substrate
specificity and catalyses isopeptide bond formation between ubiquitin and the substrate
(Hirsch et al., 2009). The human WWP1 ortholog resides on chromosome 8q21 and
shares 83% amino acid identity with the chicken Wwp1 protein (Matsumoto et al.,
2008). Human WWP1 is ubiquitously expressed with the highest expression in skeletal
muscle and brain (Wood et al., 1998). This gene therefore warrants investigation as a
candidate for human dystroglycanopathy.
The analysis of zebrafish is a powerful novel tool in the characterisation of gene
function and in the dissection of disease pathogenesis. Very recently a novel zebrafish[137]
morphant generated in the laboratory of our collaborator, Dr D Stemple at the Wellcome
Trust Sanger Institute, Cambridge University, was found to suffer clinico-pathological
features that were highly suggestive of a dystroglycanopathy (unpublished data). The
knockdown of glycogenin (Gyg) expression caused a reduction in immunoreactivity to
the monoclonal antibody IIH6, as well as causing a phenotype strikingly similar to that
resulting from Fkrp knockdown in zebrafish (Kawahara et al., 2010; Thornhill et al.,
2008). Glycogenin is a self-glucosylating protein primer that initiates the synthesis of
glycogen. Humans possess two glycogenin genes: glycogenin 1 (GYG1) resides on
chromosome 3q24-q25.1 and glycogenin 2 (GYG2) located at Xp22.3. Human GYG2 is
notably larger, and shares an overall amino acid identity with GYG1 of 40-45% (Mu et
al., 1997). Both human glycogenin proteins can self-glucosylate using UDP-glucose as
a donor, the products of which are subsequently extended with glucose monomers by
the action of glycogen synthase (encoded by GYS) [OMIM; 138570] (Lomako et al.,
2004; Mu et al., 1997). The presence of GYG2 paralogs are limited to mammals yet
absent in rodent species (Figure 20). Many other organisms have been shown to harbour
multiple glycogenin or glycogenin-like genes such as Saccharomyces cerevisiae which
harbours two genes encoding self glucosylating proteins. Interestingly GYG1, GYG2
and the proximal domain of LARGE demonstrate close homology to a bacterial GT8
glycosyltransferase protein family involved in lipooligosaccharide synthesis (Coutinho
et al., 2003). This evidence indicates that both human glycogenin genes are promising
candidates for dystroglycanopathy.[138]
Figure 20. Phylogenetic tree depicting the mammalian glycogenin family.
Phylogenetic analysis of mammalian glycogenin reveals the GYG1 paralog GYG2, is
restricted to mammals and absent from rodent species. Figure generated using TreeFam
(www.TreeFam.org).[139]
Bioinformatic tools
In order to identify further candidate genes, I applied a bioinformatics approach to the
whole genome. Endeavour software is based on the hypothesis that novel genes share
either a similar role or biological processes with those genes known to be associated
with disease (www.esat.kuleuven.be/endeavour/) (Aerts et al., 2006). In this study the
ranking of candidates was derived from similarity to a ‘training set’ of genes which
consisted of POMT1, POMT2, POMGNT1, FKTN, FKRP and LARGE. Data are
subsequently mined from a range of bioinformatics resources (including information
regarding annotation, sequence, expression, regulation and the available literature).
Individual gene rankings are then merged into a global ranking of candidate genes (for
more details please refer to section 2.2.10). Results are shown in Table 10. Two genes
obtaining the highest rankings by the Endeavour search were Golgi apparatus resident
proteins GYLTL1B and β3GNT1, both of which demonstrate significant homology to
LARGE (Figure 21). Due to the only very recent discovery of α-dystroglycan
hypoglycosylation in a patient with mutations in DPM3, this gene was absent from the
‘training set’ described above. Subsequent reanalysis generated with the inclusion of
this gene retained GYLTL1B and β3GNT within the top six candidate genes (data not
shown).[140]
Rank
* Protein (encoding gene) ** Gene ID
† Location
†† Molecular
function
‡
Subcellular
localisation
‡‡
1 glycosyltransferase-like 1B (GYLTL1B) 120071 11p11.12 Glycosyltransferase Golgi apparatus
2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 (β3GNT1) 11041 11q13.2 Glycosyltransferase Golgi apparatus
3 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1) 4245 5q35 Glycosyltransferase Golgi apparatus
4 stromal cell-derived factor 2-like 1 (SDF2L1) 23753 22q11.21 Glycosyltransferase Endoplasmic
reticulum
5 beta-1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1) 2583 12q13.3 Molecular function
unclassified Golgi apparatus
Table 10. Endeavour prioritised whole genome candidate genes.
* The top 5 ranked genes using the Endeavour gene prioritisation software (www.esat.kuleuven.be/endeavour/). The training set consisted of:
POMT1, POMT2, POMGNT1, LARGE, FCMD and FKRP. ** Gene symbols and names as per HUGO nomenclature (www.genenames.org/).
†
Entrez Gene Identifier from the NCBI database (http://www.ncbi.nlm.nih.gov/).
†† Denotes chromosomal location.
‡ Molecular function as
classified by the PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System (http://www.pantherdb.org/).
‡‡
Subcellular localisation as annotated via the Universal Protein Resource Knowledge Base (UniProtKB) (www.uniprot.org). Yellow shaded
boxes indicate those genes investigated as candidate genes.[141]
Glycosyltransferase-like 1B, encoded by GYLTL1B, is highly homologous to LARGE
and present in a number of vertebrate species. Human LARGE and GYLTL1B share 68%
amino acid identity indicating that the two genes are likely to have arisen via a gene
duplication event (Grewal et al., 2005). GYLTL1B resides on chromosome 11p11.2 and
encodes a 721 amino acid protein. Both LARGE and GYLTL1B have similar domain
structure containing two catalytic domains, N-terminal cytoplasmic tails and variable
stem region although GYLTL1B lacks the coil coil domain of LARGE (Figure 21).
Epitope tagged GYLTL1B localises to the Golgi apparatus when over expressed in
mouse myogenic C2C12 cells (Brockington et al., 2005; Grewal et al., 2005). Although
the physiological functions of both LARGE and GYLTL1B remain elusive, intriguing
properties of both proteins have recently been identified. The transient over expression
of these genes in a variety of cells lines induced a dramatic increase in α-dystroglycan
glycosylation which corresponds to an increase in high affinity binding to several
extracellular matrix ligands (Barresi et al., 2004).[142]
Figure 21. Schematic representation of the domain structures in human LARGE,
GYLTL1B and β3GNT1.
Domains were predicted by the ELM server at http://elm.en.org. Conserved DxD motifs
are indicated by *.[143]
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1, encoded by
β3GNT1, is highly homologous to the N-terminal catalytic structural domain of LARGE
(Figure 21) (Peyrard et al., 1999). The gene was originally identified by expression
cloning as an enzyme that synthesises poly-N-acetyllactosamine, the production of
which is essential for the formation of the i-antigen on human fetal blood cells (Sasaki
et al., 1997). β3GNT1 encodes a Golgi resident 397 amino acid protein and resides on
chromosome 11q13.2. Bao et al. recently reported an association between the reduction
in laminin-binding glycans and the decreased expression of β3GNT1 in aggressive
carcinoma cell lines. β3GNT1 was subsequently found to be required for laminin-
binding glycan synthesis through the formation of a complex with LARGE (Bao et al.,
2009).
Therefore the application of a bioinformatics approach has identified two promising
candidate dystroglycanopathy genes; GYLTL1B and B3GNT1.
Functional candidates
β1-6 N-acetylglucosaminyltransferase is a recently discovered glycosyltransferase
functioning in the synthesis of O-mannosyl glycans (Inamori et al., 2003; Kaneko et al.,
2003). The 792 amino acid protein is encoded by MGAT5B and resides on chromosome
17q25.3. MGAT5B has a type II membrane structure, typical of glycosyltransferases and
is distinct from its homolog GNTV with regards to substrate specificity as it is capable
of transferring to both N-linked and O-mannosyl linked acceptors (Inamori et al., 2004;
Inamori et al., 2003; Inamori et al., 2006). In vitro studies reveal that MGAT5B prefers
O-mannosyl acceptors catalysing the transfer of GlcNAc in β(1,6) linkage to the
peptide-O-linked mannose, but only if the β(1,2) linked GlcNAc formed by POMGNT1
is present (Figure 22) (Abbott et al., 2006). The
NeuAcα2,3Galβ1,4GlcNAcβ1,2[NeuAcα2,3Galβ1,4GlcNAcβ1,6]Manα-O depicted in
Figure 22 has been detected in abundance in the brain (Chai et al., 1999) (as depicted in
Figure 4, section 1.2.1). Although MGAT5B can transfer to the Man(β1,2) GlcNAc
found on non-galactosylated N-linked glycans, I selected MGAT5B as a candidate gene
due to its putative functional involvement in the branching of O-mannosyl-linked
glycans.[144]
Figure 22. Diagrammatic representation of the branching action of MGAT5B.
This 2,6-branched structure is abundant amongst mammalian brain O-mannosyl
glycans. MGAT5B has been shown to catalyse GlcNAc in β(1-6) linkage to the peptide-
O-linked mannose only if the β(1-2) linked GlcNAc formed by POMGNT1 is present.
Ser; serine, Thr; threonine, Man; mannose, GlcNAc; N-acetylglucosamine, Gal;
galactose,[145]
Dystroglycan itself has long since been considered a poor candidate gene for
dystroglycanopathy cases due to the deleterious effects of its abolition in mammalian
animal models (Williamson et al., 1997). It is likely that a severe mutation giving rise to
a dramatic reduction in protein production would not be viable. However the possibility
remains that the presence of milder mutations may give rise to a dystroglycanopathy
phenotype. It could be postulated, for example, that dystroglycan mutations affecting
the binding affinity of LARGE to the N-terminal domain rather than its structural
integrity, could perhaps induce a dystroglycanopathy-like phenotype. I therefore elected
to include DAG1 within the list of dystroglycanopathy candidate genes.
4.2.3 Mutation Analysis
To investigate whether these candidate genes are a cause of human dystroglycanopathy,
I performed mutation screening of GYLTL1B, β3GNT1, WWP1, GYG1, GYG2,
MGAT5B and DAG1. Cohort B comprised of patients in whom a mutation had not been
detected after the screening of all known genes. For details of the inclusion criteria for
cohort B please see section 2.1.1. I initially screened a subset of patients from cohort B
for mutations in GYLTL1B and MGAT5B. The cohort subsequently expanded as
additional cases were recruited. Therefore during the course of my studies, a total of
thirty seven patients were screened for mutations in β3GNT1, WWP1, GYG1, GYG2 and
DAG1. Mutation screening of the candidate genes was performed by uni-directional
sequencing on whole genome amplified DNA. DNA from the majority of patients was
successfully amplified by multiple displacement amplification. In addition to the 37
patients detailed in Table 9, a further three patients met the inclusion criteria for cohort
B yet DNA samples from these patients failed to amplify. There was insufficient DNA
remaining to assess the quantity or quality of the starting material and these patients
were excluded from further analysis. Sequencing results generated from multiple
displacement amplification samples were indistinguishable from non amplified genomic
DNA control samples.
Human GYLTL1B, β3GNT1, WWP1, GYG1, GYG2, MGAT5B and DAG1 genes are
organised into 13, 2, 23, 8, 12, 17 and 3 exons encoding 2.5 kb, 2.8 kb, 3.4 kb, 2 kb, 3.4
kb, 4.2 kb and 5.5 kb transcripts respectively. All sequence variations detected within
+50 or -50 base pairs of the intron/exon boundary are recorded in Table 11. Good[146]
quality sequencing reads from -20 to +10 base pairs of the intron/exon boundary was
established as a minimum requirement for each amplicon in accordance with guidelines
from the Clinical Molecular Genetics Society (www.cmgs.org). Both exonic and
intronic alterations were categorised as polymorphisms if they were present on the
dbSNP (http://www.ncbi.nlm.nih.gov). Variants were described in accordance with
HGVS recommendations and verified using the Alamaut software package (Interactive
software).[147]
Gene Intron/exon Nucleotide change Predicted amino acid change Combined references
GYLTL1B 1 c.163C>T p.Arg55Cys - / 1 chromosome
GYLTL1B 1 c.83G>C p.Gly28Ala - / 1 chromosome
GYLTL1B 2 c.286-22dupC intronic -
GYLTL1B 2 c.286-33G>A Intronic - / 1 chromosome
GYLTL1B 3 c.492+9C>T Intronic - / 1 chromosome
GYLTL1B 11 c.1668C>T synonymous rs939105 / 30 chromosomes
GYLTL1B 11 c.1704C>T synonymous - / 10 chromosomes
GYLTL1B 12 c.1773A>C synonymous rs11038714 / 1 chromosome
β3GNT1 1 c.117G>A synonymous rs11537930 / 1 chromosome
WWP1 8 c.1157+16T>G intronic - / 1 chromosome
WWP1 9 c.1212C>T synonymous rs60177164 / 3 chromosomes
WWP1 10 c.1387+25A>G intronic - / 1 chromosome
‡
WWP1 10 c.1387+47delinsTCTCT intronic - / 9 chromosomes
‡
WWP1 10 c.1387+47delinsTCTCTCT intronic - / 18 chromosomes
WWP1 10 c.1387+60AT(6_25) intronic rs36186318 / 52 chromosomes
‡
WWP1 17 c.1999-16T>A intronic rs7012745 / 3 chromosomes
WWP1 19 c.2274-29C>T intronic rs10110096 / 20 chromosomes
‡[148]
Gene Intron/exon Nucleotide change Predicted amino acid change Combined references
WWP1 20 c.2395-4C>T intronic - / 1 chromosome
WWP1 20 c.2395-6del intronic - / 12 chromosomes
‡
WWP1 22 c.2669+10A>G intronic rs7460650 / 20 chromosomes
‡
GYG1 5 c.552G>A synonymous rs4938 / 24 chromosomes
‡
GYG1 6 c.683C>T p.Thr228Ile - / 1 chromosome
‡
GYG2 7 c.707+35T>G Intronic rs5939133 / 4 chromosomes
GYG2 8 c.809C>T p.Ala270Glu - / 13 chromosomes
GYG2 9 c.938A>G p.His313Arg rs2306735 / 13 chromosomes
MGAT5B 1 c.68+21G>C intronic -
MGAT5B 3 c.208G>A p.Val70Ile rs571264 / 8 chromosomes
‡
MGAT5B 4 c.330-39G>A intronic rs571264 / 3 chromosomes
MGAT5B 4 c.330-47G>A intronic rs16969525 / 3 chromosomes
MGAT5B 4 c.346G>A p.Gly116Ser - / 1 chromosome
MGAT5B 4 c.376C>G p.Gln126Glu - / 1 chromosome
MGAT5B 5 c.446-12C>T intronic rs567207 / 6 chromosomes
MGAT5B 6 c.520-34C>T intronic rs537905 / 6 chromosomes
MGAT5B 7 c.691-45G>A intronic - / 2 chromosomes[149]
Gene Intron/exon Nucleotide change Predicted amino acid change Combined references
MGAT5B 8 c.856-12T>C intronic - / 1 chromosome
MGAT5B 8 c.856-34C>T intronic - / 1 chromosome
MGAT5B 9 c.1050G>C synonymous rs3889145 / 5 chromosomes
‡
MGAT5B 9 c.1107C>T synonymous rs34056052 / 4 chromosomes
‡
MGAT5B 10 c.1158-27C>T intronic rs11653088 / 37 chromosomes
‡
MGAT5B 10 c.1158-43G>A intronic rs12450749 / 37 chromosomes
‡
MGAT5B 10 c.1185C>T synonymous rs33966966 / 3 chromosomes
MGAT5B 11 c.1323C>T synonymous - / 2 chromosomes
MGAT5B 13 c.1579-55T>C intronic rs920851 / 13 chromosomes
‡
MGAT5B 13 c.1671G>A synonymous rs8081793 / 8 chromosomes
‡
MGAT5B 13 c.1714A>G p.Thr572Ala -/ 1 chromosome
‡
MGAT5B 14 c.1746C>T synonymous - / 1 chromosome
MGAT5B 15 c.1863C>T synonymous rs8067984 / 17 chromosomes
‡
MGAT5B 16 c.2157C>T Synonymous - / 7 chromosomes
MGAT5B 17 c.2175-13T>C intronic rs9894270 / 46 chromosomes
‡
MGAT5B 17 c.2175-8C>G intronic rs57502449 / 12 chromosomes
‡
MGAT5B 17 c.2373+14G>A 3' UTR - / 12 chromosomes
‡[150]
Gene Intron/exon Nucleotide change Predicted amino acid change Combined references
DAG1 2 c.259A>G p.Ile87Val het - / 1 chromosome
DAG1 2 c.285+42T>C intronic rs2329024 / 74 chromosomes
DAG1 2 c.41C>G p.Ser14Trp rs2131107 / 74 chromosomes
DAG1 3 c.286-49G>A intronic - / 1 chromosome
DAG1 3 c.599C>G p.Thr200Ser rs41290704 / 1 chromosome
DAG1 3 c.2256C>T synonymous rs1801143 / 22 chromosomes
‡
Table 11. Summary of sequence alterations detected in candidate genes.
References to the dbSNP are provided where applicable.
‡ indicates those changes detected in the heterozygous state in patients with
consanguineous parents.[151]
All dystroglycanopathy cases reported to date have been compatible with a recessive
pattern of inheritance. Animal models of DAG1 and WWP1 defects also demonstrate
recessive inheritance. I therefore hypothesized that two mutations would need to be
present in the candidate genes in order to give rise to disease.
A total of eight novel sequence variants were identified in GYLTL1B. Of these, two
non-synonymous variations were detected, each occurring only once within the cohort
studied (c.163C>T; p.Arg55Cys and c.83G>C; p.Gly28Ala). A single sequence variant
was detected in β3GNT1. This synonymous change was recorded on the dbSNP. A total
of six novel intronic sequence variants were identified in WWP1. A two base pair
intronic deletion (c.2395-6delT) was detected in the heterozygous state in twelve
individuals, two of whom had consanguineous parents. Three intronic heterozygous
single base pair substitution variants were detected (c.1157+16T>G, c.2395-4C>T and
c.1387+25A>G) each occurring only once within the cohort. Although the exact
nomenclature of the c.1387+47delinsTCTCT and c.1387+47delinsTCTCTCT variants
was not present on the SNP database, there are a number of additional variations
recorded within this highly polymorphic stretch of intronic sequence (rs36226595,
rs62510796 and rs9657012). A single novel variant was identified in GYG1 (c.683C>T;
p.Thr228Ile). This non synonymous heterozygous change was detected in a single
patient born to consanguineous parents. A single novel variant was identified in GYG2.
The non synonymous Ala270Glu change was detected in a total of 13 chromosomes.
The highest number of variations was detected in MGAT5B. A total of 26 sequence
changes were identified, eleven of which were novel. Three novel non synonymous
variants were present, each occurring only once within the cohort. The Thr572Ala
alteration was detected in the heterozygous state in a patient with consanguineous
parents. A total of two novel variants were detected in DAG1. The Ile87Val change was
detected in a single patient in whom no other variations were detected (patient B-1).
No splicing defects were predicted using the Alamut Splicing Prediction Module for
any of the unclassified variants described in Table 11. In summary, although a large
number of variants with unknown clinical significance were detected, no clearly
pathogenic sequence alterations were identified in the candidate genes studied.
4.2.4 A Functional Assay to Investigate Ile87Val in DAG1[152]
A missense change in DAG1 (p.Ile87Val) was detected in a single patient with LGMD
and no mental retardation. The variant is located within the region of LARGE binding
(amino acids 30-316) and protein sequence alignment demonstrated that the Ile87 amino
acid is conserved in all but three of the vertebrate species analysed (Figure 23). We
therefore hypothesised that this variant could potentially lead to a reduction in LARGE-
dependent modification. This change warranted further investigation using a functional
assay previously optimised to examine the pathogenic implications of similar variations
within this region. In a collaborative setting, experiments were performed by members
of Professor K Campbell’s laboratory in the Howard Hughes Medical Institute,
University of Iowa, USA. Immunoreactivity to IIH6 was compared using Ile87Val
mutant and wild type DAG1 constructs transfected into DAG1 null myoblast cell lines.
No reduction in the production of the IIH6 epitope was observed when comparing wild
type and mutant constructs, therefore indicating that the Ile87Val change does not
impair LARGE-dependent dystroglycan modification in this system.[153]
Homo IPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSW
Pan IPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSW
Macaca IPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSW
Otolemur -----------------------------VSAVGKEALPSW
Rattus IPDGTAVVGRSFRVSIPTDLIASSGEIIKVSAAGKEALPSW
Mus IPDGTAVVGRSFRVSIPTDLIASSGEIIKVSAAGKEALPSW
Cavia IPDGMAVIGRLFQVTIPTDLIASSGEIIKVSAAGKEALPSW
Oryctolagus ------VVGRSFRVTIPTDLIGSSGEVIKVSTAGKEVLPSW
Sorex -----------------------------VSAAGKEALPSW
Erinaceus IPDGTAVVGRSFRVTIPTDLISSNGEVIKVSAAGKEALPSW
Canis IPDGIAVVGRSFRVTIPMDLIASNGELVKVSAVGKEVLPSW
Felis IPDGTAVVGRSFRVTIPMDLIASNGELIKVSTAGKEALPSW
Equus IPDGTAVVGRSFRVTIPTDLIASNGEVIKVSAAGKEALPSW
Bos IPDGTAVVGRSFRVTIPTDLIASNGEVIKVSAAGKEALPSW
Dasypus IPDGTAVVGRSFRVTIPTDLFASNGEVIKVSAVGKEALPSW
Echinops IPDGTAVVGRSFRVVIPTDLIASSGEVVKXSAAGKETLPAW
Monodelphis IPDGIAVVGRSFRVAIPTDLIASNGEIIKMSEAGKEVLPSW
Ornithorhyncus IPDGTAVVGRSFRVTIPTDLIGSSGEVIKVSTAGKEVLPSW
Gallus IPDSSAVVGRFFRVSIPTDLIASNGEAVQVSEAGKESLPSW
Xenopus IPDSSAVVGRPFKIHIPTEFLASSGETIKIFEVGKEILPSW
Tetraodon IPDSSAVVGQAFQLRIPSGPANGSCN-IDLTEMGKETLPSW
Figure 23. Protein alignment (homology) plot of the N-terminal amino region of DAG1.
A total of 21 vertebrate species are shown. The arrow indicates complete conservation
of the p.Ile87Val variant in 18 of the 21 vertebrate species analysed.[154]
4.2.5 Modulation of Gene Expression During Myogenic Differentiation
To evaluate the functional involvement of candidate genes in the pathway of α-
dystroglycan glycosylation, I modulated the expression of individual candidate genes in
a mouse myogenic cell line using a ribonucleotide interference (RNAi) based strategy.
Murine myoblast C2C12 cells are a well established model of myogenic differentiation.
The differentiation of these cells is associated with a dramatic increase in the expression
and glycosylation of α-dystroglycan. This characteristic suggests that the production of
glycosylated α-dystroglycan could be modulated during myogenic cell differentiation by
reducing the expression of individual genes. The transient regulation of gene expression
was induced by the transfection of C2C12 cells with siRNA oligonucleotides targeted to
specific candidate genes.
Initial experiments using Real Time PCR demonstrated only residual expression of
Gyltl1b, Mgat5b and Wwp1 in C2C12 cells as revealed by their high cycle threshold
(>37 cycles) (data not shown). Transcripts were undetectable by Real Time PCR
performed on samples from mouse skeletal muscle tissue (data not shown). Successful
amplification of Gyltl1b, Mgat5b and Wwp1 transcripts using gene specific Real Time
probes was confirmed by the detection of expression in samples from whole mouse
brain (data not shown). Insufficient expression of these candidate genes in C2C12 cells
excluded their evaluation in this tissue culture model. As depicted in Figure 20, the
glycogenin paralog GYG2 is absent from rodent species therefore the evaluation of gene
function in this system can only be performed on murine Gyg.
Therefore, of the seven candidate genes selected for study, the expression of only Ggy
and β3gnt1 could be modulated in this system to investigate their functional effect on
dystroglycan glycosylation. Protocols were optimised using siRNA oligonucleotides
targeted to Pomt1. Relative gene expression was assayed by Real Time PCR. The level
of α-dystroglycan glycosylation was inferred on western blot. Immunoreactivity of
whole cell protein lysates to IIH6 was evaluated relative to that of β-dystroglycan.
During assay optimisation a variety of cell densities, transfection agents, siRNA
titrations and time frames were evaluated. No alteration in immunoreactivity to IIH6[155]
was observed, with only a single transfection event at all cell densities and time points
assayed (data not shown). Using siRNA oligonucleotides targeted to Pomt1, the most
dramatic reduction of α-dystroglycan glycosylation was achieved using two successive
transfection events at specific time points 48 hours apart.
The silencing of each transcript was maintained throughout the time course by
transfecting C2C12 cells with siRNA oligonucleotides at 24 and 72 hours post cell
plating. Real Time PCR assayed the effect on target gene expression at 48, 72 and 96
hours. The glycosylation of dystroglycan was examined 96 hours after plating by
western blot analysis. Both a mock transfection and the use of a scramble siRNA
oligonucleotide were included as controls. To assess the specificity of the siRNA
oligonucleotides, two probes targeted to each candidate gene were used. Due to a lack
of available antibodies to Pomt1, Gyg and β3gnt1 it was not possible to investigate any
induced reduction in protein production.
Efficient knockdown of Pomt1, β3gnt1 and Gyg messenger RNA (mRNA) was obtained
as confirmed by Real Time PCR analysis (Figure 24). Each probe successfully reduced
target transcript levels to below 50% at all time points analysed, with the exception of
β3gnt1 which rose slightly above this threshold using the s99323 oligonucleotide at the
96 hour time point (0.56; P >0.05). No significant reduction in gene silencing was
detected when comparing gene expression in mock transfected cells against those
transfected with a scramble oligonucleotide, with the exception of Gyg expression
which was reduced at the 96 hour time point (0.7; P >0.05).[156]
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Figure 24. Modulation of gene expression during myogenic differentiation examined by
Real Time PCR.
C2C12 cells were treated with siRNA oligonucleotides targeted to Pomt1, β3gnt1 and
Gyg at 24 hours and 72 hours post plating. Two different siRNA oligonucleotides per
gene were tested; the reference to each is indicated in brackets. Bar graphs show relative
expression levels of Pomt1 (A), β3gnt1 (B) and Gyg (C) at 48 hours, 72 hours and 96
hours post plating. Results are standardised against β-actin mRNA and expressed as a
ratio versus mock transfected cells. Values are expressed as the mean ± SEM of three
independent experiments (for each experiment, values are the average of three technical
replicates). Differences between groups were examined using the unpaired t-test. *P
<0.05, **P <0.01 and ***P <0.001 versus mock transfected cells.[158]
A
Figure 25. Modulation of α-dystroglycan glycosylation during myogenic differentiation
examined by western blot.
Representative western blot showing IIH6 immunoreactivity relative to β-dystroglycan.
C2C12 cells were treated with siRNA oligonucleotides targeted to Pomt1, Gyg and
β3gnt1. Two different siRNA oligonucleotides per gene were tested, the reference to
which is indicated in brackets.
†† Protein assayed 24 hours after cell plating.
‡ Protein
assayed 96 hours after cell plating.[159]
A dramatic increase in the expression and glycosylation of dystroglycan during this cell
culture system is demonstrated by comparing whole cell protein homogenates assayed
at 24 hours and 96 hours after cell plating. The effect on α-dystroglycan glycosylation
was examined on western blot by comparing immunoreactivity to IIH6 relative to that
of β-dystroglycan. Western blot analysis was performed on triplicate samples; a
representative western blot is shown in Figure 25. The inhibition of Pomt1 gene
expression was associated with a clear reduction in levels of glycosylated α-
dystroglycan. When comparing the efficiency of both siRNA oligonucleotides targeted
to Pomt1, the s97376 probe induced both a greater reduction in Pomt1 expression levels
and IIH6 immunoreactivity at all time points examined. When evaluating the effect of
the two candidate genes studied, only the modulation of β3gnt1 expression induced a
detectable reduction in α-dystroglycan glycosylation. When comparing the efficiency of
both siRNA oligonucleotides targeted to β3gnt1, the s99324 probe induced both a
greater reduction in β3gnt1 mRNA expression levels and IIH6 immunoreactivity at all
time points examined. Both siRNA oligonucleotides targeted to Gyg reduced gene
expression yet did not induce a marked reduction in IIH6 immunoreactivity.
4.2.6 The Exclusion of DPM3 Mutations
Subsequent to the study performed in chapter 3, a further causative dystroglycanopathy
gene has been identified; DPM3 (please refer to section 1.3.1) (Lefeber et al., 2009). A
single case study was reported and therefore no indication was provided as to the
prevalence of mutations within this gene or indeed the clinical spectrum associated with
this protein when defective. To ascertain whether patients comprising cohort B
harboured alterations in DPM3, mutation screening was performed in collaboration with
Professor Wevers’ laboratory at the Institute of Genetic and Metabolic Disease,
Nijmegen, The Netherlands. In this instance, a subset of 20 patients from cohort B was
screened by members of Professor Wevers’ laboratory yet no pathogenic sequence
alterations were identified.[160]
4.3 DISCUSSION
Specific gene defects have been detected in only the minority of dystroglycanopathy
cases (Bouchet et al., 2007; Godfrey et al., 2007; Mercuri et al., 2009). To date, genes
implicated in these disorders have either been putative and demonstrated
glycosyltransferases or accessory proteins of glycosyltransferases. The discovery of
mutations in the remaining molecularly undiagnosed patients presents as a challenge
and work is currently underway to identify novel loci. Due to the genetic and clinically
heterogeneous nature of these conditions as well as the lack of informative families, the
whole genome candidate gene approach presents as a viable option. Within this study,
evidence from the examination of animal models was initially used as a basis for
candidate gene identification. It has recently been demonstrated that the genes
responsible for human dystroglycanopathies are expressed in zebrafish (Moore et al.,
2008). The targeted inactivation of zebrafish Gyg in Dr D Stemple’s laboratory
recapitulated various aspects of the pattern of muscle involvement seen in patients as
well as recreating their specific immunohistochemical hallmark (unpublished data).
Aberrant glycosylation of α-dystroglycan has also been demonstrated in a naturally
occurring chicken with muscular dystrophy (Saito et al., 2005). A homozygous
missense substitution in the E3 ubiquitin ligase gene Wwp1 has been reported to
underlie disease although its precise role in pathogenesis remains unknown (Matsumoto
et al., 2008). I selected the mammalian homologs of both Gyg and Wwp1 for candidate
gene analysis. A bioinformatics approach was subsequently used and identified two
Golgi resident genes (GYLTL1B and β3GNT1) both of which showed homology to
LARGE. Two additional genes were selected on the basis of functional evidence; DAG1
and MGAT5B which is thought to be responsible for the β1,6GlcNAc-branched
structures of O-mannosyl glycans reported in brain glycoproteins (Inamori et al., 2003;
Kaneko et al., 2003). A summary of the candidate genes analysed and their putative or
demonstrated function is shown in Table 12.[161]
* Protein (encoding gene) ** Gene ID
† location
†† Molecular
function
‡
Subcellular
localisation
‡‡
glycosyltransferase-like 1B (GYLTL1B) 120071 11p11.12 Glycosyltransferase Golgi apparatus
E
n
d
e
a
v
o
u
r
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 (β3GNT1) 11041 11q13.2 Glycosyltransferase Golgi apparatus
WW domain containing E3 ubiquitin protein ligase 1 (WWP1) 602307 8q21 Ubiquitin-protein ligase No entry
Glycogenin 1 (GYG1) 603942 3q24-q25.1 Glycosyltransferase, other
transferase Cytosol
A
n
i
m
a
l
m
o
d
e
l
s
Glycogenin 2 (GYG2) 300198 Xp22.3 Glycosyltransferase, other
transferase Cytosol
Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B
(MGAT5B) 612441 17q25.3 Glycosyltransferase Golgi apparatus
F
u
n
c
t
i
o
n
Dystroglycan 1 (DAG1) 1605 3p21 Other receptor α-subunit; extracellular
β-subunit; membrane
Table 12. Summary of candidate genes studied.
* Rationale for candidate gene selection; Endeavour; Endeavour gene prioritisation software. ** Gene symbols and names as per HUGO
nomenclature (www.genenames.org/).
† Entrez Gene Identifier from the NCBI database (http://www.ncbi.nlm.nih.gov/).
†† Denotes
chromosomal location.
‡ Molecular function as classified by the PANTHER (Protein ANalysis THrough Evolutionary Relationships)
Classification System (http://www.pantherdb.org/).
‡‡ Subcellular localisation as annotated via the Universal Protein Resource Knowledge Base
(UniProtKB) (www.uniprot.org).[162]
To investigate whether mutations in any of these seven genes were present in a cohort
of patients, I performed mutation screening. Although a number of sequence variants of
unknown clinical significance were detected, no clearly pathogenic alterations were
identified. A functional assay performed by collaborators to assess the effect of a DAG1
variant was unable to demonstrate any pathogenic influence induced by this missense
change (c.259A>G; p.Ile87Val). The identification of heterozygous polymorphisms
indicates the exclusion of these loci in a number consanguineous families studied (Table
11). The possibility remains that rare mutations are present in these candidate genes
within the population tested, yet remain unidentified by the mutation detection method
chosen. Another possibility is that these genes are only very rarely involved in
dystroglycanopathies, for example mutations in LARGE have been reported in only five
cases worldwide since its original description in 2003 (Godfrey et al., 2007; Longman et
al., 2003; Mercuri et al., 2009; van Reeuwijk et al., 2007). Therefore the screening of a
larger patient cohort for mutations in GYLTL1B, β3GNT1, WWP1, GYG1, GYG2,
MGAT5B and DAG1 may be informative.
Although the inspection of expression profiling databases (GEO Profiles;
www.ncbi.nlm.nih.gov) suggests that human GYLTL1B and MGAT5B are widely
expressed, the level of tissue specific transcripts remains unclear. Northern blot analysis
of human GYLTL1B and MGAT5B demonstrate their abundant expression in the brain
yet these transcripts were undetectable in both human fetal and adult skeletal muscle
samples by Real Time PCR (data not shown). Although MGAT5B is thought to be
responsible for the branching of the 2,6-substituted mannose
(NeuAcα2,3Galβ1,4GlcNAcβ1,2[NeuAcα2,3Galβ1,4GlcNAcβ1,6]Manα-O) detected in
brain, there is currently no direct evidence to demonstrate that this glycan resides on
dystroglycan itself or indeed outside the brain (Chai et al., 1999). Moore et al. recently
reported the targeting of GYLTL1B in the zebrafish with morpholino oligonucleotides
(Moore et al., 2008). Although IIH6 immunostaining was abolished, no significant
morphological changes were observed. Both GYLTL1B and MGAT5B remain candidates
for patients presenting with isolated central nervous system involvement such as
cobblestone lissencephaly without any associated skeletal muscle involvement. Due to
the rarity of this clinical manifestation it was not possible to collate a cohort of patients
to investigate this further.[163]
The expression and post-translational modification of dystroglycan is heavily
developmentally regulated (Brown et al., 2004; Leschziner et al., 2000). Initial
experiments demonstrated that the differentiation of mouse myogenic cells resulted in a
dramatic increase in glycosylated α-dystroglycan. This suggested that the production of
the IIH6 epitope could be modulated during cell differentiation by reducing the
abundance of individual genes involved in the pathway of α-dystroglycan glycosylation.
I therefore developed an RNA interference based strategy to decrease the expression of
individual genes. The lack of Gyltl1b, Mgat5b and Wwp1 expression in C2C12 cells
precluded their functional investigation in this system. The targeting of siRNA
oligonucleotides to murine Pomt1, β3gnt1 and Gyg resulted in efficient gene silencing.
The modulation of both Pomt1 and β3gnt1 induced a marked reduction in the
production of the IIH6 epitope present on α-dystroglycan as observed on western blot. It
is unlikely that any reduction in immunoreactivity to IIH6 was caused by the
degradation of the core peptide as the molecular weight of β-dystroglycan remained
unchanged. This finding confirms β3gnt1 as a key enzyme functioning in the pathway
of α-dystroglycan glycosylation.
Despite a significant reduction in Gyg expression, no detectable inhibition of the IIH6
epitope was induced. It is important to note that this finding does not exclude this gene
in functioning to glycosylate α-dystroglycan and could be explained by the existence of
remaining mRNA or by the recycling of pre-existing Gyg protein. Due to the lack of
available antibodies against Pomt1, β3gnt1 or Gyg, the modulation of protein
production in this system could not be investigated.
Although the uncharacterised carbohydrate epitope present on α-dystroglycan and
recognised by the monoclonal antibody IIH6 is conserved across species from
invertebrates to mammals, the full extent of glycan heterogeneity between species is not
known (Ervasti and Campbell, 1991; Moore et al., 2008). Therefore the possibility
remains that although Wwp1 and Gyg mutations cause hypoglycosylation in animal
models, mutations in these genes are not responsible for a dystroglycanopathy in the
human. Limb girdle muscular dystrophy type 2H (OMIM; 254110) is caused by
mutations in the E3 ubiquitin ligase Trim32 and although its molecular pathogenesis is
quite distinct from that of the dystroglycanopathies, this finding does implicate the
ubiquitin pathway in muscular dystrophy.[164]
As far as is currently understood the initiating O-mannosyltransferases and N-
acetylglucosaminyl-transferases, known to be causative in human dystroglycanopathy,
are pathway specific. Due to the common nature of post-translational modifications,
enzymatic defects that affect more than one glycosylation pathway have been found to
induce multi-systemic consequences (i.e. congenital disorders of glycosylation).
Therefore genes such as glycogenin have long since been considered poor candidates
for inducing a specific dystroglycanopathy phenotype as they are known to function in
pathways other than those exclusively involved in dystroglycan glycosylation. This
view is challenged by the detection of DPM3 mutations in a patient with a spectrum of
disease spanning dystroglycanopathy and the congenital disorders of glycosylation. It
remains unknown as to whether the galactose and sialic acid monosaccharides present
on the NeuAcα2,3Galβ1,4GlcNAcβ1,2Manα-O-Ser/Thr glycan structure are added by
glycosyltransferases unique to this pathway or by those with more general specificity
(chapter 1, Figure 4). Various galactosyltransferases and sialyltransferase were
investigated as candidate genes for dystroglycanopathy by previous members of the
Dubowitz Neuromuscular Centre, yet no pathogenic defects were detected.
In conclusion, mutation screening data indicate that defects in GYLTL1B, β3GNT1,
WWP1, GYG1, GYG2, MGAT5B and DAG1 are not frequent causes of human
dystroglycanopathy. The optimisation of a cell culture model of dystroglycanopathy has
allowed the functional evaluation of a subset of candidate genes. This revealed that the
inhibition of β3gnt1 is associated with the induction of a dystroglycanopathy hallmark
as detected using the antibody IIH6. Although decreased β3gnt1 expression has recently
been associated with a reduction in laminin-binding glycans in invasive carcinoma cells,
these data demonstrate for the first time its involvement in a mammalian skeletal muscle
system (Bao et al., 2009). Further work is needed to understand the exact function of
β3gnt1 within the pathway of α-dystroglycan glycosylation. The future identification of
novel genes in this pathway will provide insight into the pathological mechanisms
underlying disease as well as offer potential clues as to new approaches to therapy.[165]
CHAPTER 5. REANALYSIS OF A CONSANGUINEOUS
PEDIGREE[166]
5 REANALYSIS OF A CONSANGUINEOUS PEDIGREE
5.1 INTRODUCTION
Whole genome linkage mapping has long been an essential methodology used in the
identification of novel loci responsible for genetic disease. The analysis of multiple
pedigrees in neuromuscular disorders has led to the detection of a number of causative
genes (Kobayashi et al., 1998; Yoshida et al., 2001). Due to the recent progress in
delineating pathogenic processes underlying neuromuscular conditions, mutations have
been identified in many of the large pedigrees previously recruited to the Dubowitz
Neuromuscular Centre. The remaining molecularly uncharacterised pedigrees often
include small informative families in whom affected patients have been lost to clinical
follow-up, or where biological samples are either exhausted or in short supply. This
chapter deals specifically with my analysis of one particular pedigree (referred to here
as pedigree 1) which I re-evaluated in light of newly available pathology data and the
potential application of emerging novel methodologies. This family from the United
Arab Emirates includes four affected children born to consanguineous parents and has
previously been extensively studied within the department (Figure 26). The clinical
presentation of these children was first reported in the literature over a decade ago as a
form of CMD characterised by proximal muscle weakness, muscle hypertrophy and
early respiratory failure (Muntoni et al., 1998). Both the brain imaging and intellect of
these affected children was found to be normal. For a more detailed summary of clinical
information please refer to section 2.1.1.[167]
Figure 26. Pedigree 1.
The family depicted in pedigree 1 includes four affected members born to
consanguineous parents. Squares indicate male family members and circles female
family members; filled squares and circles indicate those patients affected. Double lines
between parents indicate that the parents are related. Affected family members are
referred to as C1-1, C1-2, C1-3 and C1-4. Asterisks indicate those individuals from
whom DNA is available for study. Pedigree 1 has previously been described in
Brockington et al. and Muntoni et al. (Brockington et al., 2000; Muntoni et al., 1998).[168]
Initial immunostaining of skeletal muscle biopsies identified a reduction in laminin α-2,
yet linkage to the LAMA2 locus on chromosome 6q was excluded. In order to identify
the disease loci in this family genome wide linkage analysis was subsequently
performed (Brockington et al., 2000). DNA from each member of pedigree 1 was
genotyped using 358 fluorescent high informative (CA)n repeat microsatellite markers
located at an average of 10 cM intervals (the ABI linkage mapping set I). Homozygosity
mapping identified a locus on chromosome 1q42 between flanking markers D1S2860
and D1S2800. A second small family with similar clinical and histopathological
features was subsequently found to be compatible with this locus, generating a
cumulative LOD score of 3.57 (Brockington et al., 2000). Extensive candidate gene
analysis has been performed on this linkage interval, resulting in a number of genes
being screened for mutations by sequencing (Table 13). Despite this, the causative
mutation remains elusive.[169]
Protein (encoding gene) * Gene ID ** Molecular function
† Subcellular localisation
‡
ADP-ribosylation factor 1 (ARF1) 375 Small GTPase Golgi apparatus and cytoplasm
beta-1,3-N-acetylgalactosaminyltransferase 2 (β3GALNT2) 148789 Glycosyltransferase Golgi apparatus
UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 2 (GALNT2)
2590 Glycosyltransferase Golgi apparatus and secreted
lectin, galactoside-binding, soluble, 8 (LGALS8) 3964 Other signaling molecule, Other cell adhesion molecule Cytoplasm
nidogen 1 (NID1) 4811 Extracellular matrix glycoprotein Secreted
Obscurin (OBSCN) 84033
Actin binding cytoskeletal protein, Guanyl-nucleotide
exchange factor
Cytoplasm
Poly(ADP-ribose) polymerase family (PARP1) 142 Glycosyltransferase Nucleus
Table 13. Candidate genes previously screened within the linkage interval detected on chromosome 1q42 using microsatellite data.
Genes that were previously screened by sequencing prior to my PhD. * Gene symbols and names as per HUGO nomenclature
(www.genenames.org/). * Entrez Gene Identifier from the NCBI database (http://www.ncbi.nlm.nih.gov/).
† Molecular function as classified by
the PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System (http://www.pantherdb.org/).
‡ Subcellular
localisation as annotated via the Universal Protein Resource Knowledge Base (UniProtKB) (www.uniprot.org).[170]
Recent reanalysis of the patients' muscle pathology revealed a reduction in IIH6
immunostaining. None of the known dystroglycanopathy loci reside within the region
identified on chromosome 1q42. In addition to this, I included proband C1-1 in cohort
A and therefore mutations in FKRP, FKTN, POMT1, POMT2, POMGNT1 and LARGE
were excluded by uni-directional sequencing (please refer to chapter 3).
The application of microsatellite markers for linkage mapping has now been superseded
by the use of closely spaced single-nucleotide polymorphisms (SNPs). Despite the less
informative nature of biallelic markers when compared to the use of highly polymorphic
microsatellite markers, the sheer abundance of SNPs offers superior power to detect
linkage. Studies comparing these two approaches have indicated that previous linkage
analyses employing the use of sparse microsatellite markers could benefit from
reanalysis with high density SNP maps (Evans and Cardon, 2004; Middleton et al.,
2004).
Despite numerous investigations performed in the Dubowitz Neuromuscular Centre, the
mutation underlying this family’s condition has remained elusive. This chapter initially
describes further candidate gene analysis performed by me using the microsatellite
linkage data. In addition, with the greater coverage offered by the use of SNP arrays,
whole genome linkage analysis was repeated, the expression profile of linked genes
investigated and candidate gene analysis performed.
5.2 RESULTS
5.2.1 Genomic Mapping: Reanalysis of Microsatellite Data
Initially I confirmed that the order of fine mapping markers used in the original
multipoint linkage analysis is consistent with the current physical maps
(www.ncbi.nlm.nih.gov/unists). Therefore the calculated region of homozygosity
remains flanked by the markers D1S2860 and D1S2800 (Figure 27). This large region is
just under 17 Mb and contains in excess of 200 genes.[171]
Figure 27. Haplotypes derived from chromosome 1q42 microsatellite markers.
Haplotypes from pedigree 1 from the original whole genome linkage report. The disease
haplotype is denoted by green shaded bars. The blue section of the bar denotes an allele
that could not be unequivocally assigned during the original analysis. The critical region
identified during the study of pedigree 1 was defined by recombination events in
patients C1-2 and C1-4. Asterisks indicate those individuals from whom DNA was
available for analyses. Figure based on that from Brockington et al. (Brockington et al.,
2000).[172]
Candidate gene analysis
I further scrutinised those genes within the original loci identified on chromosome 1q
for biological candidates. Those genes considered as more obvious targets for
involvement had previously been excluded by members of the Dubowitz
Neuromuscular Centre (Table 13). Therefore I employed a bioinformatics approach in
order to identify novel candidates. Results generated by the gene ranking software
Endeavour are shown in Table 14 (as previously described in chapter 4).
The genes ranked in second, third and fifth position by this method had already been
excluded prior to this project being undertaken (UDP-N-acetyl-alpha-D-galactosamine:
polypeptide N-acetylgalactosaminyltransferase 2; GALNT2, obscurin; OBSCN and
poly(ADP-ribose) polymerase family; PARP1). Along with presenilin 2 (PSEN2)
(identified as the highest scoring gene), the potassium channel subfamily K member 1
(KCNK1) was indicated as a novel candidate.
Due to the very recent discovery of α-dystroglycan hypoglycosylation in a patient with
mutations in DPM3, this gene was absent from the ‘training set’ described above.
Subsequent reanalysis generated with the inclusion of this gene retained PSEN2 as the
top scoring candidate as well as retaining GALNT2, OBSCN, KCNK1 and PARP1 within
the top 20 genes (data not shown).
In addition to the above genes, I selected a further two for mutation screening;
tetratricopeptide repeat domain 13 (TTC13) and lamin B receptor (LBR). LBR was
included due to the involvement of nuclear envelope proteins in skeletal muscle
pathology (Bonne et al., 1999; Capell and Collins, 2006). TTC13 presented as a
candidate due to its function as a glycosyltransferase.[173]
Rank * Protein (encoding gene) ** Gene ID
† Molecular function
‡ Subcellular
localisation
‡‡
1 Presenilin 2 (PSEN2) 5664
Aspartic protease, other select calcium binding
proteins
Endoplasmic reticulum
and Golgi
2
UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 2 (GALNT2)
2590 Glycosyltransferase Golgi and secreted
3 Obscurin (OBSCN) 84033
Actin binding cytoskeletal protein, Guanyl-
nucleotide exchange factor
Cytoplasm
4 Potassium channel, subfamily K, member 1 (KCNK1) 3775 Voltage-gated potassium channel Membrane
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5 Poly(ADP-ribose) polymerase family (PARP1) 142 Glycosyltransferase Nucleus
N/A Tetratricopeptide repeat domain 13 (TTC13) 79573 Glycosyltransferase Unspecified
O
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h
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s
N/A Lamin B receptor (LBR) 3930 Receptor Nuclear membrane
Table 14. Candidate genes identified within the linkage interval detected on chromosome 1q42 using microsatellite data.
* The top 5 ranked genes within the interval on 1q42 using the Endeavour gene prioritisation software (www.esat.kuleuven.be/endeavour/). The
training set consisted of; POMT1, POMT2, POMGNT1, LARGE, FCMD and FKRP. ** Gene symbols and names as per HUGO nomenclature
(www.genenames.org/).
† Entrez Gene Identifier from the NCBI database (http://www.ncbi.nlm.nih.gov/).
‡ Molecular function as classified by
the PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System (http://www.pantherdb.org/).
‡‡ Subcellular
localisation as annotated via the Universal Protein Resource Knowledge Base (UniProtKB) (www.uniprot.org). Blue shaded boxes indicate those
genes previously screened by sequencing prior to my PhD. Yellow shaded boxes indicate those genes investigated by me as candidate genes.[174]
Mutation screening
To investigate whether mutations resided within these candidate genes, I performed
screening of PSEN2, KCNK1, TTC13 and LBR. The human PSEN2, KCNK1, TTC13
and LBR genes are organised into 13, 3, 23 and 14 exons and encode 2.3 kb, 2.2 kb, 3.3
kb and 3.7 kb transcripts respectively. To ensure the preservation of precious genetic
material, uni-directional sequencing was performed on whole genome amplified DNA
from patient C1-1. Sequencing results from the MDA sample were indistinguishable
from non amplified genomic DNA control samples. No heterozygous or homozygous
sequence variations were detected within the candidate genes studied. Good quality
sequencing reads from -20 to +10 base pairs of the intron/exon boundary were
established as a minimum requirement for each amplicon in accordance with guidelines
from the Clinical Molecular Genetics Society (www.cmgs.org).
5.2.2 Genomic Mapping: SNP Genotyping Platforms
In order to identify the underlying disease locus a whole genome scan was performed
on DNA samples from members of pedigree 1 using SNP genotyping platforms
(GeneChip Human Mapping 500K Nsp array, Affymetrix). Prior to the submission of
samples for analysis, I established the quantity and quality of DNA. Quantification was
performed using the NanoDrop ND-1000 Spectrophotometer whereas agarose gel
electrophoresis was used to establish the presence of high molecular weight DNA in
stock samples. The DNA from patient C1-3 was found to be highly degraded. Due to
the potential impact of degradation on genotype accuracy, other sources of DNA for this
patient were investigated. A single section of skeletal muscle remained from this
patient’s OCT mounted biopsy measuring approximately 12 µm x 9 mm x 9 mm. In
order to maximise the DNA yield extracted from this sample, I compared protocols
involving QIAamp DNA Micro Kit (Qiagen) and MDA performed directly on tissue
using control skeletal muscle samples. MDA performed directly on muscle sections
using a modified protocol produced a consistently high yield. Both the quality and
quantity of yield was determined using both the NanoDrop ND-1000
Spectrophotometer and agarose gel electrophoresis.[175]
I submitted DNA samples from the mother, father and four affected children for
analysis. DNA for patient C1-3 was submitted in duplicate; both the degraded sample
and MDA products derived directly from tissue. Data were generated by the UCL
Genomics facility (www.genomics.ucl.ac.uk) and genotypes examined by Professor R
Kleta and Dr H Stanescu at the department of Internal Medicine, UCL (please refer to
the methods section 2.2.1 for more detail). Comparable genotyping call rates were
generated for each sample.
Parametric LOD scores were generated. Analyses performed using the multipoint
linkage analysis programs Allegro and Simwalk revealed compatible regions of linkage
on multiple chromosomes with a maximum LOD score of over 2.5 (Figure 28). Peaks
on chromosomes 1, 2 and 17 were identified using both programs whereas an additional
two peaks on chromosomes 3 and 8 were identified using the Simwalk program only.
This most probably reflects false positive peaks deemed to appear towards the ends of
the fragments that have been generated in order to perform the Simwalk run. Therefore
those regions generated by the use of Allegro were initially interrogated.
Linkage detected on chromosome 1q contained regions consistent with both
homozygosity and heterozygosity (Figure 29). A total of six regions of homozygosity
were identified and localised between SNPs rs527213-rs1568804, rs2494195-
rs1857623, rs3766934-rs17140182, rs4846992-rs701152, rs12068313-rs41406346, and
rs6695181-rs10797534. Three regions of heterozygosity were detected between these
regions of homozygosity and were located between SNPs rs1857623-rs3766934,
rs17140182-rs4846992 and rs701152-rs12068313. These regions of interest located on
chromosome 1 spanned just over 16 Mb and also contained two small regions of non
compatibility. Two regions of homozygosity of approximately 0.7 Mb were detected on
chromosome 2 between SNPs rs6708337-rs7589821 and rs17039367-rs10495987
(Figure 30). A single region of interest was identified on chromosome 17 (Figure 31).
This region of approximately 4.7 Mb localised between SNPs rs854653 and
rs16966014. In total these 12 regions contained 226 genes; 143 on chromosome 1, 82
on chromosome 17 and 1 located on chromosome 2 (Tables 15, 16, 17 and 18).[176]
A
B
Figure 28. Whole genome linkage analysis using SNP data.
Peaks with a LOD score of approximately 3 are detected on multiple chromosomes.
Analysis performed using the multipoint linkage analysis programs Allegro (A) and
Simwalk (B). Arrow heads shown in green indicate peaks identified by both Allegro
and Simwalk whereas those in blue denote those identified using Simwalk only. Genetic
distance (in centimorgans) and individual chromosomes (1-22) are indicated on the
lower and upper x axis, respectively.[177]
Figure 29. Depiction of the linkage intervals detected on chromosome 1q.
The black bar represents a region of homozygosity detected through the analysis of whole genome microsatellite arrays. Blue and green bars
represent regions detected through the analysis of whole genome SNP arrays. Green and blue bars represent regions of homozygosity and
heterozygosity respectively. Those genes lying within regions are shown below. Maroon bars represent regions of non compatibility detected
within regions of heterozygosity. This figure was constructed using output from the UCSC Genome Browser (genome.ucsc.edu/).[178]
Figure 30. Depiction of the linkage intervals detected on chromosome 2p using SNP data.
Green bars indicated regions of homozygosity. No genes are located within the first region yet a single exon of NRXN1 lies within the second
region of homozygosity. This figure was constructed using output from the UCSC Genome Browser (genome.ucsc.edu/).[179]
Figure 31. Depiction of the linkage interval detected on chromosome 17q using SNP data.
The blue bar indicates a region of heterozygosity detected through the analysis of whole genome SNP arrays. Those genes lying within this
region are shown below the bar. This figure was constructed using output from the UCSC Genome Browser (genome.ucsc.edu/).[180]
Symbol * Protein Molecular function **
ABCB10
ATP-binding cassette, sub-family B
(MDR/TAP), member 10
ATP-binding cassette (ABC)
transporter
ACTA1 actin, alpha 1, skeletal muscle Actin and actin related protein
AGT
angiotensinogen (serpin peptidase inhibitor,
clade A, member 8)
Serine protease inhibitor
AK124056 AK124056 N/A
AX747652 AX747652 N/A
C1orf96 chromosome 1 open reading frame 96 Molecular function unclassified
CAPN9 calpain 9 Cysteine protease
COG2 component of oligomeric golgi complex 2 Molecular function unclassified
CR936804 N/A N/A
DNAH14 dynein, axonemal, heavy chain 14 N/A
Dnahc14 dynein, axonemal, heavy chain 14 N/A
ENAH enabled homolog (D. melanogaster) Non-motor actin binding protein
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) Other hydrolase
LBR lamin B receptor Receptor
NUP133 nucleoporin 133kDa Molecular function unclassified
RAB4A RAB4A, member RAS oncogene family Small GTPase
SPHAR S-phase response (cyclin related) N/A
SRP9 signal recognition particle 9kDa Molecular function unclassified
TAF5L
TAF5-like RNA polymerase II, p300/CBP-
associated factor (PCAF)-associated factor,
65kDa
Basal transcription factor
URB2
URB2 ribosome biogenesis 2 homolog (S.
cerevisiae)
N/A
Table 15. Genes located within heterozygous linkage regions detected on chromosome
1 using SNP data.
* Gene symbols as per HUGO nomenclature. ** Molecular function as classified by the
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification
System (http://www.pantherdb.org/). Chromosome 1 intervals; 223131228-224081640,
227318180-228204141 and 228695214-228979241.[181]
Symbol * Protein Molecular function **
ACBD3 acyl-Coenzyme A binding domain containing 3 Molecular function unclassified
AIDA axin interactor, dorsalization associated
Transmembrane receptor
regulatory/adaptor protein
AK025140 AK025140 N/A
AK054726 AK054726 N/A
AK055856 AK055856 N/A
AK094916 AK094916 N/A
AK124970 AK124970 N/A
ARF1 ADP-ribosylation factor 1 Small GTPase
ARV1 ARV1 homolog (S. cerevisiae) Molecular function unclassified
AURKAPS1 aurora kinase A pseudogene 1 N/A
AX748369 AX748369 N/A
BC032899 BC032899 N/A
BC032911 BC032911 N/A
BC039356 BC039356 N/A
BC045735 BC045735 N/A
BC061893 BC061893 N/A
BC086863 BC086863 N/A
BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 Nuclease, Other phosphatase
C1orf115 chromosome 1 open reading frame 115 Molecular function unclassified
C1orf124 chromosome 1 open reading frame 124 Molecular function unclassified
C1orf131 chromosome 1 open reading frame 131 Molecular function unclassified
C1orf140 N/A Molecular function unclassified
C1orf145 chromosome 1 open reading frame 145 N/A
C1orf198 chromosome 1 open reading frame 198 Molecular function unclassified
C1orf35 chromosome 1 open reading frame 35 Molecular function unclassified
C1orf55 chromosome 1 open reading frame 55 Molecular function unclassified
C1orf57 chromosome 1 open reading frame 57 Biological process unclassified[182]
Symbol * Protein Molecular function **
C1orf58 chromosome 1 open reading frame 58 Molecular function unclassified
C1orf65 chromosome 1 open reading frame 65 Molecular function unclassified
C1orf69 chromosome 1 open reading frame 69 Molecular function unclassified
C1orf95 chromosome 1 open reading frame 95 Molecular function unclassified
CABC1
chaperone, ABC1 activity of bc1 complex
homolog (S. pombe)
Chaperone
CAPN2 calpain 2, (m/II) large subunit Cysteine protease
CAPN8 calpain 8 Cysteine protease
CAPN9 calpain 9 Cysteine protease
CDC42BPA
CDC42 binding protein kinase alpha (DMPK-
like)
Non-receptor serine/threonine
protein kinase
CNIH3 cornichon homolog 3 (D. melanogaster) Membrane-bound signaling molecule
CNIH4 cornichon homolog 4 (D. melanogaster) Membrane traffic protein
CR625980 N/A N/A
DEGS1
degenerative spermatocyte homolog 1, lipid
desaturase (D. melanogaster)
Oxidoreductase
DISC1 disrupted in schizophrenia 1 Molecular function unclassified
DISC2
disrupted in schizophrenia 2 (non-protein
coding)
N/A
DISP1 dispatched homolog 1 (D. melanogaster) Molecular function unclassified
DQ573170 N/A N/A
DQ574660 N/A N/A
DQ575011 N/A N/A
DQ575955 N/A N/A
DQ575983 N/A N/A
DQ584971 N/A N/A
DQ584982 N/A N/A
DQ590432 N/A N/A
DQ597235 N/A N/A
DQ597892 N/A N/A
DQ599768 N/A N/A[183]
Symbol * Protein Molecular function **
DQ599872 N/A N/A
DQ600234 N/A N/A
DUSP10 dual specificity phosphatase 10 Kinase inhibitor, Protein phosphatase
DUSP5P dual specificity phosphatase 5 pseudogene N/A
EGLN1 egl nine homolog 1 (C. elegans) Oxidoreductase
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) Other hydrolase
EPRS glutamyl-prolyl-tRNA synthetase Aminoacyl-tRNA synthetase
EXOC8 exocyst complex component 8 Molecular function unclassified
FAM177B family with sequence similarity 177, member B N/A
FAM89A family with sequence similarity 89, member A Biological process unclassified
FBXO28 F-box protein 28 Molecular function unclassified
GALNT2
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2 (GalNAc-T2)
Glycosyltransferase
GJC2 gap junction protein, gamma 2, 47kDa N/A
GNPAT glyceronephosphate O-acyltransferase Acyltransferase
GUK1 guanylate kinase 1 Nucleotide kinase
H3F3B H3 histone, family 3B (H3.3B)
Chromatin packaging and
remodeling
HHIPL2 HHIP-like 2 N/A
HIST3H2A histone cluster 3, H2a Histone
HIST3H2BB histone cluster 3, H2bb Molecular function unclassified
HIST3H3 histone cluster 3, H3 Histone
HLX H2.0-like homeobox N/A
IARS2 isoleucyl-tRNA synthetase 2, mitochondrial Aminoacyl-tRNA synthetase, Ligase
ITPKB inositol 1,4,5-trisphosphate 3-kinase B Kinase Transferase
JMJD4 jumonji domain containing 4 Other receptor
KCNK1 potassium channel, subfamily K, member 1 Voltage-gated potassium channel
KIAA1383 KIAA1383 Molecular function unclassified
KIAA1804 N/A N/A[184]
Symbol * Protein Molecular function **
LEFTY1 left-right determination factor 1 Growth factor
LEFTY2 left-right determination factor 2 Growth factor
LIN9 lin-9 homolog (C. elegans) Transcription cofactor
LYPLAL1 lysophospholipase-like 1 Phospholipase
MARK1 MAP/microtubule affinity-regulating kinase 1
Non-motor microtubule binding
protein, Non-receptor
serine/threonine protein kinase
MIA3 melanoma inhibitory activity family, member 3 Growth factor
MIXL1 Mix1 homeobox-like 1 (X. laevis)
Homeobox transcription factor,
Other DNA-binding protein
MOSC1
MOCO sulphurase C-terminal domain
containing 1
Molecular function unclassified
MOSC2
MOCO sulphurase C-terminal domain
containing 2
Molecular function unclassified
MPN2 protease, serine, 38 (hugo gene name PRSS38) Serine protease
MRPL55 mitochondrial ribosomal protein L55 Molecular function unclassified
NVL nuclear VCP-like Molecular function unclassified
OBSCN
obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF
Actin binding cytoskeletal protein,
Guanyl-nucleotide exchange factor
PARP1 poly (ADP-ribose) polymerase 1 Glycosyltransferase
PCNXL2 pecanex-like 2 (D. melanogaster) Molecular function unclassified
PGBD5 piggyBac transposable element derived 5 Molecular function unclassified
PSEN2 presenilin 2 (Alzheimer disease 4)
Aspartic protease, Other select
calcium binding proteins
PYCR2
pyrroline-5-carboxylate reductase family,
member 2
Reductase
RAB3GAP2
RAB3 GTPase activating protein subunit 2 (non-
catalytic)
G-protein modulator
RHOU ras homolog gene family, member U Small GTPase
RNF187 ring finger protein 187 Ubiquitin-protein ligase
RRP15
ribosomal RNA processing 15 homolog (S.
cerevisiae)
N/A
SIPA1L2 signal-induced proliferation-associated 1 like 2 Other G-protein modulator[185]
Symbol * Protein Molecular function **
SLC30A10 solute carrier family 30, member 10 Other transporter
SLC35F3 solute carrier family 35, member F3 Molecular function unclassified
SNAP47 synaptosomal-associated protein, 47kDa N/A
SNORA36B small nucleolar RNA, H/ACA box 36B N/A
SUSD4 sushi domain containing 4 Molecular function unclassified
TAF1A
TATA box binding protein (TBP)-associated
factor, RNA polymerase I, A, 48kDa
Molecular function unclassified
TGFB2 transforming growth factor, beta 2 Growth factor
TLR5 toll-like receptor 5 Receptor, Extracellular matrix
TMEM63A transmembrane protein 63A Molecular function unclassified
TP53BP2 tumor protein p53 binding protein, 2 Select regulatory molecule
TRIM11 tripartite motif-containing 11 Ubiquitin-protein ligase
TRIM17 tripartite motif-containing 17 Ubiquitin-protein ligase
TRIM67 tripartite motif-containing 67 Ubiquitin-protein ligase
TSNAX translin-associated factor X
Single-stranded DNA-binding
protein
TTC13 tetratricopeptide repeat domain 13 Glycosyltransferase
WDR26 WD repeat domain 26 Molecular function unclassified
WNT3A
wingless-type MMTV integration site family,
member 3A
Other signaling molecule
WNT9A
wingless-type MMTV integration site family,
member 9A
Other signaling molecule,
Extracellular matrix structural
protein
ZNF678 zinc finger protein 678 KRAB box transcription factor
Table 16. Genes located within homozygous linkage regions detected on chromosome 1
using SNP data.
* Gene symbols as per HUGO nomenclature. ** Molecular function as classified by the
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification
System (http://www.pantherdb.org/). Chromosome 1 intervals; 216377616-217457828,
217755257-223131228, 224081640-227318180, 228204141- 228695214. 228979241-
230328893 and 230395313-232447140.[186]
Symbol * Protein Molecular function **
NRXN1 Neurexin 1 Other receptor
Table 17. Genes located within homozygous linkage regions detected on chromosome 2
using SNP data.
* Gene symbols as per HUGO nomenclature. ** Molecular function as classified by the
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification
System (http://www.pantherdb.org/). Chromosome 2 intervals; 49660621-49731956 and
50083603-50153280.[187]
Symbol * Protein Molecular function **
AATF apoptosis antagonizing transcription factor Other transcription factor
ACACA acetyl-Coenzyme A carboxylase alpha Other ligase
ARHGAP23 Rho GTPase activating protein 23 Molecular function unclassified
ARL5C ADP-ribosylation factor-like 5C N/A
C17orf37 chromosome 17 open reading frame 37 Oxidoreductase
C17orf78 chromosome 17 open reading frame 78 Molecular function unclassified
C17orf96 chromosome 17 open reading frame 96 N/A
C17orf98 chromosome 17 open reading frame 98 N/A
CACNB1
calcium channel, voltage-dependent, beta 1
subunit
Voltage-gated calcium channel
CASC3 cancer susceptibility candidate 3 Molecular function unclassified
CCDC49 coiled-coil domain containing 49 Molecular function unclassified
CCL14 chemokine (C-C motif) ligand 14 Chemokine
CCL14-CCL15 N/A N/A
CCL15 chemokine (C-C motif) ligand 15 Chemokine
CCL16 chemokine (C-C motif) ligand 16 Chemokine
CCL18
chemokine (C-C motif) ligand 18
(pulmonary and activation-regulated)
Chemokine
CCL23 chemokine (C-C motif) ligand 23 Chemokine
CCL3 chemokine (C-C motif) ligand 3 Chemokine
CCL3L1 chemokine (C-C motif) ligand 3-like 1 Chemokine
CCL3L1 chemokine (C-C motif) ligand 3-like 1 Chemokine
CCL3L3 chemokine (C-C motif) ligand 3-like 3 Chemokine
CCL3L3 chemokine (C-C motif) ligand 3-like 3 Chemokine
CCL4 chemokine (C-C motif) ligand 4 Chemokine
CCL4L1 chemokine (C-C motif) ligand 4-like 1 Chemokine
CCL4L1 chemokine (C-C motif) ligand 4-like 1 Chemokine
CCL4L2 chemokine (C-C motif) ligand 4-like 2 Chemokine
CCL4L2 chemokine (C-C motif) ligand 4-like 2 Chemokine[188]
Symbol * Protein Molecular function **
CCR7 chemokine (C-C motif) receptor 7 G-protein coupled receptor
CDC6 cell division cycle 6 homolog (S. cerevisiae) Replication origin binding protein
CISD3 CDGSH iron sulfur domain 3 N/A
CRKRS Cdc2-related kinase, arginine/serine-rich
Non-receptor serine/threonine protein
kinase
CSF3 colony stimulating factor 3 (granulocyte) Other cytokine
DDX52
DEAD (Asp-Glu-Ala-Asp) box polypeptide
52
RNA helicase
DHRS11
dehydrogenase/reductase (SDR family)
member 11
N/A
DUSP14 dual specificity phosphatase 14 Kinase inhibitor, Protein phosphatase
ERBB2
v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog (avian)
Other miscellaneous function protein
FBXL20 F-box and leucine-rich repeat protein 20 Molecular function unclassified
FBXO47 F-box protein 47 N/A
GGNBP2 gametogenetin binding protein 2 Molecular function unclassified
GJD3 gap junction protein, delta 3, 31.9kDa N/A
GPR179 G protein-coupled receptor 179 Molecular function unclassified
GRB7 growth factor receptor-bound protein 7
Transmembrane receptor
regulatory/adaptor protein
GSDMA gasdermin A N/A
GSDMB gasdermin B N/A
HNF1B HNF1 homeobox B
Other transcription factor, Nucleic acid
binding
IGFBP4 insulin-like growth factor binding protein 4 Other miscellaneous function protein
IKZF3 IKAROS family zinc finger 3 (Aiolos)
KRAB box transcription factor, Other
zinc finger transcription factor
LASP1 LIM and SH3 protein 1 Non-motor actin binding protein
LHX1 LIM homeobox 1
Homeobox transcription factor, Other
zinc finger transcription factor, Nucleic
acid binding
LOC284100 N/A Other chaperones[189]
Symbol * Protein Molecular function **
LOC90110 N/A N/A
MED1 mediator complex subunit 1
Other DNA-binding protein, Other
miscellaneous function protein
MED24 mediator complex subunit 24 Receptor
MLLT6
myeloid/lymphoid or mixed-lineage
leukemia (trithorax homolog, D.
melanogaster); translocated to, 6
Other zinc finger transcription factor,
Nucleic acid binding
MRM1
mitochondrial rRNA methyltransferase 1
homolog (S. cerevisiae)
Molecular function unclassified
MRPL45 mitochondrial ribosomal protein L45 Molecular function unclassified
MSL1
male-specific lethal 1 homolog (D.
melanogaster)
N/A
MYO19 myosin XIX N/A
NEUROD2 neurogenic differentiation 2
Basic helix-loop-helix transcription
factor, Nucleic acid binding
NR1D1
nuclear receptor subfamily 1, group D,
member 1
Nuclear hormone receptor, Transcription
factor, Nucleic acid binding
ORMDL3 ORM1-like 3 (S. cerevisiae) Other miscellaneous function protein
PCGF2 polycomb group ring finger 2 Zinc finger transcription factor
PGAP3 post-GPI attachment to proteins 3 N/A
PIGW
phosphatidylinositol glycan anchor
biosynthesis, class W
Acetyltransferase, AcyltransferasE
PIP4K2B
phosphatidylinositol-5-phosphate 4-kinase,
type II, beta
Other kinase
PLXDC1 plexin domain containing 1 Molecular function unclassified
PNMT phenylethanolamine N-methyltransferase Methyltransferase
PPP1R1B
protein phosphatase 1, regulatory (inhibitor)
subunit 1B
Other signaling molecule, Phosphatase
inhibitor
PSMB3
proteasome (prosome, macropain) subunit,
beta type, 3
Other proteases
PSMD3
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 3
Other enzyme activator
RAPGEFL1
Rap guanine nucleotide exchange factor
(GEF)-like 1
Molecular function unclassified[190]
Symbol * Protein Molecular function **
RARA retinoic acid receptor, alpha
Nuclear hormone receptor, Transcription
factor, Nucleic acid binding
RPL19 mitochondrial ribosomal protein L19 Ribosomal protein
RPL23 mitochondrial ribosomal protein L23 Ribosomal protein
SMARCE1
SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily
e, member 1
Chromatin/chromatin-binding protein,
Other DNA-binding protein
SNIP Smad nuclear interacting protein 1 Molecular function unclassified
SNORA21 small nucleolar RNA, H/ACA box 21 N/A
SNORD124 small nucleolar RNA, C/D box 124 N/A
SOCS7 suppressor of cytokine signaling 7
Cytokine, Other miscellaneous function
protein
STAC2 SH3 and cysteine rich domain 2 Molecular function unclassified
STARD3
StAR-related lipid transfer (START) domain
containing 3
Other transfer/carrier protein, Other
membrane traffic protein
SYNRG synergin, gamma N/A
TADA2A transcriptional adaptor 2A N/A
TBC1D3 TBC1 domain family, member 3 Other G-protein modulator
TBC1D3B TBC1 domain family, member 3B Other G-protein modulator
TBC1D3C TBC1 domain family, member 3C Other G-protein modulator
TBC1D3C TBC1 domain family, member 3C Other G-protein modulator
TBC1D3F TBC1 domain family, member 3F N/A
TBC1D3F TBC1 domain family, member 3F N/A
TBC1D3F TBC1 domain family, member 3F N/A
TBC1D3G TBC1 domain family, member 3G Other G-protein modulator
TBC1D3H TBC1 domain family, member 3H N/A
TCAP titin-cap (telethonin) Other cytoskeletal proteins
THRA
thyroid hormone receptor, alpha
(erythroblastic leukemia viral (v-erb-a)
oncogene homolog, avian)
Nuclear hormone receptor, Transcription
factor
TNS4 tensin 4 Ribosomal protein[191]
Symbol * Protein Molecular function **
TOP2A topoisomerase (DNA) II alpha 170kDa
DNA topoisomerase, Select regulatory
molecule, Isomerase
WIPF2
WAS/WASL interacting protein family,
member 2
Molecular function unclassified
ZNHIT3 zinc finger, HIT type 3 Transcription cofactor
ZPBP2 zona pellucida binding protein 2 Molecular function unclassified
Table 18. Genes located within heterozygous linkage regions detected on chromosome
17 using SNP data.
* Gene symbols as per HUGO nomenclature. ** Molecular function as classified by the
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification
System (http://www.pantherdb.org/). Chromosome 17 interval; 31317362-36039271.[192]
Expression array analysis
A recent study combining linkage data with expression array analysis successfully
pinpointed the causative gene in a rare form of epilepsy (Berkovic et al., 2008). Those
transcripts significantly downregulated in affected compared to unaffected individuals
were prioritised as candidate genes within the linkage interval. Analysis is based on the
hypothesis that the causative mutation may affect mRNA stability. As lymphoblastoid
cell lines were available from two affected members of pedigree 1, I used the approach
described in order to identify down regulated transcripts lying within the linkage
intervals previously detected. RNA from patient C1-1 and C1-4 was analysed against
three unrelated control cell lines. I obtained two sex matched non disease controls from
the European Collection of Cell Cultures’ (ECACC) Human Random Collection and an
unaffected age matched control was obtained from the ECACC’s Human Genetic
Collection (please refer to section 2.2.6, Table 3 for more detail). Samples were
submitted to the UCL Genomics facility for analysis using the GeneChip
(R) Human
Gene 1.0 ST Arrays (Affymetrix). These expression arrays offer whole transcript
analysis of well annotated coverage with each gene represented on the array by multiple
probes spread across the full length of the gene. In order to identify significant
differences between affected and unaffected individuals, data was analysed by the UCL
Genomics facility with a two-way empirical Bayes ANOVA approach.
Analysis of the entire dataset showed large variation in the expression of genes within
the Human Leukocyte Antigen (HLA) locus on chromosome 4. For example HLA-
DRB5, HLA-DRB1 and HLA-DRB3 were found to be significantly dysregulated in
patients C1-1 and C1-4 compared to the controls. I filtered the data generated from each
probe set by genomic position using the NetAffx and Cytoband facilities
(www.affymetrix.com). Analysis was confined to those probe sets mapping to the
linkage intervals detailed above. In order to fully interrogate the data, all probes sets
with a P value of less than or equal to 0.05 ranked by fold change (probe subset A) and
all probes sets with a P value of less than or equal to 0.001 ranked by fold change
(probe subset B) (Table 19). The gene PSEN2, detected by the probe set 7910156 and
7910147 was identified as the most down regulated transcript in probe subsets A and B
respectively. The gene KCNK1, detected by the probe set 7910614 was identified as the
most down regulated transcript in probe subset B. I had previously identified both these[193]
genes as candidates during the reanalysis of microsatellite data and excluded mutations
by uni-directional sequencing. The gene NRXN1, detected by the probe set 8052101 was
identified as the second most down regulated gene in probe subset A. This candidate
was down regulated over 2 fold in the affected members of pedigree 1 compared with
that of control (p<0.003). The gene NRXN1 encoding neurexin 1 was an appealing
candidate due its function as an extracellular matrix ligand for α-dystroglycan. It is
interesting to note that the most highly up-regulated transcript within the linkage
intervals was CDC42 binding protein kinase alpha (DMPK-like) (CDC42BPA), lying
within a region of homozygosity on chromosome 1 (Table 19).[194]
Symbol * Probe ID set Fold Change (Affected vs Control) Fold Change (Description) P-value **
PSEN2 7910156 -2.34779 Affected down vs Control 0.000514556
NRXN1 8052101 -2.30027 Affected down vs Control 0.00333748
PCNXL2 7925122 -1.62803 Affected down vs Control 0.000574992
RAB3GAP2 7924425 -1.56066 Affected down vs Control 0.00158968
P
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RAB3GAP2 7924420 -1.54135 Affected down vs Control 0.00962787
Symbol * Probe ID set Fold Change (Affected vs Control) Fold Change (Description) P-value **
KCNK1 7910614 -8.2585 Affected down vs Control 0.0476433
PSEN2 7910147 -3.41015 Affected down vs Control 0.0161064
ITPKB 7924762 -2.96634 Affected down vs Control 0.0378884
TBC1D3B 8014383 -2.80814 Affected down vs Control 0.0156976
P
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)
TBC1D3B 8014405 -2.80814 Affected down vs Control 0.0156976
Table 19. The top 5 most down regulated transcripts detected by those probe sets lying within the 12 linkage intervals interrogated.
Two subsets of probe sets were ranked by fold reduction. Subset A; probe sets reaching a P value of 0.01 or less, subset B; probe sets reaching a
P value of 0.05 or less. * Gene symbols as per HUGO nomenclature. ** P values calculated using ANOVA. Yellow shaded boxes indicate those
genes investigated by me as candidate genes as part of the re-analysis of microsatellite linkage data. The blue shaded box indicates a novel
candidate for further investigation.[195]
Candidate gene analysis
I interrogated the intervals on chromosomes 1, 2 and 17 for the presence of candidate
genes. The most promising novel candidate initially presented as TCAP. TCAP encodes
telethonin and mutations in this gene have previously been associated with limb girdle
forms of muscular dystrophy LGMD2G; NM_601954. The 12 genomic intervals were
further scrutinised by the Endeavour software package (as previously described in
chapter 4). As with the search performed on the genes lying within the original
microsatellite linkage interval, both PSEN2 and OBSCN were again identified as top
ranking candidate genes (Table 20). Subsequent reanalysis generated with the inclusion
of DPM3 within the ‘training set’ recorded PSEN2 as the top scoring candidate, OBSCN
remained as the third highest scoring candidate (data not shown).
Mutation screening
Therefore to investigate novel candidate genes within the regions newly identified by
whole genome SNP analysis, I performed mutation screening of TCAP and NRXN1. The
human TCAP and NRXN1 genes are organised into 2 and 22 exons encoding transcripts
of 2.1 kb and 7.5 kb transcripts respectively. Uni-directional sequencing was carried out
as described in section 2.2.3. No sequence variants were identified within these genes.[196]
Rank * Protein (encoding gene) ** Gene ID
† Molecular function
‡ Subcellular
localisation
‡‡
1 Presenilin 2 (PSEN2) 5664
Aspartic protease, other select calcium binding
proteins
Endoplasmic reticulum
and Golgi
2 Obscurin (OBSCN) 84033
Actin binding cytoskeletal protein, Guanyl-
nucleotide exchange factor
Cytoplasm
3 nuclear factor (erythroid-derived 2)-like 1 (NFE2L1) 4779 Other transcription factor Nucleus
4 inositol 1,4,5-trisphosphate 3-kinase B (ITPKB) 3707 Kinase, Transferase No information
E
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5 guanylate kinase 1 (GUK1) 2987 Nucleotide kinase Cytosol
N/A titin-cap (telethonin) (TCAP) 8557 Other cytoskeletal proteins Cytoplasm
O
t
h
e
r
s
N/A Neurexin 1 (NRXN1) 9378 Other receptor Integral to membrane
Table 20. Candidate genes identified from within the 12 linkage regions detected using high density SNP data.
* The top 5 ranked genes within the interval on 1q42 using the Endeavour gene prioritisation software (www.esat.kuleuven.be/endeavour/). The
training set consisted of; POMT1, POMT2, POMGNT1, LARGE, FCMD and FKRP. ** Gene symbols and names as per HUGO nomenclature
(www.genenames.org/).
† Entrez Gene Identifier from the NCBI database (http://www.ncbi.nlm.nih.gov/).
‡ Molecular function as classified by
the PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System (http://www.pantherdb.org/).
‡‡ Subcellular
localisation as annotated via the Universal Protein Resource Knowledge Base (UniProtKB) (www.uniprot.org). Blue shaded boxes indicate those
genes previously screened by sequencing prior to the commencement of my PhD. Yellow shaded boxes indicate those genes investigated by me[197]
as candidate genes. PSEN2 was previously identified as a candidate gene within the linkage interval detected on chromosome 1q42 using the
microsatellite data (Table 14).[198]
5.3 DISCUSSION
This chapter comprises of work performed on a single family of Arabic descent
originally recruited to the Dubowitz Neuromuscular Centre over twenty years ago
(referred to here as pedigree 1). Four children from this consanguineous family are
affected by a congenital form of muscular dystrophy characterised by proximal muscle
weakness, muscle hypertrophy and early respiratory failure (Muntoni et al., 1998). Prior
to the commencement of my PhD a genome wide linkage scan identified a region of
homozygosity on chromosome 1q42 using a panel of microsatellite markers
(Brockington et al., 2000). Candidate gene analysis had previously excluded a total of
seven genes from this region by sequencing.
Recent years have seen a rapid expansion in the understanding of fundamental processes
underlying CMD. Re-assessment of the pathology in pedigree 1 uncovered
hypoglycosylation of α-dystroglycan in the remaining muscle biopsy samples. This
provided further insight into the mechanism of disease in this family and part of my
studies consisted of the re-evaluation of available data. After thorough inspection of the
original region of homozygosity I generated a list of novel candidate genes. However,
after screening four genes for mutations, the pathogenic alteration in this family
remained elusive. The homozygous region on chromosome 1 contained a large number
of genes and without further clues as to the causative gene’s identity, I considered
alternative approaches.
The use of microsatellite markers has more recently been superseded by the application
of high density SNP genotyping platforms offering greater power to detect regions of
linkage. Reports have demonstrated that the reanalysis of existing microsatellite scans
with high density SNP arrays, have often detected regions of linkage missed by the
initial scan (Middleton et al., 2004). Therefore in a collaborative project with the newly
established UCL Genomics facility, Professor R Kleta and Dr H Stanescu at the
Department of Internal Medicine UCL, DNA samples from members of pedigree 1 were
examined by high density SNP genotyping platforms (GeneChip Human Mapping 500[199]
Nsp array (Affymetrix)). This technology is capable of simultaneously genotyping
250,000 SNPs per sample with an average inter-marker distance of 5.8 kb.
Regions compatible with both homozygosity and compound heterozygosity were
interrogated. Linkage to chromosome 1q was detected spanning approximately 16 Mb
and lying within the original region reported in 2000. This peak reached a maximum
LOD score of 3 and reduced the original region by around 1 Mb. Yet fine mapping of
this interval revealed a much more complex pattern of inheritance than originally
detected by the analysis of microsatellites. This interval consisted of six regions of
homozygosity, three regions of heterozygosity and two smaller regions of non
compatibility. In addition to those detected on chromosome 1, three further regions of
suggestive linkage have also been identified consisting of two smaller regions of
homozygosity on chromosome 2 (~666,000 bps and ~697,000 bps) and one region of
heterozygosity on chromosome 17 (~4.7 Mb). Genomic regions on chromosomes 1, 2
and 17 total 22.1 Mb and contain 226 annotated reference genes.
Previous candidate gene analysis performed using the original microsatellite data by me
and others, led to the exclusion of eleven genes. Using the intervals generated from the
analysis of SNP data, three of these genes no longer locate to regions of compatibility
(B3GALNT2, LGALS8 and NID1). The remaining eight genes all reside within regions
of homozygosity with the exception of LBR, which is now found to locate within a
region of heterozygosity.
Within the twelve regions of linkage reaching a LOD score of over 2.5, a total of 226
reference genes are annotated. Initially TCAP presented as promising novel candidate
gene. Telethonin (or titin-cap) encoded by TCAP, is a sarcomeric substrate of titin; a
gigantic filamentous muscle protein essential for assembly of the sarcomere. Mutations
have previously been found in cases of limb girdle muscular dystrophy (LGMD2G;
NM_601954) and dilated cardiomyopathy (CMD1N; NM_607487) (Knoll et al., 2002;
Moreira et al., 2000). Mutation screening of TCAP failed to detect any sequence
variants in members of pedigree 1.[200]
A recent study investigating the genes involved in a rare form of epilepsy combined
both mapping data and expression analysis (Berkovic et al., 2008). The authors
hypothesised that a reduction in mRNA levels of the defective protein may be a cause of
disease. Expression microarrays were used to identify down regulated transcripts in
lymphoblastoid cell lines of affected individuals compared to unaffected siblings from
two families. Expression analysis was then used to prioritise candidate genes within
regions of homozygosity. Truncating mutations in SCARB2 were identified in all three
families used for mapping (Action myoclonus–renal failure syndrome; OMIM 254900)
(Berkovic et al., 2008). To explore whether the application of this approach could prove
beneficial to the study of pedigree 1, expression analysis was performed. RNA profiles
from lymphoblastoid cells from patients C1-1 and C1-4 were compared to that of
control lymphoblastoid cells. This data was used to prioritise the 226 candidate genes
identified by linkage. Linked transcripts found to be significantly down regulated in
patients compared to controls were interrogated further. PSEN2 and KCNK1 were
amongst those genes with the highest fold changes. Both these genes were also
identified as candidates using the Endeavour prioritisation software although no
mutations were identified upon mutation screening. Interestingly NRXN1 was also
identified as a significantly down regulated transcript in patients. Human neurexins are
encoded by three genes (NRXN1; NM_600565, NRXN2; NM_600566 and NRXN3;
NM_600567) which function as cell adhesion molecules and receptors. Thousands of
neurexin isoforms are transcribed from these genes with the use of alternative promoters
and alternative splicing (Tabuchi and Sudhof, 2002). Neurexins constitute neuronal
dystroglycan ligands and recent evidence from collaborators has indicated that neurexin
transcripts could also be expressed in skeletal muscle (unpublished observation from
Professor D Górecki). Interestingly, respiratory impairment was found to be the cause
of morbidity in α-NRXN deficient mice (Dudanova et al., 2006). The authors recorded
spontaneous respiratory activity from brainstem slices showing dysfunctional rhythm
output. Despite this, mutation screening of NRXN1 failed to detect any sequence
variants in members of pedigree 1.
The utility of the approach described by Berkovic et al. is heavily reliant on the
mutation affecting mRNA stability. An adequate expression profile of the causative
gene in control cell lines is also a prerequisite for study. A further limitation is that[201]
without RNA from unaffected family members it is not possible to control for
interfamilial or ethnic transcript level variation. If additional cell lines or sufficient
skeletal muscle was available from members of pedigree 1, it would be interesting to
confirm these transcript regulation alterations further and investigate their possible
effect on protein production.
Regardless of the method used to prioritise candidate genes, a continuation of the
systematic gene by gene mutation screening approach is problematic. In a data set
comprising of such a large number of genes even robotically semi-automated Sanger
sequencing becomes both time consuming and expensive. The advent of novel
genomics based technologies now offers efficient alternatives to more traditional
mutation detection techniques. Combining targeted sequence capture and massively
parallel DNA sequencing offers a cost effective alternative to whole genome
resequencing (Ng et al., 2010). Using high density sequence capture arrays either the
entire exome (coding subsequences constituting approximately 5% of the whole
genome), or specific genomic regions are captured on a microarray and subsequently
sequenced. Therefore, work is currently underway within the department to design a
custom hybridisation array for the enrichment and deep sequencing of those genomic
regions identified on chromosomes 1, 2 and 17 which total 22.1 Mb.
In summary, I employed a combination of high density SNP genotyping platforms,
expression microarrays and sequencing data to investigate the causes of congenital
dystroglycanopathy in a single family. My analysis of this family has highlighted how
linkage peaks can remain undetected due to the insufficient coverage or information
content of sparse microsatellite makers used to generate whole genome linkage maps.
Analysis of SNP mapping data revealed additional peaks on chromosomes 2 and 17 as
well as uncovering an unexpectedly complex pattern of recombination within the
original locus identified on chromosome 1. Regions identified on these peaks span over
22 Mb of genomic sequence and contain over 226 genes. After the exclusion of 13
genes by genomic sequencing, novel genomic based mutation detection approaches are
now been applied in order to identify the causal mutation in this family.[202]
CHAPTER 6. FINAL DISCUSSION[203]
6 FINAL DISCUSSION
A reduction in α-dystroglycan’s ligand-binding capacity is now associated with a
growing subset of muscular dystrophies often associated with central nervous system
pathogenesis (Michele et al., 2002). The term ‘dystroglycanopathies’ has been ascribed
to these disorders which encompass a striking range of clinical severity (Brockington
and Muntoni, 2005; Mercuri et al., 2006; Toda et al., 2003). Diagnosis is established
upon the detection of hypoglycosylation of α-dystroglycan at the sarcolemma by
immunolabeling of skeletal muscle sections (Brown et al., 2004; Dubowitz and Sewry,
2006). Hypoglycosylation of α-dystroglycan can also be observed as a reduction in
molecular weight of α-dystroglycan on western blot (Michele et al., 2002).
Thus far, defects in seven genes have been identified in these autosomal recessive,
genetically heterogeneous disorders (Beltran-Valero de Bernabe et al., 2002;
Brockington et al., 2001a; Kobayashi et al., 1998; Lefeber et al., 2009; Longman et al.,
2003; van Reeuwijk et al., 2005b; Yoshida et al., 2001). Six of these genes are thought
to be involved in the addition of carbohydrate residues onto the α-dystroglycan peptide
either via the process of O-mannosylation (POMT1, POMT2, POMGNT1) (Akasaka-
Manya et al., 2004; Manya et al., 2003; Yoshida et al., 2001) or via other not fully
characterised mechanisms (FKTN, FKRP and LARGE) (Brockington et al., 2005;
Brown et al., 2004; Saito et al., 2006; Xiong et al., 2006). Mutations in a single patient
have also been detected in DPM3, which functions in the synthesis of Dol-P-Man acting
as the glycoyl donor for all mannosylation reactions resulting in hypoglycosylation of α-
dystroglycan (Lefeber et al., 2009).
Prior to the molecular and biochemical defects being identified, it was not appreciated
that these conditions belonged to the same broad category, nor the fact that individual
gene defects were associated with such a broad spectrum of clinical severity. The
prevalence of founder mutations in geographical subpopulations originally facilitated
the identification of a number of causative genes (Diesen et al., 2004; Kobayashi et al.,
1998). This led to the initial assumption that the severity of clinical features was
dictated, not by the nature of mutation, but by the identity of the causative gene.
However, since then a widening of the clinical spectrum associated with individual[204]
genes has been observed. This is best exemplified by the finding of FKRP mutations in
both congenital and limb girdle forms of MD (MDC1C and LGMD2I) (Brockington et
al., 2001a; Brockington et al., 2001b). To assess the individual involvement of POMT1,
POMT2, POMGNT1, LARGE and FKTN in chapter 3, I focussed on the study of a large
cohort of dystroglycanopathy patients in whom FKRP involvement had been excluded.
Not only did we expand the spectrum of clinical phenotype associated with each gene,
but we also established for the first time, the frequency of involvement of these genes in
a large population of dystroglycanopathy patients.
Interpreting the pathogenic significance of sequence alterations in chapter 3 was
complicated by the abundance of previously unreported missense mutations.
Investigations performed to ascertain the pathological significance of a POMGNT1
sequence variant (section 3.2.3) highlight the importance of cautious interpretation of
functional data, particularly when studying atypical clinical presentations. Further
studies are needed to investigate the significance of the altered POMGNT1 kinetic
profile identified in patient A20. The implementation of enzymatic assays in the context
of a diagnostic setting requires careful determination of kinetic parameters. Two of the
novel mutations detected in chapter 3 have subsequently been reported as common
founder mutations (Manzini et al., 2008; Yanagisawa et al., 2007). In particular the
FKTN c.1167_1168insA alteration detected in patients A20 and A30 has a carrier
frequency of 0.75% in the Ashkenazi Jewish population, therefore the pre-screening of
this mutation in certain patients may be appropriate (Manzini et al., 2008).
A clear limitation of the mutation screening methods employed in this thesis is that
structural and non coding variants remain undetected. The proportion of mutations that
remain undetected has yet to be established. One of the few reports describing
mutations in LARGE details a homozygous intragenic deletion spanning 63 kb in a
WWS patient with consanguineous parents (van Reeuwijk et al., 2007). The deletion
encompasses exons 9 and 10 and the intronic breakpoints were confirmed using a
combination of Multiplex Ligation-dependent Probe Amplification and Multiplex
Amplifiable Probe Hybridisation. The Large
myd mouse has a spontaneous deletion of
approximately 100 kb encompassing exons 4, 5 and 6 (Browning et al., 2005). These
findings highlight the importance of examining genomic deletions in this gene in
particular. The gene LARGE spans over 660 kb of genomic DNA despite having a[205]
coding sequence of only 4.4 kb (Peyrard et al., 1999). The overall exon content of
LARGE is similar to that of DMD in which deletion mutations predominate (Ashton et
al., 2008).
The refinement of a large cohort of patients in chapter 3 permitted further collaborative
genotype-phenotype analyses focusing on additional parameters. A subset of patients in
whom I had identified mutations in POMT1, POMT2, POMGNT1, LARGE, FKRP and
FKTN were subsequently investigated further by members of the Dubowitz
Neuromuscular Centre. A thorough analysis of muscle pathology for a subset of twenty
four patients was performed (Jimenez-Mallebrera et al., 2008). A strong correlation
between reduced α-dystroglycan epitope staining and clinical course was observed in
patients with mutations in POMT1, POMT2 and POMGNT1. However, this was not
consistently found in patients with defects in FKTN or FKRP. Some of these patients
with milder forms of LGMD and no brain involvement were found to have a profound
depletion in α-dystroglycan epitope staining. Therefore this study indicates that it is not
always possible to correlate clinical course with α-dystroglycan epitope labelling. In a
further study focusing on brain involvement, magnetic resonance image brain scans
from twenty seven patients were analysed (Clement et al., 2008a). This analysis
expanded the spectrum of structural abnormalities associated with mutations in POMT1,
POMT2, POMGNT1 and LARGE. In particular this study demonstrated that
infratentorial structures were often affected in isolation therefore highlighting their
particular susceptibility in these conditions.
After the exclusion of FKRP, we detected mutations in approximately a third of all
patients screened. Since the work in chapter 3 was performed, results from three other
populations have been reported in which mutations in POMT1, POMT2, POMGNT1,
LARGE, FKTN and FKRP were systematically screened. Each study focused on a
defined clinical presentation and mutations were detected in a total of 53%, 40% and
51% of CMD, WWS and type II lissencephaly patient cohorts respectively (Bouchet et
al., 2007; Manzini et al., 2008; Mercuri et al., 2009). In combination, these studies
confirm our finding that a high proportion of patients remain without a definitive
molecular diagnosis. Following the work of chapter 3 my research shifted focus towards
to the identification of further causative loci.[206]
The identification of causative dystroglycanopathy genes has been hindered by the
extensive genetic and clinical heterogeneity present in these disorders. To compound
these issues, as studies of common founder mutations and large informative pedigrees
are exhausted, the detection of rarely mutated genes becomes more challenging. In order
to tackle these issues I used a combination of strategies. Chapter 4 focused on the study
of a large cohort of sporadic patients and the establishment of a cell culture model of
dystroglycanopathy to assess various candidate genes. Chapter 5 focused on the analysis
of a single consanguineous family using high density SNP genotyping and expression
analysis. Despite these attempts no clearly pathogenic sequence alterations were
identified in any of the novel genes screened. It is important to note that the exclusion of
these candidate genes from the cohorts studied does not preclude their involvement in
disease pathogenesis. However, it may be inferred that mutations in GYLTL1B,
β3GNT1, WWP1, GYG1, GYG2, MGAT5B and DAG1 are not a common cause of
human dystroglycanopathy.
Chapter 4 described the establishment of a cell culture model of dystroglycanopathy by
modulating individual gene expression in a mouse myogenic cell line. This enabled the
functional assessment of individual genes in the pathway of α-dystroglycan
glycosylation. A reduction in the IIH6 epitope, as observed on western blot, could not
be induced by the modulation of Gyg1 using the conditions optimised with Pomt1
siRNA oligonucleotides. The lack of available antibodies to Gyg1 prevented the
confirmation of an induced reduction in protein production. A reduction in β3gnt1
mRNA did, however, induce a reduction of the IIH6 epitope present on α-dystroglycan.
Previous reports have demonstrated that β3GNT1 is required for the production of
laminin-binding glycans in aggressive human carcinoma cell lines (Bao et al., 2009).
Due to the tissue specific nature of α-dystroglycan glycosylation it was important to
confirm the involvement of β3GNT1 in a skeletal muscle system. As an extension, the
future development of this mouse skeletal muscle cell experimental approach using
fluorescence activated cell sorting would facilitate the accurate quantification of α-
dystroglycan epitopes. A number of candidate genes could not be studied with the cell
culture assay due to the differing expression patterns and gene complements between
the species studied. Despite the expression of WWP1 in human and chicken skeletal
muscle, this gene was not detectable at a sufficient level in C2C12 cells. The
predominant expression of both GYLTL1B and MGAT5B in brain also precluded their[207]
analysis in this mouse skeletal muscle cell system. As these genes remain candidates for
patients with isolated lissencephaly, it would be interesting to modulate their expression
in a neuronal cell system to investigate tissue specific glycosylation patterns. Evidently
the generation of mouse models for these genes would facilitate the analysis of their
function in a whole mammalian system and the assessment of potential clinic-
pathological similarities to human dystroglycanopathy patients.
Despite the relatively low abundance of α-dystroglycan, 30% of all O-linked glycans
detected in rabbit brain have been reported to be linked via mannose, indicating the
presence of other proteins with O-linked mannose in the brain (Chai et al., 1999).
Although only partial structural information is available, O-mannosyl glycans have been
identified on both cell adhesion molecule, neural 1 and tenascin R [OMIM 11690 and
601995 respectively] (Endo, 1999; Wing et al., 1992). Further studies are needed to
clarify the distribution of these structures throughout tissues, developmental stages and
under pathological conditions. Although further insights have come about from the
genetic and biochemical analysis of dystroglycanopathy patients, the exact glycans
present, the function of these glycans in ligand binding and the glycosylation pathways
involved remain uncharacterised (Yoshida-Moriguchi et al., 2010). It is likely that
defects in proteins other than glycosyltransferases (such as nucleotide sugar
transporters, convertases, glycosidases and conserved oligomeric Golgi proteins), which
all participate in the process of glycosylation, may be identified in dystroglycanopathy
patients (Muntoni et al., 2009).
The application of array based mutation detection techniques will be crucial to the
identification of novel dystroglycanopathy loci. The Dubowitz Neuromuscular Centre is
currently involved in a large European consortium based project aimed at designing,
producing and validating novel DNA-chips for neuromuscular disease diagnostics.
Arrays will be developed with oligonucleotide probes designed to all known
neuromuscular disease genes as well as a large panel of novel genes. Each candidate
gene discussed in chapter 4 has been included in the panel of candidate genes. In
addition, DNA from a subset of patients from cohort B (screened in chapter 4) will be
submitted for exome sequencing as part of the UK10K Project at the Wellcome Trust
Sanger Institute, Cambridge. The interrogation of these data will provide a wealth of
information as to the sequence variants present within patients.[208]
The relative frequency of common mutations in dystroglycanopathies, such as the
FKRP p.Leu276Ile in the Caucasian population, has been explained by the founder
effect (Frosk et al., 2005). There has been speculation that selective advantage may also
be contributing to the maintenance of these alleles (Frosk et al., 2005). A recent high
profile study analysed over three million SNPs to detect areas of positive natural
selection across the human genome (Sabeti et al., 2006). Four hundred and twenty
chromosomes from three continents were genotyped. Evidence of positive selection was
detected for loci within LARGE and DMD in the West African sample (Yoruba in
Ibadan, Nigeria) where the Lassa virus is endemic. The Lassa virus causes severe
hemorrhagic fever and is associated with a high mortality rate in humans. Alpha-
dystroglycan functions as the receptor for a range of arenaviruses including the Lassa
virus (Cao et al., 1998). Protein O-mannosylation and the specific post-translational
modification induced by LARGE are crucial for infection (Kunz et al., 2005). The
authors suggest that the presence of selected LARGE and DMD alleles in chromosomes
from the Yoruba population may correlate with disease resistance (Sabeti et al., 2006).
Detailed infection studies on genotyped cell lines as well as correlating haplotypes with
clinical outcomes are needed to further investigate these observations.
In 2004, Campbell and colleagues reported that the function of LARGE could be
exploited as a viable therapeutic strategy for dystroglycanopathy patients (Barresi et al.,
2004). The overexpression of human LARGE in the Large
myd mouse model not only
ameliorated symptoms but was well tolerated in skeletal muscle. Surprisingly the
overexpression of LARGE in patient cell lines with FKTN, POMGNT1 and POMT1
mutations resulted in the production of the IIH6 antigen and a restoration of α-
dystroglycan ligand binding. It is not yet clear how an increase in LARGE expression
restores ligand binding and thus compensating for the defects in other causative
dystroglycanopathy loci (Yoshida-Moriguchi et al., 2010). Transgenic mouse models
with ubiquitous expression of human LARGE are currently being developed in the
Dubowitz Neuromuscular Centre in order to assess any induced pathological changes,
as well as to facilitate crossing with dystroglycanopathy mouse models (Brockington et
al. submitted for publication). Although the correction of neuronal migration disorders
occurring early in fetal development presents as a significant challenge, this treatment[209]
could be valuable to patients at the milder end of the clinical spectrum in whom only
skeletal muscle is involved.
Pharmacological regulation of LARGE expression is a possible avenue for therapy
(Muntoni et al., 2009). Further studies are needed to identify pharmacological agents
that may affect the transcription or recycling of LARGE. This approach would not be
amenable in those patients with mutations in LARGE, although with only three cases
reported worldwide, this excludes only a minority of dystroglycanopathy patients.
Interestingly the production of the IIH6 antigen in cell lines can also be induced by the
expression of GYLTL1B (Brockington et al., 2005). As demonstrated in this thesis,
mutations in this gene are not a common cause of dystroglycanopathy in our cohort,
therefore the modulation of this gene offers further therapeutic potential. The increase in
ligand-binding glycans induced by LARGE overexpression requires the function of
endogenous β3GNT1 (Bao et al., 2009). Indeed Bao et al. reported that increasing
β3GNT1 expression substantially augmented the LARGE-mediated formation of α-
dystroglycan ligand-binding glycans. The presence of mutations in β3GNT1 in patients
would therefore preclude the use of LARGE modulation as a therapeutic strategy.
Therefore the exclusion of mutations in β3GNT1 and GYLTL1B (chapter 4; cohort B)
has been of significant benefit when evaluating the appropriateness of these therapeutic
strategies amongst the dystroglycanopathy population.
To date, candidate gene analysis has mainly focussed on further putative and
demonstrated glycosyltransferases (Muntoni et al., 2009). Through the application of
next generation sequencing technologies it is likely that defects in a range of cellular
pathways will be found to underlie dystroglycanopathy pathogenesis. Clues may also be
offered by the further characterisation of α-dystroglycan processing. The recent
identification of a phosphorylated O-mannosyl glycan on the mucin-like domain of α-
dystroglycan may implicate those proteins participating in phosphoryl modifications
(Yoshida-Moriguchi et al., 2010).
This thesis describes a variety of approaches used to further refine the genetics of
muscular dystrophies with defective glycosylation of α-dystroglycan. Additional
information regarding the pathogenic processes underlying these disorders will further[210]
aid in the diagnosis, treatment and development of novel therapeutic approaches for
these incapacitating diseases.[211]
APPENDICES[212]
Gene Intron/exon Nucleotide variant Amino acid change Combined references
FKTN 3 c.165-6A>G intronic rs41277795 / additional change
FKTN 4 c.165C>T p.Arg56Cys rs41277797 / additional change
FKTN 5 c.608A>G p.Arg203Gln rs34787999 / additional change / dmd.nl
FKTN 7 c.910+14G>A intronic - / additional change
FKTN 8 c.1026C>A synonymous rs17309806 / additional change / dmd.nl
FKTN 8 c.1044+44A>G intronic - / additional change
FKTN 8 c.1044+58C>T intronic - / additional change
FKTN 10 c.1336A>G p.Asn446Asp - / additional change / dmd.nl
LARGE 2 c.1-63C>T intronic - / additional change
LARGE 4 c.211G>A p.Glu71Lys - / additional change *
LARGE 5 c.435C>T synonymous - / additional change
LARGE 6 c.552G>A synonymous - / additional change
LARGE 10 c.1092C>T synonymous - / additional change *
LARGE 11 c.1287+105G>C intronic -
LARGE 11 c.1287+146T>C intronic - / additional change
LARGE 12 c.1451+38C>T intronic - *
LARGE 14 c.1878-24A>G intronic - *[213]
Gene Intron/exon Nucleotide variant Amino acid change Combined references
LARGE 15 c.1994G>A p.Arg665His - / additional change
LARGE 15 c.2073+36C>T intronic - / additional change
LARGE 16 c.2100C>T synonymous - / additional change
POMGNT1 1 c.1-11G>A intronic - / additional change *
POMGNT1 3 c.235+33T>G intronic -
POMGNT1 4 c.355-27C>T intronic - *
POMGNT1 8 c.681A>G synonymous - / additional change
POMGNT1 13 c.111-23C>T intronic - / additional change
POMGNT1 20 c.1785+31C>A intronic - *
POMGNT1 21 c.1867A>G p.Met623Val rs6659553
POMGNT1 21 c.1895+30A>G intronic - *
POMT1 2 c.122-5dupT intronic - / additional change
POMT1 3 c.129C>T synonymous - / additional change *
POMT1 5 c.318G>A synonymous - *
POMT1 5 c.428-21C>T intronic rs11243404 / additional change
POMT1 7 c.751C>T p.Gln251Trp rs3887873
POMT1 7 c.752A>G p.Gln251Trp rs2296949[214]
Gene Intron/exon Nucleotide variant Amino acid change Combined references
POMT1 8 c.766-43T>G intronic - / additional change
POMT1 8 c.766-48G>A intronic rs2018621 / additional change
POMT1 9 c.855G>C p.Leu285Phe - / dmd.nl
POMT1 10 c.922-65G>A intronic rs34159422 / additional change
POMT1 10 c.942C>T synonymous - / additional change / dmd.nl
POMT1 10 c.979G>A p.Val327Ile rs4740164 / additional change / dmd.nl
POMT1 11 c.1053-113C>G intronic rs10901068 / additional change
POMT1 11 c.1053-102G>A intronic - / additional change
POMT1 11 c.1053-39C>T intronic - *
POMT1 11 c.1113C>T synonymous rs3739494 / additional change / dmd.nl
POMT1 11 c.1148+16G>A intronic - / additional change / dmd.nl
POMT1 11 c.1148+45C>G intronic - / additional change
POMT1 12 c.1149-64C>T intronic -
POMT1 13 c.1299C>A p.Asp433Glu rs11243406 / additional change / dmd.nl
POMT1 13 c.1338+84C>T intronic - / additional change
POMT1 14 c.1432-61G>A intronic rs1547768 / additional change
POMT1 16 c.1565G>A p.Arg522Lys dmd.nl[215]
Gene Intron/exon Nucleotide variant Amino acid change Combined references
POMT1 17 c.1764+48G>C intronic rs2277152 / additional change / dmd.nl
POMT1 17 c.1758G>A synonymous rs34954751 / additional change / dmd.nl
POMT1 19 c.1922C>T p.Ala641Val rs12115566
POMT1 19 c.2069+13C>T intronic rs4740165 / dmd.nl
POMT1 20 c.2244+41C>T intronic rs3739495 / additional change / dmd.nl
POMT2 3 c.439-45C>T intronic - / additional change
POMT2 3 c.439-98A>T intronic - *
POMT2 4 c.548-77C>G intronic - *
POMT2 6 c.817-26C>T intronic - *
POMT2 8 c.1007-32G>A intronic - / additional change
POMT2 8 c.1007-46C>T intronic - *
POMT2 9 c.1116+165C>T intronic - / additional change
POMT2 9 c.1116+35A>G intronic rs2302831 / additional change
POMT2 9 c.1116+91C>T intronic - / additional change *
POMT2 9 c.1117-20C>T intronic - / additional change
POMT2 13 c.1383A>G synonymous - / additional change / dmd.nl
POMT2 14 c.1654-6A>G intronic - / additional change[216]
Gene Intron/exon Nucleotide variant Amino acid change Combined references
POMT2 15 c.1653+38G>A intronic - / additional change
POMT2 15 c.1654-41G>C intronic -
POMT2 16 c.1725+51G>C intronic - *
POMT2 17 c.1785T>C synonymous - / additional change
POMT2 18 c.1881G>A synonymous - / additional change
POMT2 18 c.1891A>G synonymous - / additional change
POMT2 19 c.1911T>G synonymous - / additional change / dmd.nl
POMT2 20 c.2148-18A>G intronic - / additional change
POMT2 21 c.2253+75C>T intronic - / additional change / dmd.nl
Appendix Table 1. List of non pathogenic variants detected in POMT1, POMT2, POMGNT1, FKTN and LARGE.
dbSNP references are provided where applicable. Additional changes in patients with a pathogenic mutation are annotated. * Variation detected
in a single individual. Dmd.nl refers to the change recorded as a polymorphism on the Leiden database (www.dmd.nl).[217]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 1 WWP1_1_F_T1_01 TTAGGGTTTTCTTTTAATGGGATG WWP1_1_R_T1_01 TATTAATCATTTAAGGGCCAATGC
PCR A 2 WWP1_2_F_T1_02 AGTAGCCCTTTTGTATTGTTTCTT WWP1_2_R_T1_02 TCACTCATTACTTTGAAGTCATTTT
PCR A 3 WWP1_3_F_T1_01 TAAGACTCCTGTGTTGGTGTTTTG WWP1_3_R_T1_01 CCACAAAGTTAATCAATCACAAGC
PCR A 4 WWP1_4_F_T1_01 TATGCACAGAAGCAATTAAAGGTG WWP1_4_R_T1_01 AAATATTCTACCTGGCAGTTGTCC
PCR A 5 WWP1_5_F_T1_01 TATAACAAACTGCAGCTCATCTCC WWP1_5_R_T1_01 TGTGTGGCAAATTCTAAACTAAGG
PCR A 6 WWP1_6_F_T1_01 CATGTCATATCTTTGTTCATTACTC WWP1_6_R_T1_01 ACAAAAAGGGAAGTGTAGGCATGG
PCR A 7 WWP1_7_F_T1_01 TCTGGATTAGGCTCTGAATAAGTG WWP1_7_R_T1_01 CAATGAAAACATTTTATGCACAC
PCR A 8 WWP1_8_F_T1_01 TTAAAATGTGGGGTATTCTCTTCC WWP1_8_R_T1_01 GCAGAATGAAAGAATCAAATTACG
PCR A 9 WWP1_9_F_T1_01 GGTAGAATGGGAAGGTAATTTAGG WWP1_9_R_T1_01 ATGTGATTATGGTCAAGGGATAGC
PCR C 10-11 WWP1_10_F_T1_02 CTTGAACTCCTGGGCTTAAGTA WWP1_11_R_T1_02 CACAAGATGAACCTTTTCTAGGTA
PCR A 12 WWP1_12_F_T1_01 AAGATCCAAGAACTCAAGGGTATG WWP1_12_R_T1_01 ATTGTCAAATGAGAGCAAAGACAG
PCR A 13 WWP1_13_F_T1_01 CATAAATACAATGTCCTTCTTTGT WWP1_13_R_T1_01 TTCTGCTAAAATCCTCCTTACCTG
PCR A 14 WWP1_14_F_T1_01 AATCTTCCTGTGGTATTTTGTTGG WWP1_14_R_T1_01 AAAACAAAGGCACTCAACAAGTG
PCR A 15 WWP1_15_F_T1_01 TCATCTCTTGAGTTAAAAGCATTG WWP1_15_R_T1_01 TCAGATCCTACATTTTGTACATTG
PCR A 16 WWP1_16_F_T1_01 AAATGGAGAGCCAGATCATAGAAG WWP1_16_R_T1_01 TTGGTAACAAAACTTGTGAATAGC[218]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 17 WWP1_17_F_T1_01 GATTGAGGCAGGGTATGGTAATAG WWP1_17_R_T1_01 GCCACATTCTTCAATGTTGTTATC
PCR A 18 WWP1_18_F_T1_01 TCTGGATAAGGTTTGAAGATTTTG WWP1_18_R_T1_01 TTTTCAAGAACATTGGTACTGGTG
PCR A 19 WWP1_19_F_T1_01 TGTTAGAACTGATTTCCTCAAATG WWP1_19_R_T1_01 CAAATGAGAGGATTCAAGATTGTG
PCR A 20 WWP1_20_F_T1_01 TTGGTTTGAGTTCAATAAACATGG WWP1_20_R_T1_01 TAAACTGTGTCCAAAAGCAGTCTC
PCR A 21 WWP1_21_F_T1_01 AACCTTTAGCACATCTTTTGAACC WWP1_21_R_T1_01 TCTAAATGAAGCCCTACCTACAGC
PCR A 22 WWP1_22_F_T1_01 CTCTGCAACAATTTTCTTCTTCAG WWP1_22_R_T1_01 AAAGTGTTCAGTTATAGAATGCTG
PCR A 23 WWP1_23_F_T1_01 AATTTAGATTACTCTAAATACTTC WWP1_23_R_T1_01 CGGAAAACATACTTTGAGAGGTTC
Appendix Table 2. WWP1 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[219]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR B 1 GNTIX_1_F_T1_01 CTCCCGGTCCCCAAAATGTGAAG GNTIX_1_R_T1_01 ATCACCAGGGGTTGAAGTGTGAAC
PCR A 2 GNTIX_2_F_T1_01 CTCATTCGTAAAACATTTGTGCAG GNTIX_2_R_T1_01 GACACCCAACTAAAGAAGCAACAC
PCR A 3 GNTIX_3_F_T1_01 CTTAGGAAATGATCCCAATGTCAC GNTIX_3_R_T1_01 AATCTTCTCCAGATTCACAAAAGG
PCR A 4 GNTIX_4_F_T1_01 TTTCCCGTATGTCTGTAATGTGTG GNTIX_4_R_T1_01 AGTTGTCCTGCTGAAAGCCTAAAC
PCR A 5 GNTIX_5_F_T1_01 CTGATGAGCTTTAAGGTGGGAAAG GNTIX_5_R_T1_01 TTTAATCATTTGCTGTGAGAAAGC
PCR A 6 GNTIX_6_F_T1_01 GGTCCTGGTTCAATCTCTTCTCTG GNTIX_6_R_T1_02 CTGGCAAGCAGCTCAGTCTCATTC
PCR A 7 GNTIX_7_F_T1_01 CCTTAGAAAGTGCAGGAGAAGCTG GNTIX_7_R_T1_01 ACAGCTTGTTTGAAGACCTATTCC
PCR A 8 GNTIX_8_F_T1_01 GCAAGCACGTGACTATCTTGTTC GNTIX_8_R_T1_01 GGATTAGGAGTGGTGATGTCCTG
PCR A 9 GNTIX_9_F_T1_01 TCCTTTCTGAGAGTCTGTGCTAAG GNTIX_9_R_T1_01 CAGGACAGTATGTTCTCCCACCTG
PCR A 10 GNTIX_10_F_T1_01 CCTAGTCCAAGTGCTAACACACAC GNTIX_10_R_T1_01 GTTCACACACTTATGGAGCAGGAG
PCR A 11 GNTIX_11_F_T1_01 GCTCTGATCTTTGTAGCAGTCTCC GNTIX_11_R_T1_01 GGGTGTCTTTAAATAGCAGTTAGG
PCR A 12 GNTIX_12_F_T1_01 CATCTTCTGACTTCCAGACCAAAG GNTIX_12_R_T1_01 CTATAGGACCTCTCCTGCCTGGTG
PCR A 13 GNTIX_13_F_T1_01 TTATAGCTCACATAACAGGCTGAG GNTIX_13_R_T1_01 GACAAAGAAAGGTACCCCATACAC
PCR A 14 GNTIX_14_F_T1_01 GTGTATGGGGTACCTTTCTTTGTC GNTIX_14_R_T1_01 CACCGTTTTCTAATCAGAGTGAAG
PCR A 15 GNTIX_15_F_T1_01 TGAGCTTTATCCTCATTGCAGTTG GNTIX_15_R_T1_01 AACTCTGGGAAGAGACTGGACAGG[220]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR B 16 GNTIX_16_F_T1_01 TGGTATTCAGTAAGCGCCCAGTAG GNTIX_16_R_T1_01 TGACTCATTGGAAAGCATTACATC
PCR B 17 GNTIX_17_F_T1_01 CAGCAGGTGGGATAAAGGAGCCG GNTIX_17_R_T1_02 CGGCATGCTGCCTCCTCCTATTC
Appendix Table 3. MGAT5b genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[221]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR B 1 GYG_1_F_T1_01 CACGTGACGGCCGCTATAAGAGC GYG_1_R_T1_01 GCTGAGGGCGGAGGAGAAGG
PCR A 2 GYG_2_F_T1_01 CTGGTTTTGCTGAATTACTGTTTG GYG_2_R_T1_01 CTAGGAGGAGGTTTCAAATACAGC
PCR A 3 GYG_3_F_T1_01 AACTGGACATGCAAATAAACACAG GYG_3_R_T1_01 ATTCCTCAAATGCCTACAGGTCTC
PCR A 4 GYG_4_F_T1_01 TTTTGTGTTGGATGACATAGGAAG GYG_4_R_T1_01 CACACACAATATTTCCCAGAAGAG
PCR A 5 GYG_5_F_T1_01 GGTCCAGTTATGTGCTCCTATAAA GYG_5_R_T1_01 CTATCTGTTATTTCCCTCGGAATG
PCR A 6 GYG_6_F_T1_01 AAGTGCTACTAAGTGCTGCTTATC GYG_6_R_T1_01 ATGCTGCTAAATATTCCACATCTC
PCR A 7 GYG_7_F_T1_01 GCGGCTCTCTAGTTAGATTCTTTC GYG_7_R_T1_01 GCAATAAATTGAAGACAGAAAAGC
PCR A 8 GYG_8_F_T1_01 TTTTTGCTACTTTGCATGATGATT GYG_8_R_T1_01 CAGACTTTTCTCAACCCAGCTCTA
Appendix Table 4. GYG genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[222]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 2 GYG2_2_F_T1_01 AGGTGACATGGAGTGGGTAGGAG GYG2_2_R_T1_01 ACAAAAGGAAACTGGTGAAATCC
PCR A 3 GYG2_3_F_T1_01 AAGGTTCCTTCATACTCCTCCTG GYG2_3_R_T1_01 AGAGTTACACTCCTGAGGGACAG
PCR A 4 GYG2_4_F_T1_01 GGAGAGGAGAGGAGGTGACTATG GYG2_4_R_T1_01 TGGTTGGGAGAATGAACTGTAAC
PCR A 5 GYG2_5_F_T1_01 ATTCTCTTTGCATTCCACGTTTG GYG2_5_R_T1_01 GTGGGAGAATCACTTGAACTCAG
PCR B 6 GYG2_6_F_T1_01 TGTAATCCCAGCTACTCAAGAGG GYG2_6_R_T1_01 CTGAGCGAGGTGTGACTGTATG
PCR A 7 GYG2_7_F_T1_01 AGGCAAGTGTTTATGTTGAGAGC GYG2_7_R_T1_01 TAAATATGCCGACAGCTGGTATG
PCR A 8 GYG2_8_F_T1_01 CATTGGGACAAGTCCTTCAGAG GYG2_8_R_T1_01 CAGGTGCTTGCTTCTCAGTATTC
PCR A 9 GYG2_9_F_T1_01 TTATTTAATGATTGGCAGATGG GYG2_9_R_T1_01 AAATAAATGCAGAGCCTTGAATG
PCR A 10 GYG2_10_F_T1_01 AACAAACACAGGTATTGGTGAGC GYG2_10_R_T1_01 AACTTATTCCAGGTGGGAGAAAC
PCR B 11 GYG2_11_F_T1_01 CCTCCTAAAATGCTGGGATTAC GYG2_11_R_T1_01 ATCAGACTTGAAGATGGCAAAAG
PCR A 12 GYG2_12_F_T1_01 ATCTCTTTTTGAGAACTGAGATGC GYG2_12_R_T1_01 ATAGAGGCACAAGGTTCAACAG
Appendix Table 5. GYG2 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[223]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR D 1 La2_1_F_T1_01 CCAGGGCTGAGTCTCCCATCTCGC La2_1_R_T1_01 CAGGTACTGTGATTCCCGCAGATG
PCR B 2 La2_2_F_T1_01 GAATCACAGTACCTGGCGTCTGTC La2_2_R_T1_01 AGGATGTTCTTACAACTGCCCTTC
PCR B 3 La2_3_F_T1_01 GGAAAAGCTCTTTGCAGATGG La2_3_R_T1_01 GACTGATGATTCTCTTCTCCAACC
PCR A 4 La2_4_F_T1_01 CCTCTCCTCTGTGTCACTGCAAG La2_4_R_T1_01 CTCTGGTTCTCCACAAGACCGATC
PCR A 5 La2_5_F_T1_01 CTTTGCTCACTTTTCTGGTGAGAG La2_5_R_T1_01 GTTCTTTTCACAGCAATGTTCTTC
PCR B 6 La2_6_F_T1_01 AAAACAAAGGACACCTTCATGACC La2_6_R_T1_01 TTGAGGTCAGACGCCTCAGAGTAG
PCR A 7 La2_7_F_T1_01 GCATGACAGCATCTCTTCATTGG La2_7_R_T1_01 AAGAATTCCACATGCTTGTTCTTC
PCR B 8 La2_8_F_T1_01 GTCTCTGCTCAGGACATCTTCAAC La2_8_R_T1_01 GGGATAGGGCAGAACAACACATC
PCR A 9 La2_9_F_T1_01 AATTTCTACCTGACCTTCCTGGAG La2_9_R_T1_01 GTAGCTCACTACCACAGCATCAGG
PCR A 10 La2_10_F_T1_01 TAAAAGTATTTGAAGGGTGCTCAG La2_10_R_T1_01 TAATACAAACCCCAATTGACAGAG
PCR A 11 La2_11_F_T1_01 GGTGGTCTAGTCCTGTGGCTAATG La2_11_R_T1_01 ACCACCACGTAGGGTTCATAGTTG
PCR A 12 La2_12_F_T1_01 CCTTCAGGTAGGAGAGGCTACTTC La2_12_R_T1_01 GGGCAGATTATTTTAATTCCACAG
PCR A 13 La2_13_F_T1_01 ACACCACTAGGCAACACTGTTAGA La2_13_R_T1_01 CCCTTCCCAGAGACCTTAAATAAT
Appendix Table 6. GYLTL1B genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[224]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR B 2 DAG_2_F_T1_01 GCTCAAGTCTAAACCTGCTTTTC DAG_2_R_T1_01 CTCTTATGAACATCAGTGGCTGTC
PCR B 3 DAG_3a_F_T1_02 CTGTCACACAATTCAGGTTAACTG DAG_3A_R_T1_02 GCTCTACTTCTGAGAAGCTCCGC
PCR B 3 DAG_3b_F_T1_01 GTATCATCTGCCTGTGCTGCGGAT DAG_3B_R_T1_01 GAGGAGCAATGGCTGGAGATGTGG
PCR B 3 DAG_3c_F_T1_01 CAGATCCATGCTACACCCACACCT DAG_3C_R_T1_01 GGTGATGGAAACTTTGGTGGTGAC
PCR B 3 DAG_3d_F_T1_01 CAACGCCTTCAACTGACTCCACC DAG_3D_R_T1_01 GAACCTTGCAGGAGCCCTATCCCC
PCR B 3 DAG_3e_F_T1_01 CACGAGTATTTCATGCATGCCAC DAG_3E_R_T1_01 CCTCTGAGGGCACTCTCCTGGGT
PCR B 3 DAG_3f_F_T1_01 CTGACTTTAAGGCCACAAGCATC DAG_3F_R_T1_01 CGCATTGGGATCCTCATCCCGCAG
PCR B 3 DAG_3g_F_T1_01 CCTCCTGAGTACCCCAACCAGAG DAG_3G_R_T1_01 CTAGGTCAGGTGTCGGCTCCCGG
Appendix Table 7. DAG1 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[225]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR B 1 iGNT_1a_F_T1_01 CGGCAGGCTGCGGTAAATCCGGGC iGNT_1a_R_T1_01 CCTCCCAGCGCTCCAGCAGACCCG
PCR B 1 iGNT_1b_F_T1_01 CCTGCTGAAGACCACCATGGACC iGNT_1b_R_T1_01 CCACTGGTTGCTCTGATCCAGCAT
PCR B 1 iGNT_1c_F_T1_01 GGGCCAACTATGCCCTGGTGATCG iGNT_1c_R_T1_01 CCAGGGCCACTCCTCATAACTCCC
PCR B 2 iGNT_2_F_T1_01 GAAGATCCAGGATACTTCCAGAGG iGNT_2_R_T1_02 GTAAAGTGGAGCGACATTTCTTAC
Appendix Table 8. β3GNT1 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[226]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 2 NRXN1_2A_F_T1_01 CCCCTTACCTTTCTGTCTCTC NRXN1_2A_R_T1_01 GTCGATGAAGAGCGTGGTGTT
PCR A 2 NRXN1_2B_F_T1_01 AGCTCAGCTTCTCCATCTTCT NRXN1_2B_R_T1_01 AGATTAGGAAGACCCCATGCAC
PCR A 3 NRXN1_3_F_T1_01 CCCCTTGAATGATAGTGATG NRXN1_3_R_T1_01 AACAAGGGTTGGAGTTAAGC
PCR A 4 NRXN1_4_F_T1_01 GGGTTTGGTTGGATTTTAAG NRXN1_4_R_T1_01 CTTTGCAGTGATGGTTTGAAAG
PCR A 5 NRXN1_5_F_T1_01 ACATGTCCTGATTGCATCTC NRXN1_5_R_T1_01 ACACATATACCTACCTCCCAGTG
PCR A 6 NRXN1_6_F_T1_01 CTGTTTGACTGAGACAGAGTTCA NRXN1_6_R_T1_01 GGAGCCCTGTATCATGTTG
PCR A 7 NRXN1_7_F_T1_01 GTGGGAGGCCTACTTGTTAG NRXN1_7_R_T1_01 CAGAAGTTGACAGGAACAGG
PCR A 8 NRXN1_8_F_T1_01 GTTCCGTCATAGGTCTAAAAACA NRXN1_8_R_T1_01 GAATTTAAAGTTGTGCCGTTT
PCR A 9 NRXN1_9_F_T1_01 CGTTGAAAGTTACATGAGCTG NRXN1_9_R_T1_01 GGCTAAAGAAACAAATGCAG
PCR A 10 NRXN1_10_F_T1_01 CCTCCAAGGAGTTAACCATC NRXN1_10_R_T1_01 TACGTTTCAATGGTCAGTGC
PCR A 11 NRXN1_11_F_T1_01 CTTTCCAGCTCACAGTTTTG NRXN1_11_R_T1_01 CCATGGCAAACAGGCTAC
PCR A 12 NRXN1_12_F_T1_01 GAGAAAGTTGCAGCCAGTC NRXN1_12_R_T1_01 TTTTACAACCCAGATGATGG
PCR A 13 NRXN1_13_F_T1_01 GTTGTCATTTTCCTTGCTTG NRXN1_13_R_T1_01 GGATTGTGTGAATACATTTCAAG
PCR A 14 NRXN1_14_F_T1_01 GTACCAAGGAGGGATTTGG NRXN1_14_R_T1_01 AGATGATTTAAACAAATGCCTTC
PCR A 15 NRXN1_15_F_T1_01 CACTGAATAATCCTCTTTGCTG NRXN1_15_R_T1_01 GCAGAAGGTACAAACACACC[227]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 16 NRXN1_16_F_T1_01 TTTAGCACTTTGGGGAAAAC NRXN1_16_R_T1_01 GAATTTTGCTGGACAGTGAG
PCR A 17 NRXN1_17_F_T1_01 CAGCCTCTCAGTTCCTAATTC NRXN1_17_R_T1_01 CATCATCACAGGATTTAGCC
PCR A 18 NRXN1_18_F_T1_01 AACTTGGTCCACTTTCTTGAG NRXN1_18_R_T1_01 AAGGAAGCATCCAAGAAGC
PCR A 19 NRXN1_19_F_T1_01 TCAATTCCCTTGAAAGTGTG NRXN1_19_R_T1_01 CCACAATTTGGTGAAACG
PCR A 20 NRXN1_20_F_T1_01 CTCATTATTCACCCCATAAAAG NRXN1_20_R_T1_01 TTCATATTCAAACGGAATGC
PCR A 21 NRXN1_21_F_T1_01 TCTACAAGTTGGCTGTCACC NRXN1_21_R_T1_01 AAGAGTCCTCATCTCACAATCAA
PCR A 22 NRXN1_22_F_T1_01 TCTCCCAGAGAACTTTAAATCAC NRXN1_22_R_T1_02 TGTGCTTCATAAAAAGGAAAGT
PCR A 23 NRXN1_BETA1_F_T1_01 ACTGTCCGAAGGAGGGAGAG NRXN1_BETA1_R_T1_01 GAGCCTTAGGAGCCCAGGAG
Appendix Table 9. NRXN1 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[228]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 2 LBR_2_F_T1_01 CTAAATCATCCTCTCAAATGATTC LBR_2_R_T1_01 GACTATGCCTCATTCATACATTC
PCR A 3 LBR_3_F_T1_01 TTTAGAGTTAATGGTAGCAGTTCC LBR_3_R_T1_01 CAACTTAGATTTGATGTTTCAGTG
PCR A 4 LBR_4_F_T1_01 AATCTGTTTTATTGCTTGATTCC LBR_4_R_T1_01 CAGCATCTCAATACAGCTATACAC
PCR A 5 LBR_5_F_T1_01 GTGTATAGCTGTATTGAGATGCTG LBR_5_R_T1_01 CTACTCCATAATCCCTCAAAATG
PCR A 6 LBR_6_F_T1_01 AACGAGTTCTGATCTTAACAAATC LBR_6_R_T1_01 TAAGTTCCTCCTAATAAGCAAGTG
PCR A 7 LBR_7_F_T1_01 ATTTAAGCACATTTAGTCTTGAGG LBR_7_R_T1_01 ATAAACAGTTGCTCTTCCAACTAC
PCR A 8 LBR_8_F_T1_01 ATAGTGGCGTAAGTTTCATGTGAG LBR_8_R_T1_01 GCAATCTATTCAAATCTGGAAATG
PCR A 9 LBR_9_F_T1_01 AGTGGAATTGTGAGCCTGGATAG LBR_9_R_T1_01 TAACAGGGCATCTTAAACCTCTG
PCR A 10 LBR_10_F_T1_01 ATGGTGCTGAGATGTCTTATTC LBR_10_R_T1_01 TAAACACAAGAACAGCTGATAAAC
PCR A 11 LBR_11_F_T1_01 TTAGAGATCTGTTATCTCCAGAGC LBR_11_R_T1_01 AATGGCATGTTTCAAGTATGTAG
PCR A 12 LBR_12_F_T1_01 AATTTCCTCAGAGCATAGAAATC LBR_12_R_T1_01 CAAACTAGCACTCTTCTGAAATG
PCR A 13 LBR_13_F_T1_01 CTTGCACGTAAGTATTGATTTATG LBR_13_R_T1_02 AGCCAGAGGAGCTTCTACAGAG
PCR A 14 LBR_14_F_T1_01 GTGGTTCCATTTTTAGAGAATTTG LBR_14_R_T1_01 CATAGTCCTGACTCAAAAAGAAAA
Appendix Table 10. LBR genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[229]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR D 1 TTC13_1_F_T1_01 CACACAATGCTTCTCCCCTTGT TTC13_1__R_T1_01 GGGCAGCCGGAGGCGTGAGG
PCR A 2 TTC13_2_F_T1_01 GTTGCCACTTTTAGTGTTATTCAC TTC13_2__R_T1_01 GTTCTATGTCCAGAATAATCAACC
PCR A 3 TTC13_3_F_T1_01 ACTGAAAGCCATAAAGTGTAAAAC TTC13_3__R_T1_01 AAAGCCAGTCTCTCTACTCCTTAC
PCR A 4 TTC13_4_F_T1_01 AGTGGTGAAAGTAGAAGAATTCAG TTC13_4__R_T1_01 AGACTATGAGTAAATTGCTTGACC
PCR A 5 TTC13_5_F_T1_01 CACATTTCATACAAATGAGCTTTA TTC13_5__R_T1_01 TGAAAGGAACTCAAACTCTAAGTC
PCR A 6 TTC13_6_F_T1_01 ATCTGTGGAATTTGTGATAGGTAG TTC13_6__R_T1_01 TAAAGGCATTAAGTACCGACATAG
PCR A 7 TTC13_7_F_T1_01 GATACAACCCAGAATGTGAAATAG TTC13_7__R_T1_01 TTAATTTCAGCTACAGAAAATGC
PCR A 8 TTC13_8_F_T1_01 AAAACTCCCAACTGTTTGAATG TTC13_8__R_T1_01 ACTTATTAACCTTTGATCCTTTCC
PCR A 9 TTC13_9_F_T1_01 AGTCCTCCTAAAAGAAAATCTGTC TTC13_9__R_T1_01 GATGAACGTTTTCTAGACCAATAC
PCR A 10 TTC13_10_F_T1_01 GAGCTGGTGAGATTTAGAAGTAAG TTC13_10__R_T1_01 ACTAGTCTACAGGACAAGAGCAAT
PCR A 11 TTC13_11_F_T1_01 CTTAAGAACTTTAAGGTGAGCATC TTC13_11__R_T1_01 CATACGAAACATAAAAGAGTCAAG
PCR A 12 TTC13_12_F_T1_01 CCCAGACTGACTGACTTATATTTG TTC13_12__R_T1_01 GGATATTCACAGGCACAAGGATA
PCR A 13 TTC13_13_F_T1_01 GACTGAAGTAAGGATTATGTGGTC TTC13_13__R_T1_01 AGTCTTCTTTCAGAATTCAGTTTG
PCR A 14 TTC13_14_F_T1_01 TACTATAGGAGTGAGGAAGAATGC TTC13_14__R_T1_01 TAACAAACTTTAGAGAGGAAAACC
PCR A 15 TTC13_15_F_T1_01 GAGTAACCTTTGATATTCATTTGC TTC13_15__R_T1_01 GTGCAGAGTCAATCAGTATGTTC[230]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 16 TTC13_16_F_T1_01 ACTGAGTTTGATGCCAGAATAG TTC13_16__R_T1_01 AATTTGATAGACCTTGTTTAGCC
PCR A 17 TTC13_17_F_T1_01 AGATGTTTCCTTAATTCTCATCTG TTC13_17__R_T1_01 AATGTGTTCATACGAGTGATTTC
PCR A 18 TTC13_18_F_T1_01 CATCTCTTGTATCAGATGACCTC TTC13_18__R_T1_01 TAACTGGTTATAACTGCTCACTGG
PCR A 19 TTC13_19_F_T1_01 AGGCAACTATCACATTTTATGAAG TTC13_19__R_T1_01 TTATTATCCTCCCCATTACTGTAG
PCR A 20 TTC13_20_F_T1_01 TTTATCCAAGAGTTGCAGTTTAAG TTC13_20__R_T1_01 GCACATGATACACAGTAAACTTTC
PCR A 21 TTC13_21_F_T1_01 TTATCTTTCATGATGGGAAGTC TTC13_21__R_T1_01 GGAGATCTATGTAACTCGTGTACC
PCR D 22 TTC13_22_F_T1_01 AATGCTTGGTTATGTATTAAGTCC TTC13_22__R_T1_01 GGATTACAGGTATGAGCTACTGTG
PCR A 23 TTC13_23_F_T1_01 AATGATAGGAATAAATATAAGCTCT TTC13_23__R_T1_01 GGTTCAGAAAAGTAAAGAAAATGA
Appendix Table 11. TTC13 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[231]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR D 1 KCNK1_1_F_T1_01 AGGAAAAGAAGGAAGAAAAACAT KCNK1_1__R_T1_01 GGACGCCAGTAAGGGGAAGGTC
PCR A 2 KCNK1_2_F_T1_01 GCAGATGATAGGCATATATTGTTT KCNK1_2__R_T1_01 CAAAATAGAGACAGAAGCCTGTAA
PCR A 3 KCNK1_3_F_T1_01 TAAAAATTAAGAAACTGGCAATGA KCNK1_3__R_T1_01 TGCATTCTGATAAAAATGAACATA
Appendix Table 12. KCNK1 genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[232]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR A 4 PSEN2_4_F_T1_01 CTCTCAAGGCCTCTTGTTTTATG PSEN2_4_R_T1_01 ATCCTCATCATTACTTCCCTTCTC
PCR A 5 PSEN2_5_F_T1_01 CAACATTCAAACTTCTCATTTCTG PSEN2_5_R_T1_01 CAAGTAGGTCACAATCCAGGAG
PCR A 6 PSEN2_6_F_T1_01 CTGGAGGACAGGAACTGCTC PSEN2_6_R_T1_01 TCTAAAGGCGGCTGTTTCAC
PCR A 7 PSEN2_7_F_T1_01 GAAGTAGCCTAATGAAGAGCATTC PSEN2_7_R_T1_01 TTAAATCAGGAACGAGACAGAAAC
PCR A 8 PSEN2_8_F_T1_01 GGGAAGGAAATGTTAGTAAAGAGG PSEN2_8_R_T1_01 CTGTTTTACAAAGGCGACTCTC
PCR A 9 PSEN2_9_F_T1_01 TGTGACTGGAGAATGAGAATTTG PSEN2_9_R_T1_01 TGCTTCCTGTCCTAACTTTCTAAG
PCR A 10 PSEN2_10_F_T1_01 ACAACGGCCTCCTAACAATG PSEN2_10_R_T1_01 TGGTTTTCAACGGACCTTTC
PCR A 11 PSEN2_11_F_T1_01 GAAGATTCAGCAAGTGTTGGAC PSEN2_11_R_T1_01 CATCTTCTACTTTCACAGAGATGC
PCR A 12 PSEN2_12_F_T1_01 GTTTTACCTGAGTTTCAGAACTGC PSEN2_12_R_T1_01 CTCAGAGGGAAGAGAAGAAATG
PCR A 13 PSEN2_13_F_T1_01 TAACAGGTGAGGTGATCTAATGG PSEN2_13_R_T1_01 CCTCACCAAGTAAACACGTACT
Appendix Table 13. PSEN2 PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[233]
PCR
Protocol
* Exon Primer name Forward primer (5’–>3’) Primer name Reverse primer (5’–>3’)
PCR 1 1 TCAP_1_F_T1_01 TCTACTTATAGCATCTGACACCAG TCAP_1_R_T1_01 CTGGTGGTAGGTCTCATGTCTC
PCR 1 2 TCAP_2_F_T1_01 AGCATGAAGCCCTGGAGAAAT TCAP_2_R_T1_01 AACTCTGGGCAAACTACAAAGC
Appendix Table 14. TCAP genomic PCR primers used for mutation analysis.
* PCR protocols are described in section 2.2.3.[234]
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